Page last updated: 2024-12-08

ceftriaxone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID5479530
CHEMBL ID161
CHEBI ID29007
SCHEMBL ID23354
MeSH IDM0003731

Synonyms (65)

Synonym
7-[2-(2-amino-thiazol-4-yl)-2-methoxyimino-acetylamino]-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid (ceftriaxone)
(6r,7r,z)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-{2-(2-amino-thiazol-4-yl)-2-[(z)-methoxyimino]-acetylamino}-3-(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r,)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-{2-(2-amino-thiazol-4-yl)-2-[(z)-methoxyimino]-acetylamino}-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
bdbm50049707
7-[2-(2-amino-thiazol-4-yl)-2-methoxyimino-acetylamino]-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid(ceftriaxone)
rocephalin
(6r,7r)-7-({(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
D07659
ceftriaxone (inn)
ceftriaxone (tn)
(6r,7r)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7^2-(z)-(o-
(6r,7r)-7-[[(2z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-3-[(2-methyl-5,6-dioxo-1h-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
ceftriazone
rocephine
C06683
DB01212
biotrakson
ceftriaxona [inn-spanish]
ceftriaxon
einecs 277-405-6
ceftriaxonum [inn-latin]
drg-0071
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-, (6r-(6alpha,7beta(z)))-
ro 139904
AC-1592
CHEMBL161 ,
(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1h-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
ceftriaxona
(6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CHEBI:29007 ,
7beta-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
ceftriaxonum
75j73v1629 ,
ceftriaxone [usan:inn:jan]
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-, (6r,7r)-
unii-75j73v1629
AKOS015960618
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-, (6r-(6.alpha.,7.beta.(z)))-
ceftriaxone [vandf]
ceftriaxone [mi]
ceftriaxone [inn]
ceftriaxone [who-dd]
HY-B0712
SCHEMBL23354
W-104454
cefatriaxone, antibiotic for culture media use only
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-, (6r,7r)-
rophex
bdbm50103601
DTXSID0022773 ,
(6r,7r)-7-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r,z)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-[[(2z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
A899928
AS-56320
EN300-23582312
dtxcid902773
j01da13
(6r,7r)-7-(((2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl)amino)-3-(((2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
ceftriaxonum (inn-latin)
ceftriaxonum natricum
7beta-(((2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl)amino)-3-(((2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl)methyl)-3,4-didehydrocepham-4-carboxylic acid
ceftriaxona (inn-spanish)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
"The utilization of the membrane transport protein PEPT1 as a drug delivery system is a promising strategy to enhance the oral bioavailability of drugs."( Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I, 2005
)
0.33
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" Pharmacokinetic profiles (PK) of GTS511 show a >6 h half-life and higher bioavailability in plasma and the brain under all three routes of administration in rats."( Design and Characterization of Novel Small Molecule Activators of Excitatory Amino Acid Transporter 2.
Altieri, A; Beld, J; Das, S; Kortagere, S; Kurkin, AV; Novoselov, AM; Trubnikov, AV, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" Over the entire dosing interval, telavancin was present in ELF and AMs at concentrations up to 8-fold and 85-fold, respectively, above its MIC 90 for methicillin-resistant Staphylococcus aureus (0."( Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
Barriere, SL; Benton, BM; Goldberg, MR; Gotfried, MH; Kitt, MM; Krause, KM; Shaw, JP, 2008
)
0.35
" For this reason, the dosage of [corrected] these drugs should be carefully evaluated [corrected] to minimize side effects."( Effects of some drugs on human cord blood erythrocyte carbonic anhydrases I and II: an in vitro study.
Aktas, M; Cankaya, M; Coban, TA; Gül, İ; Kuzucu, M, 2012
)
0.38
" Omadacycline offers once daily oral and IV dosing and a clinical tolerability and safety profile that compares favorably with contemporary antibiotics used across serious community-acquired infections where resistance has rendered many less effective."( Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
Steenbergen, J; Tanaka, SK; Villano, S, 2016
)
0.43
" Similarly, GTS467 has high oral bioavailability (80-85%) in the brain and plasma with a >1 h half-life under all three dosing routes."( Design and Characterization of Novel Small Molecule Activators of Excitatory Amino Acid Transporter 2.
Altieri, A; Beld, J; Das, S; Kortagere, S; Kurkin, AV; Novoselov, AM; Trubnikov, AV, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
EC 3.5.2.6 (beta-lactamase) inhibitorAn EC 3.5.2.* (non-peptide cyclic amide C-N hydrolase) inhibitor that interferes with the action of beta-lactamase (EC 3.5.2.6).
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
1,2,4-triazinesAny compound with a 1,2,4-triazine skeleton, in which nitrogen atoms replace carbon at positions 1, 2 and 4 of the core benzene ring structure.
1,3-thiazoles
oxime O-etherO-organyl oximes R2C=NOR' (R' =/= H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (23)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 6Rattus norvegicus (Norway rat)IC50 (µMol)840.00000.50000.50000.5000AID681363
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)IC50 (µMol)153.80000.00032.63119.0000AID1207729
Glutathione reductase, mitochondrialHomo sapiens (human)Ki17.34000.80003.45006.1000AID1803292
Carbonic anhydrase 1Homo sapiens (human)Ki22.15000.00001.372610.0000AID1803130
Carbonic anhydrase 2Homo sapiens (human)Ki22.15000.00000.72369.9200AID1803130
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)27.40000.00002.800510.0000AID1210069
D-amino-acid oxidaseHomo sapiens (human)IC50 (µMol)10.00000.00401.119910.0000AID1245149
Solute carrier family 15 member 1Homo sapiens (human)Ki30,000.00000.18003.39339.8000AID238858; AID681115
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)27.40000.01202.53129.4700AID1210069
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)IC50 (µMol)153.80000.00032.59559.0000AID1207729
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)IC50 (µMol)153.80000.00032.63119.0000AID1207729
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)153.80000.00032.25459.6000AID1207729
Solute carrier family 22 member 6Homo sapiens (human)Ki0.23000.03003.20437.8200AID681377
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki20,000.00003.00006.47788.5000AID681114
Solute carrier family 22 member 8Homo sapiens (human)Ki4.39000.04004.22979.0000AID681373
Solute carrier family 22 member 11Homo sapiens (human)Ki2.38000.20002.57716.1500AID681569
Solute carrier family 22 member 8Rattus norvegicus (Norway rat)IC50 (µMol)2,000.00006.03006.03006.0300AID681344
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-synucleinHomo sapiens (human)Kd0.53000.19002.45336.5000AID1695750
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase Shouchella clausiiKm950.00000.01003.00506.0000AID373209
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (239)

Processvia Protein(s)Taxonomy
visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
cellular oxidant detoxificationGlutathione reductase, mitochondrialHomo sapiens (human)
cellular response to oxidative stressGlutathione reductase, mitochondrialHomo sapiens (human)
glutathione metabolic processGlutathione reductase, mitochondrialHomo sapiens (human)
cell redox homeostasisGlutathione reductase, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
temperature homeostasisGlutathione peroxidase 1Homo sapiens (human)
endothelial cell developmentGlutathione peroxidase 1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGlutathione peroxidase 1Homo sapiens (human)
triglyceride metabolic processGlutathione peroxidase 1Homo sapiens (human)
glutathione metabolic processGlutathione peroxidase 1Homo sapiens (human)
sensory perception of soundGlutathione peroxidase 1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressGlutathione peroxidase 1Homo sapiens (human)
response to xenobiotic stimulusGlutathione peroxidase 1Homo sapiens (human)
response to symbiotic bacteriumGlutathione peroxidase 1Homo sapiens (human)
UV protectionGlutathione peroxidase 1Homo sapiens (human)
response to hormoneGlutathione peroxidase 1Homo sapiens (human)
response to selenium ionGlutathione peroxidase 1Homo sapiens (human)
response to gamma radiationGlutathione peroxidase 1Homo sapiens (human)
arachidonic acid metabolic processGlutathione peroxidase 1Homo sapiens (human)
lipoxygenase pathwayGlutathione peroxidase 1Homo sapiens (human)
response to estradiolGlutathione peroxidase 1Homo sapiens (human)
response to hydroperoxideGlutathione peroxidase 1Homo sapiens (human)
response to vitamin EGlutathione peroxidase 1Homo sapiens (human)
regulation of mammary gland epithelial cell proliferationGlutathione peroxidase 1Homo sapiens (human)
cellular response to oxidative stressGlutathione peroxidase 1Homo sapiens (human)
response to nicotineGlutathione peroxidase 1Homo sapiens (human)
epigenetic regulation of gene expressionGlutathione peroxidase 1Homo sapiens (human)
vasodilationGlutathione peroxidase 1Homo sapiens (human)
response to hydrogen peroxideGlutathione peroxidase 1Homo sapiens (human)
hydrogen peroxide catabolic processGlutathione peroxidase 1Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGlutathione peroxidase 1Homo sapiens (human)
skeletal muscle tissue regenerationGlutathione peroxidase 1Homo sapiens (human)
blood vessel endothelial cell migrationGlutathione peroxidase 1Homo sapiens (human)
fat cell differentiationGlutathione peroxidase 1Homo sapiens (human)
myoblast differentiationGlutathione peroxidase 1Homo sapiens (human)
cell redox homeostasisGlutathione peroxidase 1Homo sapiens (human)
fibroblast proliferationGlutathione peroxidase 1Homo sapiens (human)
skeletal muscle fiber developmentGlutathione peroxidase 1Homo sapiens (human)
neuron apoptotic processGlutathione peroxidase 1Homo sapiens (human)
myoblast proliferationGlutathione peroxidase 1Homo sapiens (human)
response to folic acidGlutathione peroxidase 1Homo sapiens (human)
biological process involved in interaction with symbiontGlutathione peroxidase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionGlutathione peroxidase 1Homo sapiens (human)
heart contractionGlutathione peroxidase 1Homo sapiens (human)
angiogenesis involved in wound healingGlutathione peroxidase 1Homo sapiens (human)
regulation of proteasomal protein catabolic processGlutathione peroxidase 1Homo sapiens (human)
cellular response to glucose stimulusGlutathione peroxidase 1Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaGlutathione peroxidase 1Homo sapiens (human)
cellular oxidant detoxificationGlutathione peroxidase 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsGlutathione peroxidase 1Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayGlutathione peroxidase 1Homo sapiens (human)
positive regulation of supramolecular fiber organizationGlutathione peroxidase 1Homo sapiens (human)
glutathione transportMicrosomal glutathione S-transferase 1Homo sapiens (human)
cellular response to lipid hydroperoxideMicrosomal glutathione S-transferase 1Homo sapiens (human)
cellular oxidant detoxificationMicrosomal glutathione S-transferase 1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
proline catabolic processD-amino-acid oxidaseHomo sapiens (human)
digestionD-amino-acid oxidaseHomo sapiens (human)
D-amino acid catabolic processD-amino-acid oxidaseHomo sapiens (human)
D-serine catabolic processD-amino-acid oxidaseHomo sapiens (human)
dopamine biosynthetic processD-amino-acid oxidaseHomo sapiens (human)
D-alanine catabolic processD-amino-acid oxidaseHomo sapiens (human)
D-serine metabolic processD-amino-acid oxidaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumD-amino-acid oxidaseHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
glutathione biosynthetic processExcitatory amino acid transporter 2Homo sapiens (human)
monoatomic ion transportExcitatory amino acid transporter 2Homo sapiens (human)
neurotransmitter transportExcitatory amino acid transporter 2Homo sapiens (human)
chemical synaptic transmissionExcitatory amino acid transporter 2Homo sapiens (human)
visual behaviorExcitatory amino acid transporter 2Homo sapiens (human)
response to xenobiotic stimulusExcitatory amino acid transporter 2Homo sapiens (human)
response to woundingExcitatory amino acid transporter 2Homo sapiens (human)
L-glutamate transmembrane transportExcitatory amino acid transporter 2Homo sapiens (human)
telencephalon developmentExcitatory amino acid transporter 2Homo sapiens (human)
adult behaviorExcitatory amino acid transporter 2Homo sapiens (human)
multicellular organism growthExcitatory amino acid transporter 2Homo sapiens (human)
response to amino acidExcitatory amino acid transporter 2Homo sapiens (human)
positive regulation of glucose importExcitatory amino acid transporter 2Homo sapiens (human)
protein homotrimerizationExcitatory amino acid transporter 2Homo sapiens (human)
transepithelial transportExcitatory amino acid transporter 2Homo sapiens (human)
L-aspartate transmembrane transportExcitatory amino acid transporter 2Homo sapiens (human)
D-aspartate import across plasma membraneExcitatory amino acid transporter 2Homo sapiens (human)
cellular response to cocaineExcitatory amino acid transporter 2Homo sapiens (human)
monoatomic anion transmembrane transportExcitatory amino acid transporter 2Homo sapiens (human)
L-glutamate import across plasma membraneExcitatory amino acid transporter 2Homo sapiens (human)
neurotransmitter reuptakeExcitatory amino acid transporter 2Homo sapiens (human)
L-aspartate import across plasma membraneExcitatory amino acid transporter 2Homo sapiens (human)
transport across blood-brain barrierExcitatory amino acid transporter 2Homo sapiens (human)
cysteine transmembrane transportExcitatory amino acid transporter 2Homo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
sensory perception of soundVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transporter activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
skeletal system developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
extraocular skeletal muscle developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
striated muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
endoplasmic reticulum organizationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
myoblast fusionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle adaptationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle fiber developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
release of sequestered calcium ion into cytosolVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cellular response to caffeineVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 11Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 11Homo sapiens (human)
organic anion transportSolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 11Homo sapiens (human)
urate metabolic processSolute carrier family 22 member 11Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (88)

Processvia Protein(s)Taxonomy
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
electron transfer activityGlutathione reductase, mitochondrialHomo sapiens (human)
NADP bindingGlutathione reductase, mitochondrialHomo sapiens (human)
glutathione-disulfide reductase (NADPH) activityGlutathione reductase, mitochondrialHomo sapiens (human)
flavin adenine dinucleotide bindingGlutathione reductase, mitochondrialHomo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
glutathione peroxidase activityGlutathione peroxidase 1Homo sapiens (human)
protein bindingGlutathione peroxidase 1Homo sapiens (human)
SH3 domain bindingGlutathione peroxidase 1Homo sapiens (human)
phospholipid-hydroperoxide glutathione peroxidase activityGlutathione peroxidase 1Homo sapiens (human)
glutathione transferase activityMicrosomal glutathione S-transferase 1Homo sapiens (human)
glutathione peroxidase activityMicrosomal glutathione S-transferase 1Homo sapiens (human)
protein bindingMicrosomal glutathione S-transferase 1Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
D-amino-acid oxidase activityD-amino-acid oxidaseHomo sapiens (human)
protein bindingD-amino-acid oxidaseHomo sapiens (human)
identical protein bindingD-amino-acid oxidaseHomo sapiens (human)
FAD bindingD-amino-acid oxidaseHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
L-glutamate transmembrane transporter activityExcitatory amino acid transporter 2Homo sapiens (human)
high-affinity L-glutamate transmembrane transporter activityExcitatory amino acid transporter 2Homo sapiens (human)
protein bindingExcitatory amino acid transporter 2Homo sapiens (human)
monoatomic anion transmembrane transporter activityExcitatory amino acid transporter 2Homo sapiens (human)
glutamate:sodium symporter activityExcitatory amino acid transporter 2Homo sapiens (human)
cysteine transmembrane transporter activityExcitatory amino acid transporter 2Homo sapiens (human)
metal ion bindingExcitatory amino acid transporter 2Homo sapiens (human)
neutral L-amino acid transmembrane transporter activityExcitatory amino acid transporter 2Homo sapiens (human)
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
ankyrin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
small molecule bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
molecular function activator activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 11Homo sapiens (human)
protein bindingSolute carrier family 22 member 11Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (63)

Processvia Protein(s)Taxonomy
photoreceptor outer segmentVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
mitochondrial matrixGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolGlutathione reductase, mitochondrialHomo sapiens (human)
external side of plasma membraneGlutathione reductase, mitochondrialHomo sapiens (human)
extracellular exosomeGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolGlutathione reductase, mitochondrialHomo sapiens (human)
mitochondrionGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
Lewy bodyGlutathione peroxidase 1Homo sapiens (human)
cytoplasmGlutathione peroxidase 1Homo sapiens (human)
mitochondrionGlutathione peroxidase 1Homo sapiens (human)
mitochondrial matrixGlutathione peroxidase 1Homo sapiens (human)
cytosolGlutathione peroxidase 1Homo sapiens (human)
mitochondrionGlutathione peroxidase 1Homo sapiens (human)
cytosolGlutathione peroxidase 1Homo sapiens (human)
mitochondrionMicrosomal glutathione S-transferase 1Homo sapiens (human)
mitochondrial outer membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
peroxisomal membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
endoplasmic reticulumMicrosomal glutathione S-transferase 1Homo sapiens (human)
endoplasmic reticulum membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
plasma membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
azurophil granule membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
mitochondrionMicrosomal glutathione S-transferase 1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
mitochondrial outer membraneD-amino-acid oxidaseHomo sapiens (human)
extracellular regionD-amino-acid oxidaseHomo sapiens (human)
cytoplasmD-amino-acid oxidaseHomo sapiens (human)
peroxisomal matrixD-amino-acid oxidaseHomo sapiens (human)
cytosolD-amino-acid oxidaseHomo sapiens (human)
cell projectionD-amino-acid oxidaseHomo sapiens (human)
presynaptic active zoneD-amino-acid oxidaseHomo sapiens (human)
cytoplasmD-amino-acid oxidaseHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
presynaptic membraneExcitatory amino acid transporter 2Homo sapiens (human)
plasma membraneExcitatory amino acid transporter 2Homo sapiens (human)
cell surfaceExcitatory amino acid transporter 2Homo sapiens (human)
membraneExcitatory amino acid transporter 2Homo sapiens (human)
axolemmaExcitatory amino acid transporter 2Homo sapiens (human)
vesicleExcitatory amino acid transporter 2Homo sapiens (human)
cell bodyExcitatory amino acid transporter 2Homo sapiens (human)
neuron projection terminusExcitatory amino acid transporter 2Homo sapiens (human)
membrane raftExcitatory amino acid transporter 2Homo sapiens (human)
astrocyte projectionExcitatory amino acid transporter 2Homo sapiens (human)
glutamatergic synapseExcitatory amino acid transporter 2Homo sapiens (human)
membrane protein complexExcitatory amino acid transporter 2Homo sapiens (human)
plasma membraneExcitatory amino acid transporter 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
sarcoplasmic reticulumVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
I bandVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
external side of plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1957)

Assay IDTitleYearJournalArticle
AID521354Antimicrobial activity against Streptococcus pneumoniae isolate 4134 obtained from sputum of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID1062041Antibacterial activity against Bacillus cereus ATCC 11778 after 24 hrs by broth microdilution method2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID571007Antimicrobial activity against Escherichia coli ATCC 25922 by serial dilution twofold broth microdilution method in presence of 40 g/L bovine serum albumin2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID528730Antibacterial activity against penicillin resistant Streptococcus pneumoniae clinical isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID531781Antibacterial activity against Acinetobacter baumannii obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID573364Antibacterial activity against ceftazidime-susceptible Morganella morganii by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1211885Total biliary clearance in beagle dog at 20 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID528823Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID574956Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 6B by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID558604Antimicrobial activity against Streptococcus pneumoniae isolate 1055 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID528916Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-14 and CTX-M-27 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID573349Antibacterial activity against ceftazidime-nonsusceptible Enterobacter cloacae by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID324843Antimicrobial activity against Neisseria gonorrhoeae 65 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID543822Antimicrobial activity against Borrelia spielmanii isolate PC-Eq17 after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID573346Antibacterial activity against ceftazidime-susceptible Enterobacter cloacae by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID543831Antimicrobial activity against Borrelia burgdorferi isolate LW2 after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID278091Overgrowth of enterococci in mouse intestine assessed in stool after 3 days2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID534868Antimicrobial activity against ESBL producing Proteus mirabilis assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID545830Antimicrobial activity against Listeria monocytogenes by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID545834Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID544956Antimicrobial activity against Proteus mirabilis extended-spectrum beta-lactamase producing isolate by Etest2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID574436Antimicrobial activity against Escherichia coli isolate 547T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from blood of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID425079Antimicrobial activity against beta lactamase-positive Bacteroides distasonis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID519640Antimicrobial activity against Escherichia coli AB14156 harboring beta-lactamase CTX-M-42 Pro167Thr mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID534643Antimicrobial activity against ESBL producing Klebsiella pneumoniae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID425109Antimicrobial activity against Clostridium cadaveris isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID548254Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID584303Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus sciuri subsp. rodentium ATCC 700061T by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID544930Antimicrobial activity against Acinetobacter johnsonii clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID528975Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID584473Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN03 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID556352Antimicrobial activity against Salmonella enterica serotype concord expressing extended-spectrum beta-lactamase SHV-12 by Etest2009Antimicrobial agents and chemotherapy, 05, Volume: 53, Issue:5
Chromosomal integration of the extended-spectrum beta-lactamase gene blaCTX-M-15 in Salmonella enterica serotype Concord isolates from internationally adopted children.
AID586053Antimicrobial activity against Staphylococcus aureus clone 4-4 harboring staphylococcal cassette chromosome mec element type 4 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID528830Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID547755Antimicrobial activity against invasive Streptococcus intermedius obtained from non-cystic fibrosis patient assessed as non-susceptible isolates grown on mueller-Hinton blood agar at 30 ug/ml after 24 hrs at 37 degC by disk diffusion method in presence of2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.
AID575102Antimicrobial activity against Streptococcus pneumoniae serotype 19F assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID573155Antibacterial activity against vancomycin-resistant Enterococcus faecium by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID511381Antibacterial activity against methicillin resistant coagulase negative Staphylococcus epidermidis by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID531590Antibacterial activity against Providencia stuartii obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID369444Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID425086Antimicrobial activity against beta lactamase-positive Prevotella corporis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID546064Antimicrobial activity against beta-lactamase-negative ampicillin resistant Haemophilus influenzae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID425091Antimicrobial activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID522169Antimicrobial activity against Anaerococcus vaginalis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID524062Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP3 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID534650Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID68853In vitro minimum inhibitory concentration required to produce antibacterial activity against Escherichia coli 259221996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID524566Antimicrobial activity against Shigella sonnei isolate AM20369 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID522135Antimicrobial activity against Bacteroides distasonis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID560220Antibacterial activity against Salmonella enterica serovar Typhimurium R70 expressing Outer membrane protein STM3031 after serial passage by Etest method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID522149Antimicrobial activity against Prevotella nanceiensis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID524202Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP1A by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID544953Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX by Etest based on multiple determinants2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID558582Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID575076Antimicrobial activity against Streptococcus pneumoniae serotype 19A assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID544936Antimicrobial activity against Acinetobacter lwoffii clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID588108Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB G120K, A121D mutant gene, PBP1 L421P mutant gene, PBP2 XXXVIII pattern, insertion of nucleotide T from mtrA promoter, MAST 3158 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID285524Antibacterial activity against Neisseria gonorrhoeae after 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID425077Antimicrobial activity against beta lactamase-positive Bacteroides ovatus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID541855Antimicrobial activity against Escherichia coli ATCC 29522 by microdilution assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.
AID425075Antimicrobial activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID511387Antibacterial activity against ciprofloxacin susceptible Escherichia coli by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID545464Antimicrobial activity against Pseudomonas fluorescens assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID528817Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID43105Rate of hydrolysis in 0.1 M sodium phosphate buffer at pH=7.0 by Beta lactamase (B.l icheniformis 749/C)1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID521353Antimicrobial activity against Streptococcus pneumoniae isolate k-421 obtained from ear of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID405792Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 5/62007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID544954Antimicrobial activity against Escherichia coli extended-spectrum beta-lactamase producing isolate by Etest2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID721641Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 isolated from cystic fibrosis patient assessed as growth inhibition by CLSI broth microdilution method2013European journal of medicinal chemistry, Feb, Volume: 60Monocyclic β-lactams as antibacterial agents: facing antioxidant activity of N-methylthio-azetidinones.
AID1543200Antimicrobial activity against Pseudomonas aeruginosa ATCC 15442 assessed as inhibition of microbial growth incubated for 16 hrs by broth microdilution method
AID522180Antimicrobial activity against Propionibacterium acnes under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID425977Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 50 passages by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID588104Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring PBP2 XXXIV pattern, MAST 51 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID522134Antimicrobial activity against Bacteroides caccae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID524070Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP4 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID543828Antimicrobial activity against Borrelia spielmanii isolate TIsar2 after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID584479Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN09 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID508670Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as reduction of bacteremia at 20 mg/kg, ip measured after 2 days post infection2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID425080Antimicrobial activity against beta lactamase-positive Prevotella bivia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID528722Antibacterial activity against Streptococcus viridans clinical isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID534909Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID342096Increase in toxin level in nonepidemic Clostridium difficile ATCC 9689 infected in CF1 mouse at 1.4 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID524044Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP1 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID545842Antimicrobial activity against ESBL-positive Escherichia coli by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID561627Antimicrobial activity against Stenotrophomonas maltophilia KJ by twofold serial agar dilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID573126Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID573140Antibacterial activity against erythromycin-nonsusceptible Streptococcus agalactiae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID558606Antimicrobial activity against Streptococcus pneumoniae isolate 1147 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID330968Antimicrobial activity against ampD deficient Escherichia coli transfected with pCF1 in medium containing EtbuPUG by serial dilution method2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID528727Antibacterial activity against Streptococcus agalactiae group B clinical isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID369448Antimicrobial activity against Streptococcus viridans after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID279261Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3665 with GyrA S81Y mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID546061Antimicrobial activity against Moraxella catarrhalis by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID1356832Antimicrobial activity against Klebsiella pneumoniae NCTC 13442 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID545846Antimicrobial activity against Proteus mirabilis by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID577458Antimicrobial activity against laboratory-derived Streptococcus pneumoniae isolate R6 harboring Thr446Ala mutant gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.
AID322321Antibacterial activity against Escherichia coli DH5 alpha-URA5776 isolates expressing CTX-M-14 enzyme by agar dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID543824Antimicrobial activity against Borrelia spielmanii isolate PJes after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID545838Antimicrobial activity against Streptococcus viridans group clinical isolate by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID531604Activity of Escherichia coli Inhibitor-resistant beta-lactamase SHV-562008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
AID544677Antimicrobial activity against class A extended spectrum beta-lactamase- producing Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID324842Antimicrobial activity against Neisseria gonorrhoeae 64 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID528847Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID573116Antibacterial activity against methicillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID573334Antibacterial activity against ceftazidime-susceptible Enterobacteriaceae by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1546111Antimicrobial activity against Salmonella typhimurium2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID573147Antibacterial activity against penicillin-nonsusceptible Streptococcus viridans assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID525347Toxicity in Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as decrease in CSF MCP-1 concentration at 50 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs by microsphere-based multiplex assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID511391Antibacterial activity against Citrobacter freundii by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID511389Antibacterial activity against Enterobacter cloacae by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID534084Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae isolate by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID528710Antibacterial activity against penicillin intermediate Streptococcus pneumoniae clinical isolate assessed as susceptibility level by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID522375Antimicrobial activity against Eubacterium limosum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID571026Antimicrobial activity against Escherichia coli ATCC 25922 in presence of bovine serum albumin2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID558802Antimicrobial activity against extended spectrum beta-lactamase-deficient Klebsiella oxytoca assessed as percent susceptible isolates by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID534928Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID422681Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 50 passages by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID531605Activity of Escherichia coli beta-lactamase SHV-112008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
AID543281Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 genomic DNA, pbp2x, pbp1a and pbp2b genes by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID573356Antibacterial activity against ceftazidime-nonsusceptible Escherichia coli assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID208139In vitro minimum inhibitory concentration required to produce antibacterial activity against Streptococcus pneumoniae 1/37(pen r)1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID575321Antimicrobial activity against Salmonella Typhimurium 06-6550 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID425964Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 after 48 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID324844Antimicrobial activity against Neisseria gonorrhoeae 67 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID524207Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP2X by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID529194Antibacterial activity against AmpC-producing Escherichia coli isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID524201Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP1A by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID573119Antibacterial activity against coagulase-negative and oxacillin-susceptible Staphylococcus aureus by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID585879Antimicrobial activity against Staphylococcus aureus clone 1-1 harboring staphylococcal cassette chromosome mec element type 5 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID534085Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae assessed as percent susceptible isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID577650Antimicrobial activity against Escherichia coli isolate 329T expressing beta-lactamase KPC2 and PFGE cluster 2 isolated from blood of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID279260Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 1077 with 23S rRNA A2058G mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID534907Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID562402Antimicrobial activity against Streptococcus pneumoniae clinical isolates assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID524433Antimicrobial activity against Shigella isolate DH10B by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID531782Antibacterial activity against Pseudomonas fluorescens obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID544897Antimicrobial activity against AmpC- producing Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID342258Effect on growth of fluoroquinolone-susceptible nonepidemic Clostridium difficile strain6 in CF1 mouse assessed as increase in bacterial density in cecal content at dosed sc for 5 days2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID532898Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID540943Antimicrobial activity against Klebsiella pneumoniae HP205 expressing CMY-36 cephalosporinase by agar dilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID573370Antibacterial activity against ceftazidime-susceptible Serratia marcescens by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID544949Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC and extended-spectrum beta-lactamase by Etest2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID645046Antibacterial activity against Escherichia coli 3350 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID585878Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type 2 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID522152Antimicrobial activity against Porphyromonas asaccharolyticus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID558589Antimicrobial activity against Streptococcus pneumoniae 1 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID528726Antibacterial activity against Streptococcus mitis clinical isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID556831Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25923 infected in human keratinocytes assessed as bacterial count per mg of cell protein at high extracellular compound concentration after 24 hrs2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
AID584478Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN08 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID522211Antimicrobial activity against Clostridium sordellii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID563518Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID544918Antimicrobial activity against Providencia stuartii clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID528971Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID531587Antibacterial activity against Proteus mirabilis obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID524031Antibacterial activity against penicillin-resistant Streptococcus pneumoniae 1564 by macrodilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID373211Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3) relative to benzyl-penicillin2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID522178Antimicrobial activity against Actinomyces odontolyticus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID577206Antimicrobial activity against Escherichia coli O157:H7 PT-32 in stationary phase encoding Stx-1 and Stx-2 gene by broth macrodilution assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Different classes of antibiotics differentially influence shiga toxin production.
AID587728Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-1-pLBII after 18 hrs by microdilution broth method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1356820Antimicrobial activity against Escherichia coli ATCC 25922 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID20342Urinary recovery in marmosets (IV dose)1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model.
AID405798Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 42007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID541513Antimicrobial activity against Moraxella catarrhalis clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID544952Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX and SHV by Etest2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID571005Binding affinity to bovine serum albumin in THB medium containing 40 g/L BSA2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID522388Activity of Aeromonas enteropelogenes Beta-lactamase TRU12010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID546060Antimicrobial activity against Stenotrophomonas maltophilia by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID558807Antimicrobial activity against extended spectrum beta-lactamase-deficient Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID736951Antimicrobial activity against Bacillus subtilis after 16 hrs by serial dilution method2013European journal of medicinal chemistry, Apr, Volume: 62New pyrazole derivatives containing 1,2,4-triazoles and benzoxazoles as potent antimicrobial and analgesic agents.
AID1404017Permeability of the compound at 500 uM after 8 hrs by PAMPA2018European journal of medicinal chemistry, Feb-10, Volume: 145Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
AID1335628Antibacterial activity against penicillin-resistant Streptococcus pneumoniae SR16675 after 20 hrs by agar dilution method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID531585Antibacterial activity against Klebsiella pneumoniae obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID546055Antimicrobial activity against Shigella spp. by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID563520Antibacterial activity against Pseudomonas aeruginosa NY215 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID736952Antimicrobial activity against Staphylococcus aureus after 16 hrs by serial dilution method2013European journal of medicinal chemistry, Apr, Volume: 62New pyrazole derivatives containing 1,2,4-triazoles and benzoxazoles as potent antimicrobial and analgesic agents.
AID558625Antimicrobial activity against Streptococcus pneumoniae isolate 3458 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID533879Antibacterial activity against amoxicillin-resistant Streptococcus pneumoniae assessed as percent susceptible isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID285509Antibacterial activity against Streptococcus viridans after 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID285439Antimicrobial activity against Citrobacter gillenii CIP 106783 after 18 hrs by disk diffusion method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID540944Antimicrobial activity against Escherichia coli DH5[alpha] transformant harboring pA172 plasmid expressing cephalosporinase CMY-31 by agar dilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID574426Antimicrobial activity against Escherichia coli isolate 339T expressing beta-lactamase KPC2 and PFGE cluster 5 isolated from peritoneal fluid of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID1356823Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID587729Antimicrobial activity against Escherichia coli DH5alpha carrying empty pBC-SK after 18 hrs by microdilution broth method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID1329020Antibacterial activity against Haemophilus influenzae PBS981 infected in CD-1 mouse assessed as reduction in bacterial load in lungs administered intravenously as single dose after 2 hrs of infection measured after 24 hrs post treatment2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID525539Toxicity in Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as decrease in CSF IL1-beta concentration at 100 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs by microsphere-based multiplex assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID531592Antibacterial activity against Serratia marcescens obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID573358Antibacterial activity against ceftazidime-susceptible Klebsiella pneumoniae by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID586080Antimicrobial activity against Neisseria gonorrhoeae isolates harboring non-mosaic penicillin-binding protein 2 penA by Etest2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Characteristics and dissemination of mosaic penicillin-binding protein 2-harboring multidrug-resistant Neisseria gonorrhoeae isolates with reduced cephalosporin susceptibility in northern Taiwan.
AID544933Antimicrobial activity against Acinetobacter junii clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID545829Antimicrobial activity against Corynebacterium jeikeium by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID543269Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 pbp2x gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID548330Antibacterial activity against Escherichia coli after 16 hrs by serial dilution method2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and biological evaluation of aminoketones.
AID324835Antimicrobial activity against Neisseria gonorrhoeae 158 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID574952Antimicrobial activity against Streptococcus pneumoniae serotype 11A by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID548533Antimicrobial activity against Beta-hemolytic Streptococcus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID522142Antimicrobial activity against Prevotella melaninogenica under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID524395Antibacterial activity against methicillin-susceptible beta-lactamase positive Staphylococcus aureus using 5x10'5 CFU/ml standard inoculum after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus.
AID528967Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID541856Antimicrobial activity against florfenicol-resistant Edwardsiella ictaluri M07-1 by microdilution assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.
AID562359Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae clinical isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID531972Antibacterial activity against Klebsiella pneumoniae blood isolate A28006 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID529898Antimicrobial activity against Leptospira weilii isolate 6 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID318651Antibacterial activity against Streptococcus pyogenes ATCC 12344 by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID544682Antimicrobial activity against AmpC beta-lactamase-producing Serratia marcescens clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID1062043Antibacterial activity against multidrug-resistant Stenotrophomonas maltophilia D457R after 24 hrs by broth microdilution method2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID202540Tested for the minimum inhibitory concentration against Saccharomyces cerevisiae NCYC 812002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin.
AID544950Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC by Etest2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID511394Antibacterial activity against Streptococcus pyogenes by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID535752Antimicrobial activity against hospital-acquired Klebsiella pneumoniae obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID522141Antimicrobial activity against Prevotella buccae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID584482Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN12 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID1356828Antimicrobial activity against Klebsiella pneumoniae ATCC BAA-2146 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID545827Antimicrobial activity against Enterococcus faecium by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID573383Antibacterial activity against beta lactamase-positive Haemophilus influenzae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID425100Antimicrobial activity against Peptoniphilus asaccharolyticus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID558600Antimicrobial activity against Streptococcus pneumoniae 12 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID546063Antimicrobial activity against beta-lactamase-positive Haemophilus influenzae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID534529Antimicrobial activity against Listeria monocytogenes KCTC 19111 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID318649Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID573337Antibacterial activity against ceftazidime-nonsusceptible Enterobacteriaceae by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID575084Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 6B assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID574435Antimicrobial activity against Escherichia coli isolate 547 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from blood of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID562612Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae clinical isolates assessed as resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID511397Antibacterial activity against Acinetobacter baumannii by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID560222Antibacterial activity against Salmonella enterica serovar Typhimurium 01-4 by CLSI M7-A7 agar dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID548471Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID425087Antimicrobial activity against beta lactamase-positive Prevotella buccae isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID544679Antimicrobial activity against AmpC beta-lactamase-producing Citrobacter freundii clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID341596Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID558611Antimicrobial activity against Streptococcus pneumoniae isolate 1564 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID531783Antibacterial activity against Stenotrophomonas maltophilia obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID582966Antimicrobial activity against beta-lactamase A-deficient Yersinia enterocolitica GY5717 after 20 hrs by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Contribution of BlaA and BlaB beta-lactamases to antibiotic susceptibility of Yersinia enterocolitica biovar 1B.
AID544958Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX by Etest based on single determinant2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID573340Antibacterial activity against ceftazidime-susceptible Citrobacter freundii by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID544680Antimicrobial activity against AmpC beta-lactamase-producing Enterobacter aerogenes clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID562361Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae clinical isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID534528Antimicrobial activity against vancomycin-resistant Enterococcus faecium CCARM 5028 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID555664Antimicrobial activity against Salmonella enterica serotype Westhampton isolate 04CEB8273SAL expressing CTX-M-53 gene by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID559698Antibacterial activity against quinolone-resistant Escherichia coli TOP10-3963 transformant harboring qnrS1 gene by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
First report of plasmid-mediated quinolone resistance determinant qnrS1 in an Escherichia coli strain of animal origin in Italy.
AID422667Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID496403Antimicrobial activity against Borrelia burgdorferi N402010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID545839Antimicrobial activity against ESBL-negative Enterobacter aerogenes by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID524045Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP1 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID534642Antimicrobial activity against Non-ESBL Klebsiella pneumoniae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1543201Antimicrobial activity against Klebsiella pneumoniae ATCC 700603 assessed as inhibition of microbial growth incubated for 16 hrs by broth microdilution method
AID529903Antimicrobial activity against Leptospira kirschneri serovar Grippotyphosa isolate 13 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID573378Antibacterial activity against imipenem-susceptible Acinetobacter assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID531588Antibacterial activity against Proteus penneri obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID1219874Inhibition of recombinant human ABCC3 expressed in baculovirus infected insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID369445Antibacterial activity against penicillin-resistant Streptococcus pneumoniae after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID522164Antimicrobial activity against Peptostreptococcus anaerobius under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID208140Minimum inhibitory concentration for antibacterial activity against Streptococcus pneumoniae Q19 (pen s)1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID573382Antibacterial activity against beta lactamase-positive Haemophilus influenzae by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID511395Antibacterial activity against Streptococcus agalactiae by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID531581Antibacterial activity against Citrobacter freundii obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID546483Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 95% human serum ultrafiltrate2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID573152Antibacterial activity against vancomycin-resistant Enterococcus faecalis by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID425983Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 50 passages by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID573354Antibacterial activity against ceftazidime-susceptible Escherichia coli assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID524200Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP1A by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID545833Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID534879Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID264472Antibacterial activity against methicillin-susceptible Staphylococcus aureus2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.
AID582764Antimicrobial activity against eaeA negative verocytotoxin-producing non-O157 Escherichia coli isolates obtained from human assessed as percentage of resistant isolates2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID534900Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID438297Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X preincubated for 1 hr before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID525349Toxicity in Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as decrease in CSF IL1-beta concentration at 50 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs by microsphere-based multiplex assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID1695750Binding affinity to alpha-synuclein (unknown origin) expressed in Escherichia coli BL21(DE3) by circular dichroism analysis2019European journal of medicinal chemistry, Apr-01, Volume: 167Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.
AID285512Antibacterial activity against Escherichia coli after 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID369443Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID575328Antimicrobial activity against Escherichia coli 08-1537TC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID684433Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 grown on calcium supplemented Mueller-Hinton broth by broth microdilution method2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Reduced pulmonary surfactant interaction of daptomycin analogs via tryptophan replacement with alternative amino acids.
AID528845Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID524055Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP2 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID545840Antimicrobial activity against ESBL-negative Enterobacter cloacae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID573362Antibacterial activity against ceftazidime-nonsusceptible Klebsiella pneumoniae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID575080Antimicrobial activity against Streptococcus pneumoniae serotype 11A assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID524046Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP1 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID524060Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP2a by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID405800Inhibition of bocillin FL binding to methicillin-resistant Staphylococcus aureus OC 3726 penicillin-binding protein 2a2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID548253Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID534086Antibacterial activity against levofloxacin-resistant Streptococcus pneumoniae isolate by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID285511Antibacterial activity against Enterobacter sp.2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID406623Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae isolates assessed as percent resistant isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID545820Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID681373TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT3-expressing S2 cells2002European journal of pharmacology, Mar-08, Volume: 438, Issue:3
Interaction of human organic anion transporters with various cephalosporin antibiotics.
AID522181Antimicrobial activity against Propionibacterium avidum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID529199Antibacterial activity against AmpC-producing Escherichia coli assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID574429Antimicrobial activity against Escherichia coli isolate 386 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from wound of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID522143Antimicrobial activity against Prevotella intermedia under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID1335636Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae SR16605 after 20 hrs by agar dilution method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID528966Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID425088Antimicrobial activity against Porphyromonas asaccharolyticus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID522198Antimicrobial activity against Clostridium aldenense under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID330963Antimicrobial activity against wild type Escherichia coli transfected with pCF1 by serial dilution method2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID342064Antimicrobial activity against epidemic Clostridium difficile BI9 by broth dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID522136Antimicrobial activity against Bacteroides merdae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID645036Antibacterial activity against erythromycin-sensitive Streptococcus pyogenes 3 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID544900Antimicrobial activity against Klebsiella oxytoca clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID522173Antimicrobial activity against Peptoniphilus harei under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID546059Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID584472Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN02 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID541501Antimicrobial activity against Pseudomonas aeruginosa clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID545841Antimicrobial activity against ESBL-negative Escherichia coli by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID508567Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 20 mg/kg, ip measured after 1 day post infection2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID558591Antimicrobial activity against Streptococcus pneumoniae 3 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID577450Antimicrobial activity against penicillin intermediate resistant Streptococcus pneumoniae isolate 8882 harboring PBP2b 443SSNA mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.
AID560052Antibacterial activity against Neisseria gonorrhoeae isolate SM5 expressing SF-B mosaic penA allele by agar dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.
AID322535Reduction of Streptococcus pneumoniae infection induced cortical brain damage in Wistar rat at 100 mg/kg, sc after 40 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID341595Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID573368Antibacterial activity against ceftazidime-susceptible Proteus mirabilis assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID574954Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19A by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID544921Antimicrobial activity against Acinetobacter calcoaceticus clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID522170Antimicrobial activity against Anaerococcus sp. under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID531788Antibacterial activity against Klebsiella oxytoca obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID534623Antimicrobial activity against ESBL producing Escherichia coli by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID524054Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP2 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID573373Antibacterial activity against multidrug-resistant Acinetobacter by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID206457In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Staphylococcus aureus (2672)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID560048Antibacterial activity against Neisseria gonorrhoeae isolate SM1 expressing SF-A mosaic penA allele by agar dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.
AID425101Antimicrobial activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID405643Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 22007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID577460Inhibition of Bocillin FL binding to PBP2b in laboratory-derived Streptococcus pneumoniae isolate R62010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.
AID425966Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 after 50 passages by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID522160Antimicrobial activity against Anaerococcus tetradius under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID406621Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
AID558630Antimicrobial activity against Streptococcus pneumoniae isolate 4747 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID318671Antibacterial activity against penicillin-resistant Streptococcus pneumoniae KT2524 in mouse dosed iv 1 hr after infection2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID369631Antimicrobial activity against beta-lactamase positive ampicillin-resistant Haemophilus influenzae by E-test2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID518816Antibacterial activity against Acinetobacter genomosp. 3 isolates by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID543482Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 murM, pbp2x, pbp2b and Streptococcus pneumoniae 3191 pbp1a genes by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID531584Antibacterial activity against Escherichia coli obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID370126Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 13 mutant NG-MAST sequence type 1623 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID558810Antimicrobial activity against Proteus mirabilis assessed as percent susceptible isolates by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID573146Antibacterial activity against penicillin-nonsusceptible Streptococcus viridans by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID342086Effect on growth of epidemic Clostridium difficile BI9 in CF1 mouse assessed as increase in bacterial density in cecal content at 2 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID543274Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2b, pbp1a and murM genes by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID422644Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 44 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID511305Antibacterial activity against methicillin resistant coagulase negative Staphylococcus by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID573372Antibacterial activity against ceftazidime-susceptible Serratia marcescens assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID528979Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID524033Antibacterial activity against penicillin-resistant Streptococcus pneumoniae 1394 by macrodilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID543285Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 genomic DNA, pbp2x, pbp1a, pbp2b and Streptococcus pneumoniae 3191 pbp1a genes by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID422684Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 after 50 passages by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID575327Antimicrobial activity against Salmonella Typhimurium 08-1537 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID522167Antimicrobial activity against Anaerococcus murdochii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID573385Antibacterial activity against beta lactamase-positive Moraxella catarrhalis by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID556832Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25923 infected in human keratinocytes assessed as change in bacterial count after 24 hrs2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
AID524397Antibacterial activity against methicillin-susceptible beta-lactamase positive Staphylococcus aureus using 5x10'7 CFU/ml high inoculum after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus.
AID528724Antibacterial activity against Streptococcus oralis clinical isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID540947Antimicrobial activity against Escherichia coli DH5[alpha] harboring pB-c36 plasmid expressing cephalosporinase CMY-36 by agar dilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID1356834Antimicrobial activity against Escherichia coli ATCC BAA-2452 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID524039Antibacterial activity against methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 by macrodilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID545821Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID575326Antimicrobial activity against Escherichia coli 08-843TC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID1335625Protein binding in ICR mouse plasma after 30 mins by ultra-filtration method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID584300Antibacterial activity against mecA-negative Staphylococcus fleurettii SFMN02 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID522200Antimicrobial activity against Clostridium citroniae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522144Antimicrobial activity against Prevotella bergensis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID532895Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID66381Tested for the minimum inhibitory concentration against Enterobacter faecalis 850E2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin.
AID573342Antibacterial activity against ceftazidime-susceptible Citrobacter freundii assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID425098Antimicrobial activity against Anaerococcus prevotii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID573135Antibacterial activity against erythromycin-nonsusceptible Streptococcus pyogenes assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID528841Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID573379Antibacterial activity against beta lactamase-negative Haemophilus influenzae by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID206461In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Staphylococcus aureus (663E)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID558793Antimicrobial activity against extended spectrum beta-lactamase-expressing Escherichia coli assessed as percent susceptible isolates by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID69825Tested for the minimum inhibitory concentration against Escherichia coli 1852E PM2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin.
AID425083Antimicrobial activity against beta lactamase-positive Prevotella nigrescens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID511388Antibacterial activity against Klebsiella pneumoniae by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID1880849Antimicrobial activity against Neisseria gonorrhoeae G strain harbouring type 2 topoisomerase GyrA S91F and ParE G410V mutant incubated for 20 to 24 hrs by CLSI protocol based broth microdilution method2022ACS medicinal chemistry letters, Jun-09, Volume: 13, Issue:6
1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum.
AID547523Antimicrobial activity against Streptococcus constellatus obtained from patient with cystic fibrosis assessed as non-susceptible isolates grown on brain heart infusion agar at 30 ug/ml after 24 hrs at 37 degC by disk diffusion method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.
AID574953Antimicrobial activity against Streptococcus pneumoniae serotype 6C by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID541495Antimicrobial activity against Burkholderia cepacia clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID577453Inhibition of Bocillin FL binding to Streptococcus pneumoniae isolate 8865 PBP2b2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.
AID522214Antimicrobial activity against Clostridium symbiosum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID562328Antimicrobial activity against Chryseobacterium indologenes 597 expressing metallo-beta-lactamase IND-6 after 18 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID681114TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in SKPT cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID543483Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2x, pbp2b, pbp1a and Streptococcus pneumoniae 72521 murM genes by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID342256Effect on growth of fluoroquinolone-resistant epidemic Clostridium difficile NAP1 in CF1 mouse assessed as increase in bacterial density in cecal content at 2.0 mg/day, sc for 5 days2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID544671Antimicrobial activity against Citrobacter koseri clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID422672Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 19 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID434508Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 by standard checkerboard method in presence of 0.2 to 1 mg/ml pulmonar surfactant2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID531583Antibacterial activity against Enterobacter cloacae obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID525350Toxicity in Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as decrease in CSF IL-10 concentration at 50 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs by microsphere-based multiplex assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID522185Antimicrobial activity against Eubacterium contortum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522210Antimicrobial activity against Clostridium paraputrificum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID534924Antimicrobial activity against Ceftazidime susceptible Serratia marcescens assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID322313Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID206459In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Staphylococcus aureus (3072)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID1211880Unbound biliary clearance in Sprague-Dawley rat at 20 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID278094Overgrowth of vancomycin-resistant enterococci growth in mouse intestine assessed in stool 2 days after 5 days treatment relative to saline2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID546235Protein binding in rat serum by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID583093Antimicrobial activity against Escherichia coli XL1-Blue harboring pBC-SK plasmid by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID558599Antimicrobial activity against Streptococcus pneumoniae 11 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1356824Antimicrobial activity against Klebsiella pneumoniae ATCC BAA-1905 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID516139Antibacterial activity against Pulsotype F Acinetobacter genomosp. 3 isolate 4 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS18, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID531787Antibacterial activity against Enterobacter aerogenes obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID558629Antimicrobial activity against Streptococcus pneumoniae isolate 3791 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID405642Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 1a2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID521350Antimicrobial activity against Streptococcus pneumoniae isolate 40 obtained from blood of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID555669Antimicrobial activity against Escherichia coli DH10B harboring natural plasmid pWES-1 carrying CTX-M-53 gene by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID545844Antimicrobial activity against ESBL-positive Klebsiella pneumoniae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID573361Antibacterial activity against ceftazidime-nonsusceptible Klebsiella pneumoniae by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID546052Antimicrobial activity against Proteus stuartii by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID522194Antimicrobial activity against Clostridium perfringens under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID534088Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae isolate by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID556829Ratio of MIC for hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33591 by microdilution method at pH 5.5 to MIC for beta-lactamase-negative methicillin-susceptible Staphylococcus aureus ATCC 25923 by microdilution method at pH 5.52009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
AID528731Antibacterial activity against penicillin intermediate Streptococcus pneumoniae clinical isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID425096Antimicrobial activity against Micromonas micros isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID438298Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X preincubated for 4 hrs before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID425969Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 20 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID545837Antimicrobial activity against macrolide-susceptible Streptococcus pyogenes by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID571006Antimicrobial activity against Escherichia coli ATCC 25922 by serial dilution twofold broth microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID1762803Antibacterial activity against Escherichia coli 01 assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID369627Antimicrobial activity against beta-lactamase negative ampicillin-susceptible Haemophilus influenzae by E-test2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID522182Antimicrobial activity against Eggerthella lenta under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID543270Antimicrobial activity against Streptococcus pneumoniae by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID565168Antimicrobial activity against Staphylococcus aureus ATCC 29213 assessed as post antibiotic effect at 10 times MIC after 2 hr by plate counting method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Postantibiotic effect of ceftaroline against gram-positive organisms.
AID660263Ratio of MIC for wild type Salmonella typhimurium SH5014 to MIC for Salmonella typhimurium SH7616 harboring missense mutation in acrA/acrB gene by two-fold serial dilution method2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID1546171Antimicrobial activity against Bacillus thuringiensis2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID560051Antibacterial activity against Neisseria gonorrhoeae isolate SM4 expressing SF-B mosaic penA allele by agar dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.
AID522186Antimicrobial activity against Eubacterium cylindroides under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID529196Antibacterial activity against ESBL-producing Escherichia coli isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID322315Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID369447Antimicrobial activity against Streptococcus group B after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID516147Antibacterial activity against Pulsotype D Acinetobacter genomosp. 3 isolate 18 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, repAcil, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID529195Antibacterial activity against ESBL-producing Escherichia coli assessed as sensitive isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID1875451Activation of human EAAT2 overexpressed in MDCK cells assessed as glutamate reuptake incubated for 5 mins by LCMS assay2022ACS medicinal chemistry letters, Oct-13, Volume: 13, Issue:10
Design and Characterization of Novel Small Molecule Activators of Excitatory Amino Acid Transporter 2.
AID534082Antibacterial activity against cefotaxime-resistant Streptococcus pneumoniae isolate by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID522165Antimicrobial activity against Peptostreptococcus stomatis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID425099Antimicrobial activity against Anaerococcus tetradius isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID522174Antimicrobial activity against Peptoniphilus lacrimalis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID528704Antibacterial activity against Streptococcus intermedius clinical isolate assessed as susceptibility level by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID573148Antibacterial activity against penicillin-nonsusceptible Streptococcus viridans assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID716937Antibacterial activity against methicillin-resistant Staphylococcus aureus UAMS-1 after 24 hrs by CLSI broth microdilution method2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Design and synthesis of 2-aminothiazole based antimicrobials targeting MRSA.
AID544530Antimicrobial activity against Borrelia spielmanii isolate PC-Eq17 assessed as reduction in bacterial count at 2 ug/ml after 72 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID405638Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 42007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID519734Antibacterial activity against Escherichia coli DH5alpha with deltaampC by agar dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID322318Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID574430Antimicrobial activity against Escherichia coli isolate 386T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from wound of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID405813Inhibition of bocillin FL binding to penicillin-resistant Streptococcus pneumoniae OC 8819 penicillin-binding protein 2b2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID575322Antimicrobial activity against Escherichia coli 06-6550TC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID588105Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB G120K, A121D mutant gene, PBP1 L421P mutant gene, PBP2 XXXVIII pattern, deletion of nucleotide A from mtrA promoter, MAST 3563 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID529893Antimicrobial activity against Leptospira interrogans serovar Bataviae isolate 1 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID325446Antibacterial activity against Salmonella enterica serovar Typhimurium LT2 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID522175Antimicrobial activity against Actinomyces israelii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID210362In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Streptococcus pneumoniae (4629)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID528723Antibacterial activity against Streptococcus constellatus clinical isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID525352Toxicity in Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as increase in CSF MIP-1alpha concentration at 100 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs by microsphere-based multiplex assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID511386Antibacterial activity against ciprofloxacin resistant Escherichia coli by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID575320Antimicrobial activity against Escherichia coli 06CEB6542SALTC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID522193Antimicrobial activity against Lactobacillus rhamnosus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522158Antimicrobial activity against Veillonella spp. under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID546058Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID1335622AUC (0 to infinity) in monkey at 20 mg/kg, iv administered as bolus dose by HPLC method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID524204Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP1B by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID558620Antimicrobial activity against Streptococcus pneumoniae isolate 3282 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID558583Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID573118Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID559582Antimicrobial activity against Chlamydophila psittaci infected in Vero cells2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.
AID1543199Antimicrobial activity against Acinetobacter baumannii ATCC 19606 assessed as inhibition of microbial growth incubated for 16 hrs by broth microdilution method
AID522391Inhibition of Aeromonas enteropelogenes Beta-lactamase TRU12010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID534662Antimicrobial activity against Non-ESBL Proteus mirabilis by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID530837Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 2 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID573131Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID522188Antimicrobial activity against Eubacterium saburreum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID532913Antimicrobial activity against Escherichia coli Genehogs by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID528820Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID545819Antimicrobial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID279264Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3676 after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID528838Antimicrobial activity against vancomycin-resistant Enterococcus sp. assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID583097Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 A64W mutant beta-lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID522148Antimicrobial activity against Prevotella loescheii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID422648Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 50 passages by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID532896Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID264474Antibacterial activity against Haemophilus influenzae2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.
AID425095Antimicrobial activity against Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID544927Antimicrobial activity against Acinetobacter haemolyticus clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID562363Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae clinical isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID565810Antimicrobial activity against Neisseria meningitidis by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.
AID567458Antimicrobial activity against Salmonella enterica serovar Typhi isolate 080048Ty by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Plasmid-mediated resistance to cephalosporins in Salmonella enterica serovar Typhi.
AID555674Antimicrobial activity against Escherichia coli DH5[alpha] harboring recombinant plasmid carrying CTX-M-53 gene by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID207880Inhibitory concentration against purified beta-Lactam-resistant PBP2 from Staphylococcus epidermidis1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID425093Antimicrobial activity against Fusobacterium varium isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID264469Antibacterial activity against Streptococcus pneumoniae2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.
AID544684Antimicrobial activity against Citrobacter freundii clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID546057Antimicrobial activity against Burkholderia cepacia by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID522137Antimicrobial activity against Bacteroides ovatus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID544685Antimicrobial activity against Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID209467In vitro antibacterial activity against the gram-positive bacteria, erythromycin resistant Streptococcus pyogenes1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID532911Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 ST 327 expressing beta-lactamase TEM-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID571015Bactericidal activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 at 8 times MIC after 24 hrs by time kill analysis in presence of 40 g/L human serum albumin2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID645038Antibacterial activity against erythromycin-sensitive Streptococcus pyogenes 12 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID425974Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 50 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID511289Antibacterial activity against Escherichia coli DH5alpha pB-ges-12010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID322319Antibacterial activity against Escherichia coli DH5 alpha isolates by agar dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID545836Antimicrobial activity against macrolide-resistant Streptococcus pyogenes by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID573355Antibacterial activity against ceftazidime-nonsusceptible Escherichia coli by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID405635Antibacterial activity against Escherichia coli MC4100 by CLSI method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID534899Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535754Antimicrobial activity against hospital-acquired Klebsiella pneumoniae expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID573380Antibacterial activity against beta lactamase-negative Haemophilus influenzae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID534919Antimicrobial activity against Ceftazidime susceptible Serratia marcescens by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID89996Compound is evaluated for serum protein binding in human blood (protein binding in marmoset blood)1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model.
AID1880850Antimicrobial activity against wild type Neisseria gonorrhoeae ATCC 49226 incubated for 20 to 24 hrs by CLSI protocol based broth microdilution method2022ACS medicinal chemistry letters, Jun-09, Volume: 13, Issue:6
1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum.
AID528702Antibacterial activity against Streptococcus constellatus clinical isolate assessed as susceptibility level by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID522213Antimicrobial activity against Clostridium subterminale under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID52958In vitro minimum inhibitory concentration required to produce antibacterial activity against Citrobacter freundii 9021996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID541507Antimicrobial activity against beta-lactamase-negative Haemophilus influenzae clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID543829Antimicrobial activity against Borrelia spielmanii isolate TIsar3 after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID541498Antimicrobial activity against Stenotrophomonas maltophilia clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID556834Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 infected in human keratinocytes assessed as bacterial count per mg of cell protein at low extracellular compound concentration after 24 hrs2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
AID546482Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID369985Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 4 mutant NG-MAST sequence type 69 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID544526Antimicrobial activity against Borrelia garinii isolate M2094 after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID370130Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 13 mutant NG-MAST sequence type 1413 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID529892Antimicrobial activity against Leptospira interrogans isolate 7 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID369984Antimicrobial activity against multiresistant Gonococcus2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID370128Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 13 mutant NG-MAST sequence type 1676 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID543284Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2x, pbp2b, murM and Streptococcus pneumoniae 72521 pbp1a genes by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID521355Antimicrobial activity against Streptococcus pneumoniae isolate 657 obtained from sputum of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID544673Antimicrobial activity against Enterobacter cloacae clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID544959Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV by Etest based on single determinant2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID531780Antibacterial activity against Pseudomonas aeruginosa obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID573143Antibacterial activity against penicillin-susceptible Streptococcus viridans by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID522140Antimicrobial activity against Prevotella bivia under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID545831Antimicrobial activity against Streptococcus agalactiae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID525348Toxicity in against Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as decrease in CSF IL-18 concentration at 50 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs by microsphere-based multiplex ass2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID588118Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB G120K, A121D mutant gene, PBP2 XXXVI pattern, deletion of nucleotide A from mtrA promoter, MAST 3596 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID531589Antibacterial activity against Proteus vulgaris obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID544906Antimicrobial activity against Morganella morganii clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID1762806Antibacterial activity against Escherichia coli 08 assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID508685Antibacterial activity against 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in therapeutic C57BL/6 mouse model assessed as survival rate at 20 mg/kg, ip qd beginning at time of infection measured after 6 days post infection2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID1576576Effective permeability of compound by PAMPA2019MedChemComm, Dec-01, Volume: 10, Issue:12
Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.
AID521838Antibacterial activity against Klebsiella pneumoniae isolate VA375 with blaKPC-3, qnrA1, blaTEM-1, blaSHV-11 genes by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID531591Antibacterial activity against Salmonella spp. obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID588117Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB G120K, A121D mutant gene, PBP1 L421P mutant gene, PBP2 XXXVIII pattern, deletion of nucleotide A from mtrA promoter, MAST 3570 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID405796Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 22007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID577649Antimicrobial activity against Escherichia coli isolate 329 expressing beta-lactamase KPC2, CTX-M-2, TEM and PFGE cluster 2 isolated from blood of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID528728Antibacterial activity against Streptococcus pyogenes group A clinical isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID544683Antimicrobial activity against Enterobacter aerogenes clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID545845Antimicrobial activity against Morganella morganii by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID561628Antimicrobial activity against ampD1-deficient Stenotrophomonas maltophilia KJ by twofold serial agar dilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID565662Antimicrobial activity against beta-lactamase negative ampicillin-resistant Haemophilus influenzae assessed as susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re
AID546228Ratio of MIC for Staphylococcus aureus ATCC 29213 grown in CAMHB medium in presence of 95% dog serum to MIC for Staphylococcus aureus ATCC 29213 in presence of 95% dog serum ultrafiltrate2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID322541Effect on Streptococcus pneumoniae infection induced brain injury in Wistar rat hippocampal dentate gyrus assessed as number of apoptotic cells at 100 mg/kg, sc after 40 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID369987Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 5 mutant NG-MAST sequence type 1410 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID573141Antibacterial activity against erythromycin-nonsusceptible Streptococcus agalactiae by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID533877Antibacterial activity against amoxicillin-intermediate Streptococcus pneumoniae assessed as percent susceptible isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID522192Antimicrobial activity against Lactobacillus casei under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID573367Antibacterial activity against ceftazidime-susceptible Proteus mirabilis by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID522133Antimicrobial activity against Bacteroides fragilis spp. under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID543427Antimicrobial activity against Escherichia coli XL-1 Blue harboring plasmid CL1920 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID511287Antibacterial activity against Pseudomonas aeruginosa NL68 expressing GES-13 beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID285689Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4012 isolate expressing carbapenemase KPC22007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID279266Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 3243 with L22 insertion 93SFRPRA94 mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID524056Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP2a by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID544894Antimicrobial activity against class A extended spectrum beta-lactamase- and class D OXA- producing Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID425097Antimicrobial activity against Peptostreptococcus anaerobius isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID543821Antimicrobial activity against Borrelia spielmanii isolate PSig2 after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID511398Antibacterial activity against Pseudomonas aeruginosa by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID586048Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type U1 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID285518Antibacterial activity against Streptococcus pyogenes2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID405806Inhibition of bocillin FL binding to penicillin-susceptible Streptococcus pneumoniae OC 8865 penicillin-binding protein 2b2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID548329Antibacterial activity against Bacillus subtilis after 16 hrs by serial dilution method2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and biological evaluation of aminoketones.
AID573129Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1211804Drug excretion in Sprague-Dawley rat assessed as compound excreted into bile at 20 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID577455Inhibition of Bocillin FL binding to PBP2b PBP2b 443SSNA mutant in Streptococcus pneumoniae isolate 8009 harboring E333G, N470K, E476G, T489S, E506D, and N538D mutant genes2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.
AID1062032Bactericidal activity against Staphylococcus aureus ATCC 29213 after 24 hrs by CFU counting assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID522138Antimicrobial activity against Bacteroides uniformis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID422652Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID558605Antimicrobial activity against Streptococcus pneumoniae isolate 1146 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID330967Antimicrobial activity against ampD deficient Escherichia coli transfected with pCF1 by serial dilution method2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID425980Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 14 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID548473Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID322316Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID342089Effect on growth of nonepidemic Clostridium difficile J29 in CF1 mouse assessed as increase in bacterial density in cecal content at 1.4 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID285339Antimicrobial activity against streptomycin-resistant Escherichia coli J53 by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
AID588107Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB G120K, A121D mutant gene, PBP1 L421P mutant gene, PBP2 XXXVIII pattern, deletion of nucleotide A from mtrA promoter, MAST 3158 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID522199Antimicrobial activity against Clostridium bolteae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522153Antimicrobial activity against Porphyromonas somerae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID544528Antimicrobial activity against Staphylococcus aureus ATCC 29213 after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID264473Antibacterial activity against Staphylococcus epidermidis2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.
AID543277Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2x and pbp2b genes by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID516142Antibacterial activity against Pulsotype L Acinetobacter genomosp. 3 isolate 7 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID534611Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID586044Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type 4 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID322326Antimicrobial activity against Streptococcus pneumoniae WB4 by broth macrodilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.
AID279813Antimicrobial activity against Escherichia coli DH5-alpha pYW1 transformants expressing KPC2 gene by agar dilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID534192Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
AID370005Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 12 mutant NG-MAST sequence type 604 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID556833Bacteriostatic activity against methicillin-susceptible Staphylococcus aureus ATCC 25923 infected in human keratinocytes assessed as change in bacterial count after 24 hrs2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
AID524220Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP3 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID524221Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP3 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID586039Antimicrobial activity against Staphylococcus aureus clone 1-1 harboring staphylococcal cassette chromosome mec element type 4 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID522191Antimicrobial activity against Solobacterium moorei under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID545843Antimicrobial activity against ESBL-negative Klebsiella pneumoniae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID543830Antimicrobial activity against Borrelia burgdorferi B31 after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID530845Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 10 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID556828Ratio of MIC for hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33591 by microdilution method at pH 7.4 to ratio of MIC for hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33591 by microdilution method at pH 5.52009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
AID543826Antimicrobial activity against Borrelia spielmanii isolate PMai after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID1335632Antibacterial activity against Moraxella catarrhalis SR24290 after 20 hrs by agar dilution method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID423749Antibacterial activity against blaCMY-expressing Salmonella enterica subsp. enterica serovar Newport isolated from food animals2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Antimicrobial resistance genes associated with Salmonella enterica serovar newport isolates from food animals.
AID19419Partition coefficient (logD7.4)1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
AID425078Antimicrobial activity against beta lactamase-positive Bacteroides vulgatus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID509870Antibacterial activity against Acinetobacter baumannii isolate 5191 isolated from human urine2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID341618Effect on extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae P62 infected in sc dosed CF1 mouse with high-density bacterial colonization administered daily for 9 days assessed as promotion of persistent bacterial overgrowth by measuring stoo2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
AID1546105Antimicrobial activity against Bacillus subtilis2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID285441Antimicrobial activity against Escherichia coli DH10B after 18 hrs by disk diffusion method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID529897Antimicrobial activity against Leptospira interrogans serovar Pyrogenes isolate 5 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID545828Antimicrobial activity against vancomycin-susceptible Enterococcus faecium by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID210366In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Streptococcus pneumoniae (3272)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID425108Antimicrobial activity against Clostridium paraputrificum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID369996Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 10 mutant NG-MAST sequence type 1677 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID1546876Antibacterial activity against ESBL-producing Escherichia coli ATCC 35218 assessed as reduction in microbial growth after 16 hrs by broth microdilution method2020Journal of natural products, 01-24, Volume: 83, Issue:1
Reisolation and Configurational Reinvestigation of Cottoquinazolines E-G from an Arthropod-Derived Strain of the Fungus
AID533878Antibacterial activity against amoxicillin-resistant Streptococcus pneumoniae isolate by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID574955Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19F by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID522156Antimicrobial activity against Fusobacterium mortiferum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID341614Antibacterial activity against extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae P62 by broth dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
AID519740Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-72 by agar dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID324846Antimicrobial activity against Neisseria gonorrhoeae 35 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID521347Antimicrobial activity against Streptococcus pneumoniae isolate k-598 obtained from bronchoalveolar lavage fluid of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID522145Antimicrobial activity against Prevotella corporis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID574439Antimicrobial activity against Escherichia coli DH10B by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID520778Antibacterial activity against beta-lactamase KPC-2 producing Escherichia coli isolate E1 by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID341613Antibacterial activity against extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolate2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
AID573122Antibacterial activity against coagulase-negative and oxacillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID574438Antimicrobial activity against Escherichia coli isolate 1679T expressing beta-lactamase KPC2, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID522151Antimicrobial activity against Prevotella tannerae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID425094Antimicrobial activity against beta lactamase-positive Fusobacterium mortiferum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID562331Antimicrobial activity against Escherichia coli DH5alpha harboring metallo-beta-lactamase IND-6 after 18 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID425103Antimicrobial activity against Clostridium innocuum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID543282Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 pbp2x, pbp1a, pbp2b genes and Streptococcus pneumoniae 3191 genomic DNA by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID528977Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID558581Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID43755Rate of hydrolysis in 0.1 M sodium phosphate buffer at pH=7.0 by Beta lactamase (SHV-2)1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID577209Antimicrobial activity against Escherichia coli C600::933W in logarithmic phase encoding Stx-2 gene by broth macrodilution assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Different classes of antibiotics differentially influence shiga toxin production.
AID279815Antimicrobial activity against Escherichia coli DH5-alpha with pGEM-T EASY expressing TEM1 gene by agar dilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID544675Antimicrobial activity against class A extended spectrum beta-lactamase- and class D OXA- producing Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID522189Antimicrobial activity against Mogibacterium timidum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID560215Antibacterial activity against Salmonella enterica serovar Typhimurium 01-4 by Etest method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID528706Antibacterial activity against Streptococcus agalactiae group B clinical isolate assessed as susceptibility level by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID318668Antibacterial activity against methicillin-susceptible Staphylococcus aureus Smith in mouse dosed iv 1 hr after infection2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID543825Antimicrobial activity against Borrelia spielmanii isolate PAnz after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID531966Antibacterial activity against Klebsiella pneumoniae urine isolate A28009 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID519738Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-1 by agar dilution method in presence of 2 ug/ml clavulanic acid2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID528984Antimicrobial activity against Haemophilus influenzae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID522139Antimicrobial activity against Bacteroides vulgatus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID209887Inhibitory concentration against purified cephalosporin-resistant PBP2x.604 from Streptococcus pneumoniae1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID370134Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 18 mutant NG-MAST sequence type 864 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID369993Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 9 mutant NG-MAST sequence type 21 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID541510Antimicrobial activity against Haemophilus parainfluenzae clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID573117Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID395730Antimicrobial activity against imipenem-resistant invasive nontypeable Haemophilus influenzae isolate 183 by Etest2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID534530Antimicrobial activity against multidrug-resistant Pseudomonas aeruginosa CCARM 2161 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID209886Inhibitory concentration against purified cephalosporin-resistant PBP2x.505 from Streptococcus pneumoniae1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID561252Antibacterial activity against Streptococcus pneumoniae assessed as resistant isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID264470Antibacterial activity against Enterococcus spp2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.
AID373209Activity of Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3)2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID544891Antimicrobial activity against class A extended spectrum beta-lactamase- producing Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID545824Antimicrobial activity against methicillin-susceptible coagulase-negative Staphylococcus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID575318Antimicrobial activity against Escherichia coli 05-9280TC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID573347Antibacterial activity against ceftazidime-susceptible Enterobacter cloacae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID539912Antibacterial activity against Pseudomonas aeruginosa after 16 hrs by serial dilution method2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, characterization and anti-microbial studies of some novel 2,4-disubstituted thiazoles.
AID573359Antibacterial activity against ceftazidime-susceptible Klebsiella pneumoniae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1698701Antibacterial activity against Prevotella melaninogenica JCM6325 by CLSI method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID716934Antibacterial activity against Escherichia coli C600 N/puc19 after 24 hrs by CLSI broth microdilution method2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Design and synthesis of 2-aminothiazole based antimicrobials targeting MRSA.
AID520776Antibacterial activity against beta-lactamase KPC-2 producing Serratia marcescens isolate S1 to S21 by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID573336Antibacterial activity against ceftazidime-susceptible Enterobacteriaceae assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID544967Antimicrobial activity against Proteus mirabilis expressing beta-lactamase AmpC by Etest2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID558603Antimicrobial activity against Streptococcus pneumoniae isolate 37 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID573366Antibacterial activity against ceftazidime-susceptible Morganella morganii assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID533874Antibacterial activity against penicillin-nonsusceptible Streptococcus pneumoniae isolate by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID545825Antimicrobial activity against Enterococcus faecalis by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID369633Antimicrobial activity against beta-lactamase positive amoxicillin/clavulanate-resistant Haemophilus influenzae by E-test2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID524215Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP2B by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID681569TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT4-expressing S2 cells2002European journal of pharmacology, Mar-08, Volume: 438, Issue:3
Interaction of human organic anion transporters with various cephalosporin antibiotics.
AID1356826Antimicrobial activity against Klebsiella pneumoniae NCTC 13438 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID542585Antimicrobial activity against plasmid encoded beta-lactamase OXA-58 deficient Acinetobacter radioresistens by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.
AID567457Antimicrobial activity against Salmonella enterica serovar Typhi isolate 080049Ty by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Plasmid-mediated resistance to cephalosporins in Salmonella enterica serovar Typhi.
AID575077Antimicrobial activity against Streptococcus pneumoniae serotype 3 assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID285508Antibacterial activity against Streptococcus pneumoniae by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID528831Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID565167Antimicrobial activity against Streptococcus pneumoniae ATCC 6306 assessed as post antibiotic effect at 10 times MIC after 2 hr by plate counting method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Postantibiotic effect of ceftaroline against gram-positive organisms.
AID565815Antimicrobial activity against Neisseria gonorrhoeae assessed as resistant isolates by CLSI method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID573123Antibacterial activity against coagulase-negative and oxacillin-resistant Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1880855Antimicrobial activity against wild type Neisseria gonorrhoeae V strain harbouring type 2 topoisomerase GyrA S91F, D95G and ParC S87R mutant incubated for 20 to 24 hrs by CLSI protocol based broth microdilution method2022ACS medicinal chemistry letters, Jun-09, Volume: 13, Issue:6
1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum.
AID324848Antimicrobial activity against Neisseria gonorrhoeae 90 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID544909Antimicrobial activity against Proteus mirabilis clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID524205Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP1B by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID584484Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN14 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID516143Antibacterial activity against Pulsotype B Acinetobacter genomosp. 3 isolate 8 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID279269Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81Y and ParC D83Y mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID534622Antimicrobial activity against Non-ESBL Escherichia coli by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID532899Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 ST 340 expressing beta-lactamase TEM-1 and SHV-11 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID422688Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 after 50 passages by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID330961Antimicrobial activity against wild type Escherichia coli by serial dilution method2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID557209Antibacterial activity against Beta-lactamase-negative Neisseria meningitidis assessed as percent susceptible isolates by Etest method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.
AID522206Antimicrobial activity against Clostridium celerecrescens under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID425975Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID584302Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus sciuri subsp. sciuri ATCC 29062T by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID575331Antimicrobial activity against Salmonella 4,5,12:i:- 08-2712 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID645033Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 6 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID522147Antimicrobial activity against Prevotella disiens under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID1501984Antibacterial activity against Klebsiella pneumoniae ATCC 700603 after 16 hrs by broth microdilution method2017Journal of natural products, 09-22, Volume: 80, Issue:9
Bioassay-Guided Isolation of Antibacterial Metabolites from Emericella sp. TJ29.
AID573149Antibacterial activity against vancomycin-susceptible Enterococcus faecalis by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID163919In vitro minimum inhibitory concentration required to produce antibacterial activity against Pseudomonas aeruginosa ATCC 278531996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID573125Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID586086Antimicrobial activity against verocytotoxin-producing Escherichia coli isolate O157 obtained from animals and food assessed as percentage of resistant isolates by disk diffusion method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26.
AID341619Effect on extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae P10045 infected in sc dosed CF1 mouse with high-density bacterial colonization administered daily for 9 days assessed as promotion of persistent bacterial overgrowth by measuring s2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
AID533876Antibacterial activity against amoxicillin-intermediate Streptococcus pneumoniae isolate by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID522207Antimicrobial activity against Clostridium difficile under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID425090Antimicrobial activity against Porphyromonas levii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID573128Antibacterial activity against penicillin-resistant Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID534927Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1576578Fraction absorbed of the compound by PAMPA2019MedChemComm, Dec-01, Volume: 10, Issue:12
Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.
AID520779Antibacterial activity against Escherichia coli EC600 by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID575083Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19F assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID575082Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19A assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID322519Antibacterial activity against Streptococcus pneumoniae ATCC 496192007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID562408Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae clinical isolates assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID571009Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 by serial dilution twofold broth microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID544678Antimicrobial activity against AmpC beta-lactamase-producing Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID1762804Antibacterial activity against against Escherichia coli 04 assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID285688Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA2404 isolate expressing carbapenemase KPC22007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID238858Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
AID558593Antimicrobial activity against Streptococcus pneumoniae 5 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1257070Antibacterial activity against methicillin-resistant Staphylococcus aureus XJ 75302 after 20 hrs by CLSI broth microdilution method2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Synthesis of biscoumarin and dihydropyran derivatives with promising antitumor and antibacterial activities.
AID496405Antimicrobial activity against Borrelia burgdorferi B312010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID524222Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP3 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID558622Antimicrobial activity against Streptococcus pneumoniae isolate 3374 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID520780Antibacterial activity against Escherichia coli EC600 transconjugant harboring beta-lactamase KPC-2 by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID322529Effect on Streptococcus pneumoniae infection induced elevation of MMP9 level in Wistar rat CSF assessed as MMP-9/MMP-2 index at 100 mg/kg, sc after 40 hrs by gel zymography2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID522146Antimicrobial activity against Prevotella denticola under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID534869Antimicrobial activity against ESBL producing Proteus mirabilis assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1356821Antimicrobial activity against Klebsiella pneumoniae ATCC 43816 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID543283Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 pbp2x, pbp1a, pbp2b and Streptococcus pneumoniae 3191 murM genes by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID531582Antibacterial activity against Enterobacter amnigenus obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID558617Antimicrobial activity against Streptococcus pneumoniae isolate 3260 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID534527Antimicrobial activity against Micrococcus luteus KCTC 9341 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID584483Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN13 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID325449Antibacterial activity against Staphylococcus aureus ATCC 3556 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID425984Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 by NCCLS M7-A7 method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID544912Antimicrobial activity against Proteus vulgaris clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID573386Antibacterial activity against beta lactamase-positive Moraxella catarrhalis assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID369988Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 5 mutant NG-MAST sequence type 1688 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID528920Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-14 and CTX-M-27 and other bla gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID422666Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 35 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID574951Antimicrobial activity against Streptococcus pneumoniae serotype 7F by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID545452Antimicrobial activity against extended-spectrum beta-lactamase-positive Proteus mirabilis assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID560050Antibacterial activity against Neisseria gonorrhoeae isolate SM3 expressing SF-A mosaic penA allele by agar dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.
AID487486Antibacterial activity against Escherichia coli after 16 hrs by serial dilution method2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Novel chromeno [2,3-b]-pyrimidine derivatives as potential anti-microbial agents.
AID425112Antimicrobial activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID528791Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 and other bla gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID534880Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID543276Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 pbp2x and pbp2b genes by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID522179Antimicrobial activity against Actinomyces turicensis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID529575Activity of Erwinia carotovora subsp. atroseptica DSM 30184 beta-lactamase CAR-12008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID322324Antibacterial activity against Escherichia coli INSRA5924 isolates expressing CTX-M-32 and TEM-1B enzymes by agar dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID531580Antibacterial activity against Citrobacter braakii obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID342097Increase in toxin level in nonepidemic Clostridium difficile J29 infected CF1 mouse at 1.4 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID511281Antimicrobial activity against Klebsiella pneumoniae clinical isolate assessed as resistance isolates by disk diffusion method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals.
AID533863Antibacterial activity against toxin-positive Clostridium difficile clinical isolate by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.
AID522166Antimicrobial activity against Anaerococcus lactolyticus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID1698705Antibacterial activity against genotype penicillin-resistant Streptococcus pneumoniae by CLSI method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID531586Antibacterial activity against Morganella morganii obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID324841Antimicrobial activity against Neisseria gonorrhoeae 30 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID528837Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1546169Antimicrobial activity against Proteus mirabilis2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID342092Increase in toxin level in nonepidemic Clostridium difficile ATCC 9689 infected in CF1 mouse at 2 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID534610Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID522205Antimicrobial activity against Clostridium cadaveris under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID543279Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 pbp2x, pbp1a and pbp2b genes by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID645034Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 24 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID518824Antibacterial activity against Pulsotype L Acinetobacter genomosp. 3 isolate 2 containing IMP-8, OXA-58, ADC-43, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID405641Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 1b2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID522184Antimicrobial activity against Colinsella aerofaciens under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID547528Antimicrobial activity against Streptococcus intermedius obtained from patient with cystic fibrosis assessed as non-susceptible isolates grown on mueller-Hinton blood agar at 30 ug/ml after 24 hrs at 37 degC by disk diffusion method in presence of 5% defr2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.
AID546245Ratio of MIC for Staphylococcus aureus ATCC 29213 grown in CAMHB medium in presence of 95% human serum to MIC for Staphylococcus aureus ATCC 29213 in presence of 95% human serum ultrafiltrate2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID342019Antibacterial activity against plasmid pK29 transconjugant Escherichia coli J53 by Etest2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
AID324837Antimicrobial activity against Neisseria gonorrhoeae 201 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID528846Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID323690Antibacterial activity against TEM92 ESBL-producing Acinetobacter baumannii by CLSI method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.
AID557208Antibacterial activity against Beta-lactamase-negative Neisseria meningitidis by Etest method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.
AID43757Rate of hydrolysis in 0.1 M sodium phosphate buffer at pH=7.0 by Beta lactamase (TEM-3)1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID528848Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID524035Antibacterial activity against penicillin-resistant Streptococcus pneumoniae 3413 by macrodilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID406622Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae isolates assessed as percent susceptible isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
AID342242Increase in toxin level in epidemic Clostridium difficile BI6-8-17 infected CF1 mouse at 1.4 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID548534Antimicrobial activity against viridans group Streptococcus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID546062Antimicrobial activity against beta-lactamase-negative Haemophilus influenzae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID681377TP_TRANSPORTER: inhibition of PAH uptake in OAT1-expressing S2 cells2002European journal of pharmacology, Mar-08, Volume: 438, Issue:3
Interaction of human organic anion transporters with various cephalosporin antibiotics.
AID322527Effect on Streptococcus pneumoniae infection induced elevation of MMP9 level in Wistar rat CSF assessed as MMP-9/MMP-2 index at 100 mg/kg, sc after 20 hrs by gel zymography2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID524065Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP3 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID546054Antimicrobial activity against Serratia marcescens by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID548256Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID1062034Bactericidal activity against multidrug-resistant Pseudomonas aeruginosa PAO1 after 24 hrs by CFU counting assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID534602Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1062040Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by broth microdilution method2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID342066Antimicrobial activity against fluoroquinolone-resistant epidemic Clostridium difficile NAP1 by broth dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID541504Antimicrobial activity against beta-lactamase-producing Haemophilus influenzae clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID522392Ratio of Kcat Km for Aeromonas enteropelogenes Beta-lactamase TRU12010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID425076Antimicrobial activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID573138Antibacterial activity against erythromycin-susceptible Streptococcus agalactiae by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1880853Antimicrobial activity against wild type Neisseria gonorrhoeae O strain incubated for 20 to 24 hrs by CLSI protocol based broth microdilution method2022ACS medicinal chemistry letters, Jun-09, Volume: 13, Issue:6
1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID524203Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP1B by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID516140Antibacterial activity against Pulsotype M Acinetobacter genomosp. 3 isolate 5 containing IMP-1, OXA-58, ADC-43, ISAba2, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID330965Antimicrobial activity against ampD deficient Escherichia coli by serial dilution method2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID575319Antimicrobial activity against Salmonella Llandoff 06CEB6542SAL by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID528784Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID561249Antibacterial activity against Streptococcus pneumoniae by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID528973Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID533866Antibacterial activity against toxin-positive Clostridium difficile clinical isolate assessed as percent of susceptible isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.
AID573132Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID544915Antimicrobial activity against Providencia rettgeri clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID342088Effect on growth of nonepidemic Clostridium difficile ATCC 9689 in CF1 mouse assessed as increase in bacterial density in cecal content at 1.4 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID522196Antimicrobial activity against Clostridium inoculum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID544903Antimicrobial activity against Serratia marcescens clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID546240Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 95% dog serum2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID509869Antibacterial activity against Acinetobacter baumannii isolate 4860 isolated from human urine2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID342067Antimicrobial activity against fluoroquinolone-susceptible nonepidemic Clostridium difficile strain6 by broth dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID562608Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae clinical isolates assessed as resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID571013Bactericidal activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 at 8 times MIC after 24 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID573341Antibacterial activity against ceftazidime-susceptible Citrobacter freundii assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID532904Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID534651Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID522209Antimicrobial activity against Clostridium hylemonae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID405639Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID544966Antimicrobial activity against Proteus mirabilis expressing extended-spectrum beta-lactamase by Etest based on multiple determinants2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID425085Antimicrobial activity against beta lactamase-positive Prevotella denticola isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID534627Antimicrobial activity against Non-ESBL Escherichia coli assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID588116Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring PBP1 L421P mutant gene, PBP2 XXXVII pattern, deletion of nucleotide A from mtrA promoter, MtrR G45D mutant MAST 299 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID322323Antibacterial activity against Escherichia coli DH5 alpha-URA5905 isolates expressing CTX-M-15 and TEM-1B enzymes by agar dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID521834Antibacterial activity against Klebsiella pneumoniae isolate VA367 with blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, blaSHV-12, aac(6')-1b genes by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID573339Antibacterial activity against ceftazidime-nonsusceptible Enterobacteriaceae assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID546056Antimicrobial activity against Salmonella spp. by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID645043Antibacterial activity against methicillin-resistant Staphylococcus aureus C530 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID528981Antimicrobial activity against Haemophilus influenzae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID373052Antimicrobial activity against Escherichia coli DH10B carrying pJIM2246 expressing Bacillus clausii NR beta-lactamase BCL1 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID534087Antibacterial activity against levofloxacin-resistant Streptococcus pneumoniae assessed as percent susceptible isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID528818Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID425104Antimicrobial activity against Clostridium ramosum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID522154Antimicrobial activity against Fusobacterium nucleatum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID535755Antimicrobial activity against community-acquired Escherichia coli obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID573134Antibacterial activity against erythromycin-nonsusceptible Streptococcus pyogenes by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID546053Antimicrobial activity against Proteus vulgaris by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID532893Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID548746Antimicrobial activity against viridans group Streptococcus assessed as percent susceptible isolate by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID544676Antimicrobial activity against Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID577203Antimicrobial activity against Escherichia coli O157:H7 PT-40 in logarithmic phase encoding Stx-2 gene by broth macrodilution assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Different classes of antibiotics differentially influence shiga toxin production.
AID1658984Antibacterial activity against Streptococcus pneumoniae ATCC 49619 assessed as reduction in pneumolysin release at 0.25 to 0.5 times MIC incubated for 16 to 20 hrs by Western blot analysis2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors.
AID534533Antimicrobial activity against Citrobacter freundii KCTC 2359 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID575099Antimicrobial activity against Streptococcus pneumoniae serotype 15A assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID545455Antimicrobial activity against Pseudomonas aeruginosa assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID544532Antimicrobial activity against Borrelia clinical isolate after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID560049Antibacterial activity against Neisseria gonorrhoeae isolate SM2 expressing SF-A mosaic penA allele by agar dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.
AID528783Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID1062035Bactericidal activity against multidrug-resistant Stenotrophomonas maltophilia D457R after 24 hrs by CFU counting assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID573388Antibacterial activity against Pasteurella multocida by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID508549Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in therapeutic C57BL/6 mouse model assessed as bacterial count in lung at 20 mg/kg, ip measured after 3 days post infection2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID342018Antibacterial activity against Klebsiella pneumoniae NK29 by Etest2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
AID529899Antimicrobial activity against Leptospira weilii isolate 8 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID558587Antimicrobial activity against Streptococcus pneumoniae 19A by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID573113Antibacterial activity against methicillin-susceptible Staphylococcus aureus by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID522163Antimicrobial activity against Peptoniphilus asaccharolyticus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1335633Antibacterial activity against Escherichia coli NIHJ JC-2 after 20 hrs by agar dilution method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID573343Antibacterial activity against ceftazidime-nonsusceptible Citrobacter freundii by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID522132Antimicrobial activity against Bacteroides thetaiotaomicron under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID285338Antimicrobial activity against streptomycin-resistant Escherichia coli J53 transconjugant with qnrA1 producing urinary specimen isolate 13.52 by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
AID342093Increase in toxin level in nonepidemic Clostridium difficile J29 infected CF1 mouse at 2 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID394493Antimicrobial activity against Escherichia coli MC4100 harboring pA-acc1 plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID525538Toxicity in against Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as increase in CSF IL-18 concentration at 100 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs by microsphere-based multiplex as2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID573338Antibacterial activity against ceftazidime-nonsusceptible Enterobacteriaceae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID508552Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in therapeutic C57BL/6 mouse model assessed as reduction of bacteremia at 20 mg/kg, ip measured after 4 days post infection2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID1546879Antibacterial activity against Klebsiella pneumoniae ATCC BAA2146 assessed as reduction in microbial growth after 16 hrs by broth microdilution method2020Journal of natural products, 01-24, Volume: 83, Issue:1
Reisolation and Configurational Reinvestigation of Cottoquinazolines E-G from an Arthropod-Derived Strain of the Fungus
AID529894Antimicrobial activity against Leptospira interrogans serovar Grippotyphosa isolate 2 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID1257071Antibacterial activity against methicillin-resistant Staphylococcus aureus Mu50 ATCC 700699 after 20 hrs by CLSI broth microdilution method2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Synthesis of biscoumarin and dihydropyran derivatives with promising antitumor and antibacterial activities.
AID558609Antimicrobial activity against Streptococcus pneumoniae isolate 1397 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID660261Ratio of MIC for wild type Escherichia coli JC7623 to MIC for acrAB-deficient Escherichia coli JZM1202012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID521352Antimicrobial activity against Streptococcus pneumoniae ATCC BAA-6122008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID586079Antimicrobial activity against multidrug-resistant Neisseria gonorrhoeae isolates harboring mosaic penicillin-binding protein 2 penA by Etest2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Characteristics and dissemination of mosaic penicillin-binding protein 2-harboring multidrug-resistant Neisseria gonorrhoeae isolates with reduced cephalosporin susceptibility in northern Taiwan.
AID369446Antimicrobial activity against Streptococcus group A after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID405797Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID206460In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Staphylococcus aureus (3849)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID511390Antibacterial activity against Proteus mirabilis by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID279258Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID394494Antimicrobial activity against Escherichia coli MC4100 harboring pACYC184 plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID522204Antimicrobial activity against Clostridium butyricum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID544951Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase CTX by Etest based on multiple determinants2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID574950Antimicrobial activity against Streptococcus pneumoniae serotype 35B by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID1211816Drug excretion in iv dosed human assessed as compound excreted into bile after 6 to 8 hrs by duodenal perfusion method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID573115Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID524573Antimicrobial activity against Shigella isolate DH-26336 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID534920Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID588119Antimicrobial activity against Neisseria gonorrhoeae clinical isolates after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID285523Antibacterial activity against Moraxella catarrhalis after 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID524568Antimicrobial activity against Shigella sonnei isolate AM22451 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID548745Antimicrobial activity against Beta-hemolytic Streptococcus assessed as percent susceptible isolate by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID559578Antimicrobial activity against Waddlia chondrophila ATCC VR-1470 infected in Vero cells2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.
AID573391Antibacterial activity against ceftazidime-susceptible Providencia sp. by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID531535Antibacterial activity against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Extended-spectrum beta-lactamase production is associated with an increase in cell invasion and expression of fimbrial adhesins in Klebsiella pneumoniae.
AID285522Antibacterial activity against Haemophilus influenzae after 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID573360Antibacterial activity against ceftazidime-susceptible Klebsiella pneumoniae assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID524052Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP2 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID210363In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Streptococcus pneumoniae (4630)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID558813Antimicrobial activity against Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID322317Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID522212Antimicrobial activity against Clostridium sphenoides under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID528842Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID534603Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID544924Antimicrobial activity against Acinetobacter baumannii clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID522197Antimicrobial activity against Clostridium clostridioforme under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID573353Antibacterial activity against ceftazidime-susceptible Escherichia coli assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID264471Antibacterial activity against methicillin-resistant Staphylococcus aureus2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.
AID571002Protein binding in pooled human plasma by microdialysis2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID530840Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 5 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID565813Antimicrobial activity against Neisseria gonorrhoeae assessed as susceptible isolates by CLSI method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID425081Antimicrobial activity against beta lactamase-positive Prevotella disiens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID586046Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type 2 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID1335630Antibacterial activity against beta-lactamase non-producing penicillin-resistant Haemophilus influenzae SR11435 after 20 hrs by agar dilution method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID1762801Antibacterial activity against vancomycin-resistant Enterococcus faecium assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID1698698Antibacterial activity against Clostridioides difficile ATCC 700057 by CLSI method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID529896Antimicrobial activity against Leptospira interrogans serovar Pomona isolate 4 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID528980Antimicrobial activity against Haemophilus influenzae assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID545847Antimicrobial activity against Proteus rettgeri by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID360051Inhibition of Enterococcus faecium LD-transpeptidase assessed by formation of Ac2-L-Lys-D-[14C]Ala from Ac2-L-Lys-D-Ala and D-[14C]Ala2007The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42
Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID543275Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2x and pbp1a genes by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID561384Antibacterial activity against Escherichia coli isolate ARL05-909 harboring beta-lactamase CMY 29 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID1335629Antibacterial activity against penicillin-resistant Streptococcus pneumoniae SR16750 after 20 hrs by agar dilution method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID264468Antibacterial activity against Streptococcus pyogenes2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.
AID547529Antimicrobial activity against Streptococcus intermedius obtained from patient with cystic fibrosis assessed as non-susceptible isolates grown on brain heart infusion agar at 30 ug/ml after 24 hrs at 37 degC by disk diffusion method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.
AID522190Antimicrobial activity against Slackia exigua under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID521836Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA367 containing blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, aac(6')-1b genes by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID405803Inhibition of bocillin FL binding to penicillin-susceptible Streptococcus pneumoniae OC 8865 penicillin-binding protein 1b2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID524067Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP4 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID534609Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID534534Antimicrobial activity against Salmonella enterica KCTC 2930 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID522131Antimicrobial activity against Bacteroides fragilis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID524051Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP2 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID543262Antimicrobial activity against Streptococcus pneumoniae R6 by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID547516Antimicrobial activity against Streptococcus anginosus obtained from patient with cystic fibrosis assessed as non-susceptible isolates grown on mueller-Hinton blood agar at 30 ug/ml after 24 hrs at 37 degC by disk diffusion method in presence of 5% defrib2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.
AID511303Antibacterial activity against ciprofloxacin susceptible and methicillin resistant Staphylococcus aureus by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID405811Inhibition of bocillin FL binding to penicillin-resistant Streptococcus pneumoniae OC 8819 penicillin-binding protein 2x2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID405812Inhibition of bocillin FL binding to penicillin-resistant Streptococcus pneumoniae OC 8819 penicillin-binding protein 2a2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID1546170Antimicrobial activity against Rhodococcus equi2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID545425Antimicrobial activity against Enterobacter aerogenes obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID422649Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 by NCCLS M7-A7 method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID535760Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 00-027 expressing beta-lactamase TEM-1, MLST type ST-1921 and MAST type ST-1817 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID285510Antibacterial activity against Acinetobacter baumannii after 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID575081Antimicrobial activity against Streptococcus pneumoniae serotype 6C assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID1428627Antimycobacterial activity against Mycobacterium smegmatis MC2 155 after 3 days by broth macrodilution method2017European journal of medicinal chemistry, Feb-15, Volume: 127Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
AID522208Antimicrobial activity against Clostridium glycolicum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID548472Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID535756Antimicrobial activity against hospital-acquired Escherichia coli obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID544961Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase CTX by Etest based on single determinant2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID521425Antibacterial activity against Stenotrophomonas maltophilia isolate KJ by Etest2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID524058Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP2a by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID511399Antibacterial activity against Haemophilus influenzae by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID535757Antimicrobial activity against community-acquired Escherichia coli expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID524436Antimicrobial activity against Shigella flexneri isolate AM19035 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID684434Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method in presence of 1% pulmonary surfactant2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Reduced pulmonary surfactant interaction of daptomycin analogs via tryptophan replacement with alternative amino acids.
AID545823Antimicrobial activity against methicillin-resistant coagulase-negative Staphylococcus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID574948Antimicrobial activity against Streptococcus pneumoniae serotype 19A by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID529895Antimicrobial activity against Leptospira interrogans serovar Icterohaemorrhagiae isolate 3 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID522159Antimicrobial activity against Anaerococcus prevotii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522202Antimicrobial activity against Clostridium baratii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID543411Antimicrobial activity against Shigella sonnei UIH-1 expressing beta-lactamase CTX-M-64 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID511302Antibacterial activity against methicillin susceptible Staphylococcus aureus by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID534632Antimicrobial activity against ESBL producing Escherichia coli assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID574949Antimicrobial activity against Streptococcus pneumoniae serotype 3 by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID545826Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID373051Antimicrobial activity against Bacillus clausii ATCC 21537 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID544681Antimicrobial activity against AmpC beta-lactamase-producing Enterobacter cloacae clinical isolate after 18 to 22 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID545661Antimicrobial activity against Enterobacteriaceae Extended-Spectrum beta-lactamase positive assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID582965Antimicrobial activity against Yersinia enterocolitica Biovar 1B 8081 after 20 hrs by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Contribution of BlaA and BlaB beta-lactamases to antibiotic susceptibility of Yersinia enterocolitica biovar 1B.
AID660265Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID577454Inhibition of Streptococcus pneumoniae isolate 8882 Bocillin FL binding to PBP2b 443SSNA mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.
AID558601Antimicrobial activity against Streptococcus pneumoniae isolate 24 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID563521Antibacterial activity against Pseudomonas aeruginosa NY217 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID1356829Antimicrobial activity against Klebsiella pneumoniae ATCC BAA-2472 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID522172Antimicrobial activity against Gemella sanguinis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID394492Antimicrobial activity against Escherichia coli MC4100 harboring pA-acc4 plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID370000Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 11 mutant NG-MAST sequence type 1420 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID543820Antimicrobial activity against Borrelia spielmanii isolate PMew after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID522177Antimicrobial activity against Actinomyces neuii subsp. anitratus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID69824Tested for the minimum inhibitory concentration against Escherichia coli 1852E + 3 ug/mL PMBN2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin.
AID544523Antimicrobial activity against Borrelia afzelii isolate G600 after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID543823Antimicrobial activity against Borrelia spielmanii isolate PHap after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID511304Antibacterial activity against ciprofloxacin and methicillin resistant Staphylococcus aureus by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID528729Antibacterial activity against multidrug-resistant Streptococcus pneumoniae clinical isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID546236Protein binding in dog serum by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID524071Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP4 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID330966Antimicrobial activity against ampD deficient Escherichia coli in medium containing EtbuPUG by serial dilution method2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID520775Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K1 to K9 by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID511393Antibacterial activity against Levofloxacin resistant Streptococcus pneumoniae by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID533875Antibacterial activity against penicillin-nonsusceptible Streptococcus pneumoniae assessed as percent susceptible isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID405637Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 52007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID405810Inhibition of bocillin FL binding to penicillin-resistant Streptococcus pneumoniae OC 8819 penicillin-binding protein 1b2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID535761Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 04-025 expressing beta-lactamase TEM-135, MLST type ST-1597 and MAST type ST-1549 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID524061Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP3 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID318648Antibacterial activity against Staphylococcus epidermidis ATCC 12228 by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID487482Antibacterial activity against Staphylococcus aureus after 16 hrs by serial dilution method2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Novel chromeno [2,3-b]-pyrimidine derivatives as potential anti-microbial agents.
AID425102Antimicrobial activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID529901Antimicrobial activity against Leptospira interrogans serovar Icterohaemorrhagiae isolate 10 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID547540Antimicrobial activity against invasive Streptococcus constellatus obtained from non-cystic fibrosis patient assessed as non-susceptible isolates grown on mueller-Hinton blood agar at 30 ug/ml after 24 hrs at 37 degC by disk diffusion method in presence o2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.
AID425115Antimicrobial activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID534531Antimicrobial activity against Escherichia coli KCTC 1039 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID545832Antimicrobial activity against levofloxacin-resistant Streptococcus pneumoniae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID511396Antibacterial activity against Streptococcus viridans by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID360078Inhibition of Enterococcus faecium LD-transpeptidase assessed by formation of Ac2-L-Lys-D-[14C]Ala from Ac2-L-Lys-D-Ala and D-[14C]Ala at 0.5 ug/ml2007The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42
Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID544955Antimicrobial activity against Klebsiella pneumoniae extended-spectrum beta-lactamase producing isolate by Etest2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID1062031Bactericidal activity against methicillin-resistant Staphylococcus aureus BW61 after 24 hrs by CFU counting assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID534631Antimicrobial activity against ESBL producing Escherichia coli assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID279265Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3243 after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID524057Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP2a by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID278092Drug level in mouse stool after 3 days2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID525540Toxicity in Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as decrease in CSF IL-10 concentration at 100 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs by microsphere-based multiplex assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID574425Antimicrobial activity against Escherichia coli isolate 339 expressing beta-lactamase KPC2, TEM and PFGE cluster 5 isolated from peritoneal fluid of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID342087Effect on growth of epidemic Clostridium difficile BI6-8-17 in CF1 mouse assessed as increase in bacterial density in cecal content at 2 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID520777Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K10 by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID540945Antimicrobial activity against Escherichia coli DH5[alpha] transformant harboring pH205 plasmid expressing cephalosporinase CMY-36 by agar dilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID534889Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID370136Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 20 mutant NG-MAST sequence type 211 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID279270Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 24 with GyrA S81Y, GyrB P413S and ParC S79F mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID584468Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus vitulinus SVMP04 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID528836Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID549336Antimicrobial activity against Escherichia coli isolate 49 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID573352Antibacterial activity against ceftazidime-susceptible Escherichia coli by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID519638Antimicrobial activity against ceftazidime-resistant Escherichia coli Irk2320 harboring beta-lactamase CTX-M-42 Pro167Thr mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID575079Antimicrobial activity against Streptococcus pneumoniae serotype 7F assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID207361In vitro minimum inhibitory concentration required to produce antibacterial activity against Staphylococcus aureus 743 MRSA1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID584305Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus vitulinus SVMP02 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID524063Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP3 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID519744Antibacterial activity against Klebsiella pneumoniae INSRA1229 harboring SHV-72 Ile8Phe, Ala146Val, and Lys234Arg mutations by agar dilution method in presence of 2 ug/ml clavulanic acid2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID511288Antibacterial activity against Escherichia coli DH5alpha pB-ges-13 plasmid2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID524218Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP2B by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID567459Antimicrobial activity against Escherichia coli W3110 transformant harboring bla CTX-M-15 gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Plasmid-mediated resistance to cephalosporins in Salmonella enterica serovar Typhi.
AID511392Antibacterial activity against Levofloxacin susceptible Streptococcus pneumoniae by broth dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID562357Antimicrobial activity against Streptococcus pneumoniae clinical isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID681115TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in Caco-2 cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID524435Antimicrobial activity against Shigella isolate DH-13291 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID1335634Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae SR16605 infected in sc dosed mouse assessed as protection against bacterial infection by measuring increase in mouse survival administered 1 and 5 hrs post infection measured a2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID370135Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 18 mutant NG-MAST sequence type 1621 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID1902630Antibacterial activity against Methicillin-drug resistant Staphylococcus aureus C0621 incubated for 18 hrs by by disc diffusion method2022ACS medicinal chemistry letters, Feb-10, Volume: 13, Issue:2
Antibacterial Activity of Metergoline Analogues: Revisiting the Ergot Alkaloid Scaffold for Antibiotic Discovery.
AID584470Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus vitulinus SVMP06 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID549334Antimicrobial activity against Escherichia coli isolate 100 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID565504Antimicrobial activity against beta-lactamase negative ampicillin-resistant -Haemophilus influenzae by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re
AID322314Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID565666Antimicrobial activity against beta-lactamase positive (amoxicillin)clavulanate-resistant Haemophilus influenzae by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re
AID206194Tested for the minimum inhibitory concentration against Staphylococcus aureus 853E2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin.
AID425084Antimicrobial activity against beta lactamase-positive Prevotella melaninogenica isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID524049Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP1 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID571028Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 63032008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID584292Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP02 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID519138Antimicrobial activity against community-acquired methicillin resistant Staphylococcus aureus expressing PVL and mec type IV gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID586049Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type U6 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID369999Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 10 mutant NG-MAST sequence type 925 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID521840Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA375 containing qnrA1, blaTEM-1, blaSHV-11genes by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID279816Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID584471Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN01 (ATCC 51145T) by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID285513Antibacterial activity against Klebsiella pneumoniae2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID370133Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 17 mutant NG-MAST sequence type 1620 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID370125Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 13 mutant NG-MAST sequence type 1409 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID522201Antimicrobial activity against Clostridium hathewayi under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID543827Antimicrobial activity against Borrelia spielmanii A14S after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID528835Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID521345Antimicrobial activity against Streptococcus pneumoniae isolate k-637 obtained from CSF of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID558612Antimicrobial activity against Streptococcus pneumoniae isolate 2617 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID544964Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase DHA by Etest2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID545434Antimicrobial activity against extended-spectrum beta-lactamase-positive Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID544962Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV and CTX by Etest2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID522183Antimicrobial activity against Atopobium parvulum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID528850Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID558624Antimicrobial activity against Streptococcus pneumoniae isolate 3455 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID360050Antimicrobial activity against Enterococcus faecium M512 by agar dilution method after 48 hrs2007The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42
Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID496416Reduction in ospA gene expression in heart base tissue of SCID mouse transplanted with tibiotarsal and heart base tissue from Borrelia burgdorferi infected 12.5 mg/kg treated mouse2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
AID1356835Antimicrobial activity against Escherichia coli ATCC BAA-2469 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID318647Antibacterial activity against methicillin-resistant Staphylococcus aureus KMP9 clinical isolate by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID571030Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 in presence of human serum albumin2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID534867Antimicrobial activity against ESBL producing Proteus mirabilis assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID524214Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP2A by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID535762Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 05-042 expressing beta-lactamase TEM-1, MLST type ST-1588 and MAST type ST-4012 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID573120Antibacterial activity against coagulase-negative and oxacillin-susceptible Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID522215Antimicrobial activity against Clostridium tertium under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID585877Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type 4 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID528844Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID575078Antimicrobial activity against Streptococcus pneumoniae serotype 35B assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID405805Inhibition of bocillin FL binding to penicillin-susceptible Streptococcus pneumoniae OC 8865 penicillin-binding protein 2a2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID540949Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBCSK plasmid by agar dilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID324838Antimicrobial activity against Neisseria gonorrhoeae 253 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID533880Antibacterial activity against cefotaxime-intermediate Streptococcus pneumoniae isolate by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID278095Overgrowth of Klebsiella pneumonia growth in mouse intestine assessed in stool 2 days after 5 day treatment relative to saline2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID425116Antimicrobial activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID519140Antimicrobial activity against community-acquired methicillin resistant Staphylococcus aureus expressing PVL and mec type IV gene assessed as resistant strains by broth microdilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID43754Rate of hydrolysis in 0.1 M sodium phosphate buffer at pH=7.0 by Beta lactamase (Proteus vulgaris 1028)1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID535753Antimicrobial activity against community-acquired Klebsiella pneumoniae expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID341597Antibacterial activity against sEscherichia coli GeneHogs harboring blaKPC-encoding plasmids2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID422683Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 by NCCLS M7-A7 method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID369986Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 4 mutant NG-MAST sequence type 327 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID544525Antimicrobial activity against Borrelia garinii isolate PSth after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID522161Antimicrobial activity against Finegoldia magna under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID528709Antibacterial activity against penicillin resistant Streptococcus pneumoniae clinical isolate assessed as susceptibility level by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID524216Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP2B by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID545835Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID524396Antibacterial activity against methicillin-susceptible beta-lactamase negative Staphylococcus aureus using 5x10'5 CFU/ml standard inoculum after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus.
AID573376Antibacterial activity against imipenem-susceptible Acinetobacter by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID558615Antimicrobial activity against Streptococcus pneumoniae isolate 2874 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID279254Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81Y and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID555684Antimicrobial activity against Escherichia coli DH10B by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID528828Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID588106Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB A121S mutant gene, PBP1 L421P mutant gene, PBP2 XXXVIII pattern, deletion of nucleotide A from mtrA promoter, MAST 3116 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID522195Antimicrobial activity against Clostridium ramosum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID584469Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus vitulinus SVMP05 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID544522Antimicrobial activity against Borrelia afzelii isolate FEM1 after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID573389Antibacterial activity against Pasteurella multocida assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID528978Antimicrobial activity against methicillin-susceptible Staphylococcus aureus assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID425114Antimicrobial activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID558610Antimicrobial activity against Streptococcus pneumoniae isolate 1424 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID561629Antimicrobial activity against ampD2-deficient Stenotrophomonas maltophilia KJ by twofold serial agar dilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID1257069Antibacterial activity against Staphylococcus aureus ATCC 29213 after 20 hrs by CLSI broth microdilution method2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Synthesis of biscoumarin and dihydropyran derivatives with promising antitumor and antibacterial activities.
AID425979Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 49 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID20050Human absorption A (%)1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
AID524398Antibacterial activity against methicillin-susceptible beta-lactamase negative Staphylococcus aureus using 5x10'7 CFU/ml high inoculum after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus.
AID573345Antibacterial activity against ceftazidime-nonsusceptible Citrobacter freundii assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID522171Antimicrobial activity against Gemella morbillorum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID544524Antimicrobial activity against Borrelia afzelii isolate G1039 after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID524571Antimicrobial activity against Shigella isolate DH-22855 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID524206Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP1B by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID210364In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Streptococcus pneumoniae (4635)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID394497Antimicrobial activity against Escherichia coli MC4100 harboring pBCSK plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID645041Antibacterial activity against Staphylococcus aureus ATCC 43300 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID425082Antimicrobial activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID425089Antimicrobial activity against Porphyromonas gingivalis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID422671Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 50 passages by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID528701Antibacterial activity against Streptococcus viridans clinical isolate assessed as susceptibility level by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID341594Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 469 transformants producing KPC2, OXA4 and CTX-M-10 carbapenemases2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID318653Antibacterial activity against vancomycin-susceptible Enterococcus faecium ATCC 19434 by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID534647Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID534607Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID584301Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus sciuri subsp. carnaticus ATCC 700058T by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID522157Antimicrobial activity against Fusobacterium varium under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID534864Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID528826Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID342084Effect on growth of nonepidemic Clostridium difficile ATCC 9689 in CF1 mouse assessed as increase in bacterial density in cecal content at 2 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID67568In vitro minimum inhibitory concentration required to produce antibacterial activity against Enterococcus faecalis ATCC 292121996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID405640Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 22007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID573357Antibacterial activity against ceftazidime-nonsusceptible Escherichia coli assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID508550Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in therapeutic C57BL/6 mouse model assessed as bacterial count in blood at 20 mg/kg, ip measured after 3 days post infection2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID422665Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 by NCCLS M7-A7 method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID559696Antibacterial activity against Escherichia coli 3963 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
First report of plasmid-mediated quinolone resistance determinant qnrS1 in an Escherichia coli strain of animal origin in Italy.
AID1356831Antimicrobial activity against Klebsiella pneumoniae NCTC 13443 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID534906Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID279256Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81F and ParC D83N mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID528725Antibacterial activity against Streptococcus intermedius clinical isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID519737Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-1 by agar dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID561385Antibacterial activity against Escherichia coli isolate ARL06-39 harboring beta-lactamase CMY 30 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID342062Antimicrobial activity against nonepidemic Clostridium difficile ATCC 9689 by broth dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID324836Antimicrobial activity against Neisseria gonorrhoeae 188 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID370127Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 13 mutant NG-MAST sequence type 1624 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID558596Antimicrobial activity against Streptococcus pneumoniae 8 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1211872Total biliary clearance in Sprague-Dawley rat at 20 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID342244Increase in toxin level in nonepidemic Clostridium difficile J29 infected CF1 mouse at 0.2 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID522168Antimicrobial activity against Anaerococcus octavius under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID322518Antibacterial activity against Streptococcus pneumoniae serotype 32007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID533881Antibacterial activity against cefotaxime-intermediate Streptococcus pneumoniae assessed as percent susceptible isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID528969Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID369998Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 10 mutant NG-MAST sequence type 835 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID532908Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID528970Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID422673Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 18 passages with levofloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID524040Antibacterial activity against methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 by macrodilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID524209Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP2X by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID529900Antimicrobial activity against Leptospira interrogans serovar Icterohaemorrhagiae isolate 9 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID342091Effect on growth of epidemic Clostridium difficile BI6-8-17 in CF1 mouse assessed as increase in bacterial density in cecal content at 1.4 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID584297Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP07 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID405634Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 1a2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID405808Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae OC 8865 by CLSI method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID522203Antimicrobial activity against Clostridium bifermentans under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID645042Antibacterial activity against methicillin-resistant glycopeptide-intermediate Staphylococcus aureus Mu50 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID342094Increase in toxin level in epidemic Clostridium difficile BI9 infected CF1 mouse at 2 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID571021Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 assessed as growth rate constant2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID279814Antimicrobial activity against Escherichia coli DH5-alpha with pYW2 expressing KPC2 and TEM1 gene by agar dilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID525351Toxicity in Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as increase in CSF IL-18 concentration at 50 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs by microsphere-based multiplex assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID584304Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus vitulinus SVMP01 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID586040Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type 1 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID425092Antimicrobial activity against Fusobacterium necrophorum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID425967Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 by NCCLS M7-A7 method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID522155Antimicrobial activity against Fusobacterium necrophorum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID524050Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP2 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID575324Antimicrobial activity against Escherichia coli 07-819TC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID573371Antibacterial activity against ceftazidime-susceptible Serratia marcescens assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID207362In vitro minimum inhibitory concentration required to produce antibacterial activity against Staphylococcus aureus 887MSSA1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID318646Antibacterial activity against methicillin-resistant Staphylococcus aureus KT0116 clinical isolate by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID342065Antimicrobial activity against epidemic Clostridium difficile BI6-8-17 by broth dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID369997Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 10 mutant NG-MAST sequence type 326 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID528983Antimicrobial activity against Haemophilus influenzae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1356833Antimicrobial activity against Escherichia coli ATCC BAA-2340 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID322320Antibacterial activity against Escherichia coli INSRA5776 isolates expressing CTX-M-14 and TEM-1B enzymes by agar dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID370129Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 13 mutant NG-MAST sequence type 1148 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID521433Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L2 beta lactamase gene at 50 ug/ml2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID425113Antimicrobial activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID558786Antimicrobial activity against Citrobacter freundii assessed as percent susceptible isolates by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID509868Antibacterial activity against Acinetobacter baumannii isolate 2898 isolated from human ankle2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID555679Antimicrobial activity against Escherichia coli DH5[alpha] harboring phagemid pBK-CMV by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID66741Inhibitory concentration against purified beta-Lactam resistant PBP5 from Enterococcus durans1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID342098Increase in toxin level in epidemic Clostridium difficile BI9 infected CF1 mouse at 1.4 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID425985Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 20 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID522162Antimicrobial activity against Parvimonas micra under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID330964Antimicrobial activity against wild type EtbuPUG treated Escherichia coli transfected with pCF1 by serial dilution method2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID528976Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID422661Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 15 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID524068Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP4 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID1501983Antibacterial activity against Pseudomonas aeruginosa ATCC 15442 after 16 hrs by broth microdilution method2017Journal of natural products, 09-22, Volume: 80, Issue:9
Bioassay-Guided Isolation of Antibacterial Metabolites from Emericella sp. TJ29.
AID511280Antimicrobial activity against Escherichia coli isolate obtained from patient's blood assessed as resistance isolates by disk diffusion method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals.
AID519139Antimicrobial activity against community-acquired methicillin resistant Staphylococcus aureus expressing PVL gene and mec type IV gene assessed as susceptible strains by broth microdilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID342257Effect on growth of fluoroquinolone-susceptible epidemic Clostridium difficile ATCC 9689 in CF1 mouse assessed as increase in bacterial density in cecal content dosed sc for 5 days2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID549015Antimicrobial activity against viridans group Streptococcus assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
AID529582Ratio of Kcat to Km for Bradyrhizobium japonicum beta-Lactamase BJP-12008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID1335627Antibacterial activity against Staphylococcus aureus SMITH after 20 hrs by agar dilution method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID565670Antimicrobial activity against beta-lactamase positive (amoxicillin)clavulanate-resistant Haemophilus influenzae assessed as susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re
AID546239Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 95% dog serum ultrafiltrate2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID575317Antimicrobial activity against Salmonella Typhimurium 05-9280 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID534887Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID583431Antimicrobial activity against methicillin-resistant and tetracycline-sensitive Staphylococcus aureus COLn2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level β-lactam resistance contains mutations in three genes.
AID405795Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 12007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID324840Antimicrobial activity against Neisseria gonorrhoeae 196 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID534929Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID575329Antimicrobial activity against Salmonella Typhimurium 08-1745 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID509867Antibacterial activity against Acinetobacter baumannii isolate 2824 isolated from human urine2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID645045Antibacterial activity against Escherichia coli ATCC 25922 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID577207Antimicrobial activity against Escherichia coli C600::H19B in stationary phase encoding Stx-1 gene by broth macrodilution assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Different classes of antibiotics differentially influence shiga toxin production.
AID586038Antimicrobial activity against Staphylococcus aureus clone 1-1 harboring staphylococcal cassette chromosome mec element type U assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID546230Protein binding in mouse serum by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID394495Antimicrobial activity against Escherichia coli MC4100 harboring pB-acc4 plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID563523Antibacterial activity against Pseudomonas aeruginosa NY220 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID519643Antimicrobial activity against Escherichia coli EPI300 transformant harboring pCC1 by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID325448Antibacterial activity against Staphylococcus aureus Mu50 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID575101Antimicrobial activity against Streptococcus pneumoniae serotype 23B assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID325443Antibacterial activity against Escherichia coli K10 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID546484Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 95% human serum2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID516146Antibacterial activity against Pulsotype J Acinetobacter genomosp. 3 isolate 15 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID645035Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 47 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID546234Protein binding in human serum by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID524069Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP4 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID524199Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP1A by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID509866Antibacterial activity against Acinetobacter baumannii isolate 510 isolated from human sputum2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID577208Antimicrobial activity against Escherichia coli C600::H19B in logarithmic phase encoding Stx-1 gene by broth macrodilution assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Different classes of antibiotics differentially influence shiga toxin production.
AID530843Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 8 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID588111Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB G120K, A121D mutant gene, PBP1 L421P mutant gene, PBP2 XXXIV pattern, deletion of nucleotide A from mtrA promoter, MAST 225 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID681363TP_TRANSPORTER: inhibition of PAH uptake in OAT1-expressing S2 cells2002Life sciences, Mar-08, Volume: 70, Issue:16
Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1.
AID322539Effect on Streptococcus pneumoniae infection induced brain injury in Wistar rat hippocampal dentate gyrus assessed as number of apoptotic cells at 100 mg/kg, sc after 20 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID370131Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 13 mutant NG-MAST sequence type 1425 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID577457Antimicrobial activity against laboratory-derived Streptococcus pneumoniae isolate R6 by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.
AID524059Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP2a by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID573392Antibacterial activity against ceftazidime-susceptible Providencia sp. assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID584298Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP08 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID91060In vitro plasma protein binding was evaluated by using Human plasma at 20 ug/mL1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Discovery and structure-activity relationship of a series of 1-carba-1-dethiacephems exhibiting activity against methicillin-resistant Staphylococcus aureus.
AID422645Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID545431Antimicrobial activity against Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID285521Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID586042Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type U3 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID524198Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP4 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID342255Effect on growth of fluoroquinolone-resistant epidemic Clostridium difficile NAP1 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.2 mg/day, sc for 5 days2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID645037Antibacterial activity against erythromycin-sensitive Streptococcus pyogenes 9 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID405790Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID571011Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 by serial dilution twofold broth microdilution method in presence of 40 g/L human serum albumin2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID544957Antimicrobial activity against Escherichia coli expressing beta-lactamase SHV by Etest2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID422657Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 by NCCLS M7-A7 method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID681786TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Ceftriaxone: 2000 uM) in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, Aug, Volume: 290, Issue:2
The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1.
AID429062Antimicrobial activity against Proteus mirabilis JIE273 expressing 16S rRNA methyltransferase RmtC2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
RmtC 16S rRNA methyltransferase in Australia.
AID573137Antibacterial activity against erythromycin-susceptible Streptococcus agalactiae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID528703Antibacterial activity against Streptococcus oralis clinical isolate assessed as susceptibility level by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID571020Antimicrobial activity against Escherichia coli ATCC 25922 assessed as growth rate constant2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID547541Antimicrobial activity against invasive Streptococcus constellatus obtained from non-cystic fibrosis patient assessed as non-susceptible isolates grown on brain heart infusion agar at 30 ug/ml after 24 hrs at 37 degC by disk diffusion method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.
AID525353Toxicity in Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as increase in CSF MCP-1 concentration at 100 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs by microsphere-based multiplex assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID524048Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP1 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID558783Antimicrobial activity against Enterobacter aerogenes assessed as percent susceptible isolates by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID561250Antibacterial activity against Streptococcus pneumoniae assessed as susceptible isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID342090Effect on growth of epidemic Clostridium difficile BI9 in CF1 mouse assessed as increase in bacterial density in cecal content at 1.4 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID574433Antimicrobial activity against Escherichia coli isolate 543T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from synovial fluid of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID575323Antimicrobial activity against Salmonella London 07-819 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID342020Antibacterial activity against Escherichia coli J53 by Etest2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
AID565816Antimicrobial activity against Neisseria gonorrhoeae assessed as resistant isolates by EUCAST method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID422670Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 by NCCLS M7-A7 method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID369991Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 7 mutant NG-MAST sequence type 1422 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID322327Antimicrobial activity in Streptococcus pneumoniae WB4 infected New Zealand white rabbit meningitis model assessed as decrease in viable cells in CSF at 125 mg/kg after 8 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.
AID532907Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 ST 376 expressing beta-lactamase SHV-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID535727Antibacterial activity against Klebsiella pneumoniae urine isolate A28011 PFGE pattern A expressing KPC-2 CTX-M-2 beta-lactamase by agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID425106Antimicrobial activity against Clostridium clostridioforme isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID341593Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 469 isolate producing KPC2, OXA4 and CTX-M-10 carbapenemases2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID545446Antimicrobial activity against extended-spectrum beta-lactamase-negative Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID547522Antimicrobial activity against Streptococcus constellatus obtained from patient with cystic fibrosis assessed as non-susceptible isolates grown on mueller-Hinton blood agar at 30 ug/ml after 24 hrs at 37 degC by disk diffusion method in presence of 5% def2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.
AID521346Antimicrobial activity against Streptococcus pneumoniae isolate 2904 obtained from blood of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID560770Antibacterial activity against Neisseria gonorrhoeae isolate SW1 expressing nonmosaic penA allele by agar dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.
AID369995Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 10 mutant NG-MAST sequence type 1424 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID539910Antibacterial activity against Escherichia coli after 16 hrs by serial dilution method2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, characterization and anti-microbial studies of some novel 2,4-disubstituted thiazoles.
AID558590Antimicrobial activity against Streptococcus pneumoniae 2 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID546621Antimicrobial activity against Escherichia coli harboring plasmid pPCRScript by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID539908Antibacterial activity against Bacillus subtilis after 16 hrs by serial dilution method2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, characterization and anti-microbial studies of some novel 2,4-disubstituted thiazoles.
AID373054Antimicrobial activity against Escherichia coli BL21(DE3) carrying pET9a expressing Bacillus clausii beta-lactamase BCL1 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID560223Antibacterial activity against Salmonella enterica serovar Typhimurium R200 expressing Outer membrane protein STM3031 by CLSI M7-A7 agar dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID571024Plasma protein binding in healthy human 1t 1 g/kg, iv administered as single dose by LC-MS-MS method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID422651Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 26 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID558598Antimicrobial activity against Streptococcus pneumoniae 10 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID405799Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by CLSI method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID522150Antimicrobial activity against Prevotella oris under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID545440Antimicrobial activity against Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID561386Antibacterial activity against Escherichia coli isolate ARL04-413 harboring beta-lactamase CMY 2 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID534925Antimicrobial activity against Ceftazidime susceptible Serratia marcescens assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID528822Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID373053Antimicrobial activity against Escherichia coli DH10B by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID532894Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID528834Antimicrobial activity against CTX-M ESBL producing Escherichia coli assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1210069Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID524038Antibacterial activity against methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 by macrodilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID545658Antimicrobial activity against Acinetobacter sp. assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID285440Antimicrobial activity against Escherichia coli DH10B expressing GIL1 after 18 hrs by disk diffusion method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID524570Antimicrobial activity against Shigella sonnei isolate AM22855 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID540948Antimicrobial activity against Escherichia coli DH5[alpha] harboring pB-c2 plasmid expressing cephalosporinase CMY-2 by agar dilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID524043Antibacterial activity against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 by macrodilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID565814Antimicrobial activity against Neisseria gonorrhoeae assessed as susceptible isolates by EUCAST method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID582967Antimicrobial activity against beta-lactamase B-deficient Yersinia enterocolitica GY5542 after 20 hrs by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Contribution of BlaA and BlaB beta-lactamases to antibiotic susceptibility of Yersinia enterocolitica biovar 1B.
AID322325Antibacterial activity against Escherichia coli DH5 alpha-URA5924 isolates expressing CTX-M-32 by agar dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID1543198Antimicrobial activity against ESBL-producing Escherichia coli ATCC 35218 assessed as inhibition of microbial growth incubated for 16 hrs by broth microdilution method
AID543415Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 transconjugant by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID584476Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN06 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID577210Antimicrobial activity against Escherichia coli C600::933W in stationary phase encoding Stx-2 gene by broth macrodilution assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Different classes of antibiotics differentially influence shiga toxin production.
AID549333Antimicrobial activity against Escherichia coli isolate 36 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID206315Tested for the minimum inhibitory concentration against Staphylococcus aureus col2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin.
AID545437Antimicrobial activity against extended-spectrum beta-lactamase-negative Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID342095Increase in toxin level in epidemic Clostridium difficile BI6-8-17 infected CF1 mouse at 2 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID369994Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 10 mutant NG-MAST sequence type 1414 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID422675Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 25 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID577451Antimicrobial activity against penicillin intermediate resistant Streptococcus pneumoniae isolate 8009 harboring PBP2b 443SSNA mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID534908Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID561630Antimicrobial activity against ampD1-, ampD2-deficient Stenotrophomonas maltophilia KJ by twofold serial agar dilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID1698702Antibacterial activity against Porphyromonas gingivalis JCM8525 by CLSI method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID405809Inhibition of bocillin FL binding to penicillin-resistant Streptococcus pneumoniae OC 8819 penicillin-binding protein 1a2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID534649Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID547517Antimicrobial activity against Streptococcus anginosus obtained from patient with cystic fibrosis assessed as non-susceptible isolates grown on brain heart infusion agar at 30 ug/ml after 24 hrs at 37 degC by disk diffusion method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.
AID1762809Antibacterial activity against Carbapenem-resistant Pseudomonas aeruginosa assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID546480Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 95% rat serum2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID544960Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV by Etest based on multiple determinants2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID546619Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-18 by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID318645Antibacterial activity against methicillin-susceptible Staphylococcus aureus Smith by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID549331Antimicrobial activity against Escherichia coli isolate 32 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID534630Antimicrobial activity against ESBL producing Escherichia coli assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID543278Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2x and Streptococcus pneumoniae 72521 pbp2b genes by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID573121Antibacterial activity against coagulase-negative and oxacillin-susceptible Staphylococcus aureus assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID548257Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1356830Antimicrobial activity against Klebsiella pneumoniae ATCC BAA-2473 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID560190Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by M7-A7 dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID68366In vitro minimum inhibitory concentration required to produce antibacterial activity against Enterobacter cloacae 908SSI1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID422682Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 14 passages with clindamycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID279257Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID524036Antibacterial activity against penicillin-resistant Streptococcus pneumoniae 2527 by macrodilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID508683Antibacterial activity against 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as reduction of bacteremia at 20 mg/kg, ip measured after 1 day post infection2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID586043Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type U5 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID369990Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 7 mutant NG-MAST sequence type 1622 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1219875Inhibition of recombinant human ABCC4 expressed in baculovirus infected insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID1219873Inhibition of recombinant human ABCC2 expressed in insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID546474Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 95% mouse serum2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID544527Antimicrobial activity against Borrelia garinii isolate G1 after 72 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID528825Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID528972Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID318669Antibacterial activity against methicillin-resistant Staphylococcus aureus KT0116 in mouse dosed iv 1 hr after infection2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID529902Antimicrobial activity against Leptospira interrogans serovar Pomona isolate 12 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID1762808Antibacterial activity against Klebsiella pneumoniae assessed as reduction in bacterial growth incubated for 24 hrs by by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID584481Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN11 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID571012Bactericidal activity against Escherichia coli ATCC 25922 at 8 times MIC after 24 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID539906Antibacterial activity against Staphylococcus aureus after 16 hrs by serial dilution method2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, characterization and anti-microbial studies of some novel 2,4-disubstituted thiazoles.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID588110Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring porB G120K, A121D mutant gene, PBP2 XXXVIII pattern, deletion of nucleotide A from mtrA promoter, MAST 3158 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID558623Antimicrobial activity against Streptococcus pneumoniae isolate 3412 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID736949Antimicrobial activity against Pseudomonas aeruginosa after 16 hrs by serial dilution method2013European journal of medicinal chemistry, Apr, Volume: 62New pyrazole derivatives containing 1,2,4-triazoles and benzoxazoles as potent antimicrobial and analgesic agents.
AID1062044Antibacterial activity against vancomycin-resistant Acinetobacter haemolyticus BW62 after 24 hrs by broth microdilution method2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID405804Inhibition of bocillin FL binding to penicillin-susceptible Streptococcus pneumoniae OC 8865 penicillin-binding protein 2x2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID530838Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 3 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID279259Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID534532Antimicrobial activity against Klebsiella oxytoca KCTC 1686 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID487488Antibacterial activity against Pseudomonas aeruginosa after 16 hrs by serial dilution method2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Novel chromeno [2,3-b]-pyrimidine derivatives as potential anti-microbial agents.
AID571003Binding affinity to human serum albumin in THB medium containing 40 g/L HSA2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID521436Ratio of induction of xylE gene expression in Stenotrophomonas maltophilia isolate KJ deficient in L1 beta lactamase gene to induction of xylE gene expression in Stenotrophomonas maltophilia isolate KJ deficient in L2 beta lactamase gene assessed as catec2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID1546110Antimicrobial activity against Proteus vulgaris2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID548475Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID562404Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae clinical isolates assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID524437Antimicrobial activity against Shigella isolate DH-19035 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID516145Antibacterial activity against Pulsotype I Acinetobacter genomosp. 3 isolate 11 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID645032Antibacterial activity against Streptococcus pyogenes ATCC 19615 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID278088Inhibition of growth in Vancomycin-resistant Enterococci C68 by mouse colonization study2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID540942Antimicrobial activity against Salmonella enterica serotype Newport AM17274 expressing CMY-31 cephalosporinase by agar dilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID521426Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L1 beta lactamase gene by Etest2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID716936Antibacterial activity against methicillin-resistant Staphylococcus aureus USA-300 after 24 hrs by CLSI broth microdilution method2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Design and synthesis of 2-aminothiazole based antimicrobials targeting MRSA.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID425107Antimicrobial activity against Clostridium sordellii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID522176Antimicrobial activity against Actinomyces meyeri under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID588114Antimicrobial activity against Neisseria gonorrhoeae clinical isolates assessed as percent susceptible isolates after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID318650Antibacterial activity against penicillin-resistant Streptococcus pneumoniae KT2524 clinical isolate by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID528821Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID322329Antimicrobial activity in Streptococcus pneumoniae WB4 infected New Zealand white rabbit meningitis model assessed as increase in [3H]choline release in CSF at 125 mg/kg after 4 to 6 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID521351Antimicrobial activity against Streptococcus pneumoniae isolate k-585 obtained from bronchoalveolar lavage fluid of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID557210Antibacterial activity against Beta-lactamase-negative Neisseria meningitidis assessed as percent intermediate isolates by Etest method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.
AID405793Antibacterial activity against Pseudomonas aeruginosa PAO1 after 1.5 hrs by CLSI method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID562610Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae clinical isolates assessed as resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID524569Antimicrobial activity against Shigella isolate DH-22451 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID1211835Total biliary clearance in iv dosed human after 6 to 8 hrs by duodenal perfusion method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID210365In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Streptococcus pneumoniae (4636)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID558595Antimicrobial activity against Streptococcus pneumoniae 7 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID571018Antimicrobial activity against Escherichia coli ATCC 25922 assessed as maximum killing rate constant2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID577647Antimicrobial activity against Escherichia coli isolate 157 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 3 isolated from urine of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID518823Antibacterial activity against Pulsotype C Acinetobacter genomosp. 3 isolate 1 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID322531Antimicrobial activity against Streptococcus pneumoniae infected Wistar rat CSF assessed as decrease in bacterial titer at 100 mg/kg, sc after 2 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID511282Antimicrobial activity against Klebsiella pneumoniae isolate obtained from patient's blood assessed as resistance isolates by disk diffusion method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals.
AID528829Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1698699Antibacterial activity against Peptostreptococcus anaerobius ATCC 27337 by CLSI method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID681344TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT3-expressing S2 cells2002Life sciences, Mar-08, Volume: 70, Issue:16
Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1.
AID531607Ratio of Kcat to Km for Escherichia coli beta-lactamase SHV-112008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
AID584296Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP06 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID575315Antimicrobial activity against Salmonella Newport 03-8748 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID558799Antimicrobial activity against extended spectrum beta-lactamase-expressing Klebsiella oxytoca assessed as percent susceptible isolates by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID342246Increase in toxin level in epidemic Clostridium difficile BI6-8-17 infected CF1 mouse at 0.2 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID422686Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID534663Antimicrobial activity against ESBL producing Proteus mirabilis by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID43758Rate of hydrolysis in 0.1 M sodium phosphate buffer at pH=7.0 by Beta lactamase (TEM-4)1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID518817Antibacterial activity against Acinetobacter genomosp. 3 isolates assessed as percent of resistance isolates by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID1335626Protein binding in cynomolgus monkey plasma after 30 mins by ultra-filtration method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID534884Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID405636Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 62007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID434509Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by standard checkerboard method in presence of 0.2 to 1 mg/ml pulmonar surfactant2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID534886Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID278090Inhibition of intestinal colonization of Bacteroides sp in mouse assessed in stool after 3 days relative to saline2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID534628Antimicrobial activity against Non-ESBL Escherichia coli assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID369632Antimicrobial activity against beta-lactamase positive amoxicillin/clavulanate-resistant Haemophilus influenzae by broth microdilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID425995Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 50 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID395738Antimicrobial activity against Haemophilus influenzae Rd transformed with ftsI gene from imipenem-resistant invasive nontypeable Haemophilus influenzae isolate 183 by Etest2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID558618Antimicrobial activity against Streptococcus pneumoniae isolate 3263 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID524567Antimicrobial activity against Shigella isolate DH-20369 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID405801Antibacterial activity against methicillin-resistant Staphylococcus aureus OC 3726 by CLSI method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID543273Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2x gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID543484Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2x, pbp2b, pbp1a genes by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID556337Antimicrobial activity against Escherichia coli ATCC 25922 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID1062046Antibacterial activity against multidrug-resistant Escherichia coli BW54 after 24 hrs by broth microdilution method2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID373210Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3)2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID519641Antimicrobial activity against Escherichia coli EPI300 harboring pCC1 carrying beta-lactamase CTX-M-3 gene by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID558621Antimicrobial activity against Streptococcus pneumoniae isolate 3346 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID279272Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 37 with GyrA S81Y, GyrB E474K and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID369992Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 9 mutant NG-MAST sequence type 5 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID425988Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 29 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1329019Antibacterial activity against Haemophilus influenzae PBS9812016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID586054Antimicrobial activity against Staphylococcus aureus clone 4-4 harboring staphylococcal cassette chromosome mec element type 5 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID405633Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 1b2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID545655Antimicrobial activity against Stenotrophomonas maltophilia assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID535768Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 08-046 expressing beta-lactamase TEM-1, MLST type ST-1584 and MAST type ST-1478 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID558602Antimicrobial activity against Streptococcus pneumoniae isolate 33 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1210074Inhibition of CYP1A2 in human liver microsomes using phenacetin substrate by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID736950Antimicrobial activity against Escherichia coli after 16 hrs by serial dilution method2013European journal of medicinal chemistry, Apr, Volume: 62New pyrazole derivatives containing 1,2,4-triazoles and benzoxazoles as potent antimicrobial and analgesic agents.
AID558592Antimicrobial activity against Streptococcus pneumoniae 4 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID40924Tested for the minimum inhibitory concentration against Bacillus subtilis 66332002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin.
AID528707Antibacterial activity against Streptococcus pyogenes group A clinical isolate assessed as susceptibility level by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID534089Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae assessed as percent susceptible isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID1210070Inhibition of CYP2D6 in human liver microsomes using bufuralol substrate by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID586056Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type 6 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID584291Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP01(CCUG 43834T) by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID528849Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID543272Antimicrobial activity against Streptococcus pneumoniae 72521 by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID534612Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID524213Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP2A by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID524208Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP2X by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID532900Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID558628Antimicrobial activity against Streptococcus pneumoniae isolate 3681 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID521348Antimicrobial activity against Streptococcus pneumoniae isolate 187 obtained from bronchoalveolar lavage fluid of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID563522Antibacterial activity against Pseudomonas aeruginosa NY219 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID1880856Antimicrobial activity against wild type Neisseria gonorrhoeae Y strain harbouring type 2 topoisomerase GyrA S91F, D95G and ParC S87R mutant incubated for 20 to 24 hrs by CLSI protocol based broth microdilution method2022ACS medicinal chemistry letters, Jun-09, Volume: 13, Issue:6
1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum.
AID577461Inhibition of Bocillin FL binding to PBP2b Thr446Ala mutant in laboratory-derived Streptococcus pneumoniae isolate R62010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.
AID1062033Bactericidal activity against Bacillus cereus ATCC 11778 after 24 hrs by CFU counting assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID558614Antimicrobial activity against Streptococcus pneumoniae isolate 2688 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID573350Antibacterial activity against ceftazidime-nonsusceptible Enterobacter cloacae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID560218Antibacterial activity against Salmonella enterica serovar Typhimurium R10 expressing Outer membrane protein STM3031 after serial passage by Etest method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID405807Inhibition of bocillin FL binding to penicillin-susceptible Streptococcus pneumoniae OC 8865 penicillin-binding protein 32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID324839Antimicrobial activity against Neisseria gonorrhoeae 273 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID285690Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4036 isolate expressing carbapenemase KPC22007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID529576Ratio of Kcat to Km for Erwinia carotovora subsp. atroseptica DSM 30184 beta-Lactamase CAR-12008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID528917Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-14 and CTX-M-27 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID545461Antimicrobial activity against Pasteurella sp. assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID559579Antimicrobial activity against Parachlamydia acanthamoebae infected in Acanthamoeba castellanii amoeba cells2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.
AID360049Antimicrobial activity against Enterococcus faecium D344S by agar dilution method after 48 hrs2007The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42
Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID370132Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 17 mutant NG-MAST sequence type 1342 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID556827Ratio of MIC for beta-lactamase-negative methicillin-susceptible Staphylococcus aureus ATCC 25923 by microdilution method at pH 7.4 to ratio of MIC for beta-lactamase-negative methicillin-susceptible Staphylococcus aureus ATCC 25923 by microdilution metho2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
AID1335619AUC (0 to infinity) in mouse at 20 mg/kg, iv administered as bolus dose by HPLC method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID558631Antimicrobial activity against Streptococcus pneumoniae isolate 4755 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID546620Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-2 by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID1062036Bactericidal activity against vancomycin-resistant Acinetobacter haemolyticus BW62 after 24 hrs by CFU counting assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID549335Antimicrobial activity against Escherichia coli isolate Z1 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID1698703Antibacterial activity against Fusobacterium nucleatum JCM8532 by CLSI method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID545458Antimicrobial activity against Serratia marcescens assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID206458In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Staphylococcus aureus (853)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID405791Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 42007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID678718Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID575100Antimicrobial activity against Streptococcus pneumoniae serotype 22F assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID528705Antibacterial activity against Streptococcus mitis clinical isolate assessed as susceptibility level by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID395737Antimicrobial activity against imipenem-susceptible Haemophilus influenzae Rd by Etest2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID560224Antibacterial activity against Salmonella enterica serovar Typhimurium R200 expressing stm3031 gene deletion mutant by CLSI M7-A7 agar dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID43756Rate of hydrolysis in 0.1 M sodium phosphate buffer at pH=7.0 by Beta lactamase (SHV-4)1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID577648Antimicrobial activity against Escherichia coli isolate 157T expressing beta-lactamase KPC2 and PFGE cluster 3 isolated from urine of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID1546168Antimicrobial activity against Streptococcus pneumoniae2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID521432Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L1 beta lactamase gene at 50 ug/ml2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID322540Effect on Streptococcus pneumoniae infection induced brain injury in Wistar rat hippocampal dentate gyrus assessed as number of apoptotic cells at 100 mg/kg, sc after 24 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID534926Antimicrobial activity against Ceftazidime susceptible Serratia marcescens assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1257072Antibacterial activity against methicillin-resistant Staphylococcus aureus USA 300 LAC after 20 hrs by CLSI broth microdilution method2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Synthesis of biscoumarin and dihydropyran derivatives with promising antitumor and antibacterial activities.
AID422656Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 50 passages by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID530846Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 2469 isolate 11 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID586045Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type 1 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID322523Decrease on TNFalpha level in Streptococcus pneumoniae infected Wistar rat CSF at 100 mg/kg, sc after 24 hrs by ELISA2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID521344Antimicrobial activity against Streptococcus pneumoniae ATCC BAA-3432008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID544529Antimicrobial activity against Borrelia spielmanii isolate PC-Eq17 after 120 hrs by colorimetric assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.
AID573124Antibacterial activity against coagulase-negative and oxacillin-resistant Staphylococcus aureus assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID528921Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-14 and CTX-M-27 gene and other bla gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID716935Antibacterial activity against methicillin-resistant Staphylococcus aureus RN8175 after 24 hrs by CLSI broth microdilution method2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Design and synthesis of 2-aminothiazole based antimicrobials targeting MRSA.
AID369630Antimicrobial activity against beta-lactamase positive ampicillin-resistant Haemophilus influenzae by broth microdilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID532905Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 ST 376 expressing beta-lactamase SHV-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID545422Antimicrobial activity against Citrobacter freundii obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID586052Antimicrobial activity against Staphylococcus aureus clone 4-4 harboring staphylococcal cassette chromosome mec element type 2 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID279273Antibacterial activity against Streptococcus pneumoniae assessed as period of suppression of bacterial growth2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID545443Antimicrobial activity against extended-spectrum beta-lactamase-positive Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID586055Antimicrobial activity against Staphylococcus aureus clone 4-4 harboring staphylococcal cassette chromosome mec element type U3 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID521842Antibacterial activity against Escherichia coli J53 by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID394496Antimicrobial activity against Escherichia coli MC4100 harboring pB-acc1 plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID534885Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID545822Antimicrobial activity against vancomycin-resistant Staphylococcus aureus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID529904Antimicrobial activity against Leptospira interrogans serovar Canicola isolate 11 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID534648Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID528792Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 and other bla gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID583098Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 beta-lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID528833Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1356827Antimicrobial activity against Klebsiella pneumoniae NCTC 13439 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID546226Ratio of MIC for Staphylococcus aureus ATCC 29213 grown in CAMHB medium in presence of 95% mouse serum to MIC for Staphylococcus aureus ATCC 29213 in presence of 95% mouse serum ultrafiltrate2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID549332Antimicrobial activity against Escherichia coli isolate 86 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID573348Antibacterial activity against ceftazidime-susceptible Enterobacter cloacae assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID531969Antibacterial activity against Klebsiella pneumoniae blood isolate A28008 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID209885Inhibitory concentration against purified PBP2x from Streptococcus pneumoniae1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID516144Antibacterial activity against Pulsotype I Acinetobacter genomosp. 3 isolate 10 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID575103Antimicrobial activity against Streptococcus pneumoniae serotype 23A assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID577459Antimicrobial activity against laboratory-derived Streptococcus pneumoniae isolate R6 harboring Thr446Ala/Ala-619-Gly mutant gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.
AID559697Antibacterial activity against Escherichia coli TOP10 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
First report of plasmid-mediated quinolone resistance determinant qnrS1 in an Escherichia coli strain of animal origin in Italy.
AID278096Overgrowth of vancomycin-resistant enterococci growth in mouse intestine assessed in stool 2 days after 6 days treatment relative to saline2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID546618Antimicrobial activity against Pseudomonas aeruginosa isolate 243-31C expressing beta-lactamase VIM-18 isolated from sputum of patient by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID1223490Apparent permeability across human differentiated Caco2 cells2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID524064Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP3 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID562406Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae clinical isolates assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID535765Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 08-041 expressing beta-lactamase TEM-1, MLST type ST-1584 and MAST type ST-1478 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID535767Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 08-044 expressing beta-lactamase TEM-1, MLST type ST-7823 and MAST type ST-1288 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID322522Effect on TNFalpha level in Streptococcus pneumoniae infected Wistar rat CSF at 100 mg/kg, sc after 2 to 6 hrs y ELISA2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID1335635Antibacterial activity against penicillin-resistant Streptococcus pneumoniae SR16754 infected in sc dosed mouse assessed as protection against bacterial infection by measuring increase in mouse survival administered 1 and 5 hrs post infection measured aft2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID370001Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 11 mutant NG-MAST sequence type 5 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID534629Antimicrobial activity against Non-ESBL Escherichia coli assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1211855Unbound biliary clearance in iv dosed human after 6 to 8 hrs by duodenal perfusion method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID571029Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 in presence of bovine serum albumin2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID571010Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 by serial dilution twofold broth microdilution method in presence of 40 g/L bovine serum albumin2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID586047Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type 6 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID278089Inhibition of growth in Klebsiella pneumoniae P62 by mouse colonization study2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID546246Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 95% mouse serum ultrafiltrate2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID545449Antimicrobial activity against extended-spectrum beta-lactamase-positive Klebsiella oxytoca assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID524066Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP3 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID560217Antibacterial activity against Salmonella enterica serovar Typhimurium R5 expressing Outer membrane protein STM3031 after serial passage by Etest method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID425973Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 50 passages by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1356825Antimicrobial activity against Klebsiella pneumoniae ATCC BAA-1904 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID530841Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 6 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID370003Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 12 mutant NG-MAST sequence type 1703 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID532901Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 ST 376 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID1211887Unbound biliary clearance in beagle dog at 20 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID524047Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP1 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID422674Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 21 passages with gemifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID528788Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID547756Antimicrobial activity against invasive Streptococcus intermedius obtained from non-cystic fibrosis patient assessed as non-susceptible isolates grown on brain heart infusion agar at 30 ug/ml after 24 hrs at 37 degC by disk diffusion method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.
AID571014Bactericidal activity against Escherichia coli ATCC 25922 at 8 times MIC after 24 hrs by time kill analysis in presence of 40 g/L human serum albumin2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID318656Antibacterial activity against Haemophilus influenzae TH13 by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID583433Antimicrobial activity against beta-lactam-resistant and chromosomal mecA deficient Staphylococcus aureus CRB harboring PBP4 E183A F241R, GdpP N182K and AcrB I960V mutant genes selected after 21 days of serial passage in ceftobiprole2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level β-lactam resistance contains mutations in three genes.
AID547534Antimicrobial activity against invasive Streptococcus anginosus obtained from non-cystic fibrosis patient assessed as non-susceptible isolates grown on mueller-Hinton blood agar at 30 ug/ml after 24 hrs at 37 degC by disk diffusion method in presence of 52010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.
AID279263Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3676 with GyrA E85G, GyrB S478I and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID532902Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID582968Antimicrobial activity against beta-lactamase A and B-deficient Yersinia enterocolitica GY5718 after 20 hrs by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Contribution of BlaA and BlaB beta-lactamases to antibiotic susceptibility of Yersinia enterocolitica biovar 1B.
AID549337Antimicrobial activity against Escherichia coli ATCC 25922 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID531606Ratio of Kcat to Km for Escherichia coli Inhibitor-resistant beta-lactamase SHV-562008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
AID577456Inhibition of Bocillin FL binding to PBP2b in Streptococcus pneumoniae isolate 8819 harboring E333G, I361L, E369D, S412P, N422Y, T426K, Q427L, Q438E, L455I, S473T, E476G, S480A, T489A, N538D, D561E, Q564K, and D625G mutant genes2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.
AID342085Effect on growth of nonepidemic Clostridium difficile J29 in CF1 mouse assessed as increase in bacterial density in cecal content at 2 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID577449Antimicrobial activity against penicillin sensitive Streptococcus pneumoniae isolate 8865 by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.
AID574434Antimicrobial activity against Escherichia coli isolate 544 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from abscess of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID369626Antimicrobial activity against beta-lactamase negative ampicillin-susceptible Haemophilus influenzae by broth microdilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID330962Antimicrobial activity against wild type Escherichia coli in medium containing EtbuPUG by serial dilution method2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID573144Antibacterial activity against penicillin-susceptible Streptococcus viridans assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID562334Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid pBC-SK after 18 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID524434Antimicrobial activity against Shigella flexneri isolate AM13291 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID524212Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP2A by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID1210071Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID534608Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID531976Antibacterial activity against Escherichia coli DH10B expressing KPC-2 CTX-M-2 by agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID487484Antibacterial activity against Bacillus subtilis after 16 hrs by serial dilution method2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Novel chromeno [2,3-b]-pyrimidine derivatives as potential anti-microbial agents.
AID425111Antimicrobial activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID534866Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID588109Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring PBP2 XXXV pattern, deletion of nucleotide A from mtrA promoter, MAST 546 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID1335637Antibacterial activity against penicillin-resistant Streptococcus pneumoniae SR16754 after 20 hrs by agar dilution method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID1335631Antibacterial activity against beta-lactamase non-producing penicillin-resistant Haemophilus influenzae SR24106 after 20 hrs by agar dilution method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID279262Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3665 after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1880852Antimicrobial activity against Neisseria gonorrhoeae K strain harbouring type 2 topoisomerase GyrA S91F, D95N and ParC S87R, S88P mutant incubated for 20 to 24 hrs by CLSI protocol based broth microdilution method2022ACS medicinal chemistry letters, Jun-09, Volume: 13, Issue:6
1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum.
AID511279Antimicrobial activity against Escherichia coli clinical isolate assessed as resistance isolates by disk diffusion method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals.
AID561387Antibacterial activity against Escherichia coli isolate ARL05-705 harboring beta-lactamase CMY 7 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID573127Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID528832Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID541857Antimicrobial activity against Escherichia coli ATCC 29522 carrying Edwardsiella ictaluri pM07-1 by microdilution assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.
AID574427Antimicrobial activity against Escherichia coli isolate 360 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from urine of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID318670Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 in mouse dosed iv 1 hr after infection2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID519639Antimicrobial activity against ceftazidime-resistant Escherichia coli Irk2322 harboring beta-lactamase CTX-M-42 Pro167Thr mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID324849Antimicrobial activity against Neisseria gonorrhoeae 91 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID574432Antimicrobial activity against Escherichia coli isolate 543 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 4 isolated from synovial fluid of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID425993Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 50 passages by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1062037Bactericidal activity against ESBL-producing Escherichia coli BW55 after 24 hrs by CFU counting assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID422680Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 by NCCLS M7-A7 method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID571019Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 assessed as maximum killing rate constant2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID645039Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID562606Antimicrobial activity against Streptococcus pneumoniae clinical isolates assessed as resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID318655Antibacterial activity against Moraxella catarrhalis K1209 by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID69139Inhibitory concentration against purified penicillin-binding protein(PBP) 1bgamma of Escherichia coli1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID1335620Half life in mouse at 20 mg/kg, iv administered as bolus dose by HPLC method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID325447Antibacterial activity against Staphylococcus aureus N315 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID534888Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1698700Antibacterial activity against Bacteroides fragilis ATCC 25285 by CLSI method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID531974Antibacterial activity against Escherichia coli DH10B by agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID524053Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP2 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID571022Plasma protein binding in human at < 100 ug/ml2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID548331Antibacterial activity against Pseudomonas aeruginosa after 16 hrs by serial dilution method2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and biological evaluation of aminoketones.
AID422658Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 49 passages with clindamycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID530839Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 4 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID558613Antimicrobial activity against Streptococcus pneumoniae isolate 2686 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID584485Antibacterial activity against mecA-negative Staphylococcus lentus ATCC 29070T by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID571004Binding affinity to pooled adult bovine serum albumin2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID324834Antimicrobial activity against Neisseria gonorrhoeae 119 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID559580Antimicrobial activity against Chlamydia trachomatis infected in Vero cells2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.
AID516141Antibacterial activity against Pulsotype K Acinetobacter genomosp. 3 isolate 6 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID584295Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP05 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID574437Antimicrobial activity against Escherichia coli isolate 1679 expressing beta-lactamase KPC2, SHV-12, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID577205Antimicrobial activity against Escherichia coli O157:H7 PT-32 in logarithmic phase encoding Stx-1 and Stx-2 gene by broth macrodilution assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Different classes of antibiotics differentially influence shiga toxin production.
AID1211809Drug excretion in beagle dog assessed as compound excreted into bile at 20 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID543280Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 pbp2x, pbp2b and Streptococcus pneumoniae 3191 pbp1a genes by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID560219Antibacterial activity against Salmonella enterica serovar Typhimurium R25 expressing Outer membrane protein STM3031 after serial passage by Etest method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID193178In vitro plasma protein binding was evaluated using Sprauge-Dawley rat at 20 ug/mL1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Discovery and structure-activity relationship of a series of 1-carba-1-dethiacephems exhibiting activity against methicillin-resistant Staphylococcus aureus.
AID542584Antimicrobial activity against Acinetobacter radioresistens 251-39C expressing beta-lactamase OXA-133 by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.
AID528824Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID584294Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP04 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID422664Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 50 passages by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID558619Antimicrobial activity against Streptococcus pneumoniae isolate 3275 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID558627Antimicrobial activity against Streptococcus pneumoniae isolate 3587 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID535758Antimicrobial activity against hospital-acquired Escherichia coli expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID425105Antimicrobial activity against Clostridium bifermentans isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID422690Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 after 30 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1062039Antibacterial activity against methicillin-resistant Staphylococcus aureus BW61 after 24 hrs by broth microdilution method2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID529198Antibacterial activity against AmpC-producing Escherichia coli assessed as sensitive isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID560771Antibacterial activity against Neisseria gonorrhoeae isolate SW2 expressing nonmosaic penA allele by agar dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.
AID524572Antimicrobial activity against Shigella flexneri isolate AM26336 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID558616Antimicrobial activity against Streptococcus pneumoniae isolate 2880 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID573335Antibacterial activity against ceftazidime-susceptible Enterobacteriaceae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID535751Antimicrobial activity against community-acquired Klebsiella pneumoniae obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID556354Antimicrobial activity against Salmonella enterica serotype concord expressing extended-spectrum beta-lactamase CTX-M-15 by Etest2009Antimicrobial agents and chemotherapy, 05, Volume: 53, Issue:5
Chromosomal integration of the extended-spectrum beta-lactamase gene blaCTX-M-15 in Salmonella enterica serotype Concord isolates from internationally adopted children.
AID546227Ratio of MIC for Staphylococcus aureus ATCC 29213 grown in CAMHB medium in presence of 95% rat serum to MIC for Staphylococcus aureus ATCC 29213 in presence of 95% rat serum ultrafiltrate2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID559576Antimicrobial activity against Waddlia chondrophila ATCC VR-1470 infected in Acanthamoeba castellanii amoeba cells2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.
AID528816Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID535763Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 06-041 expressing beta-lactamase TEM-1, MLST type ST-1588 and MAST type ST-4012 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID588113Antimicrobial activity against Neisseria gonorrhoeae clinical isolates assessed as percent resistant isolates after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID532906Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID573375Antibacterial activity against multidrug-resistant Acinetobacter assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID575330Antimicrobial activity against Salmonella Typhimurium 08-2211 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID324847Antimicrobial activity against Neisseria gonorrhoeae 82 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID557394Antibacterial activity against Beta-lactamase-negative Neisseria meningitidis assessed as percent resistant isolates by Etest method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.
AID534194Antimicrobial activity against Pseudomonas putida expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
AID279271Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 2527 after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID558608Antimicrobial activity against Streptococcus pneumoniae isolate 1394 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID571016Bactericidal activity against Escherichia coli ATCC 25922 at 8 times MIC after 24 hrs by time kill analysis in presence of 40 g/L bovine serum albumin2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID528974Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID558790Antimicrobial activity against Enterobacter cloacae assessed as percent susceptible isolates by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID405814Inhibition of bocillin FL binding to penicillin-resistant Streptococcus pneumoniae OC 8819 penicillin-binding protein 32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID573374Antibacterial activity against multidrug-resistant Acinetobacter assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID425986Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 41 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID534525Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3696 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID530836Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 1 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID567460Antimicrobial activity against Salmonella enterica serovar Typhi isolate 080048Ty transconjugant harboring bla CTX-M-15 gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Plasmid-mediated resistance to cephalosporins in Salmonella enterica serovar Typhi.
AID532897Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 ST 340 expressing beta-lactamase TEM-1, SHV-11 and OXA-2 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID558626Antimicrobial activity against Streptococcus pneumoniae isolate 3481 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID540946Antimicrobial activity against Escherichia coli DH5[alpha] harboring pB-c31 plasmid expressing cephalosporinase CMY-31 by agar dilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID369989Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 7 mutant NG-MAST sequence type 1619 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID519735Antibacterial activity against Escherichia coli DH5alpha with deltaampC by agar dilution method in presence of 2 ug/ml clavulanic acid2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID573114Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID206456In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Staphylococcus aureus (2619)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID556830Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25923 infected in human keratinocytes assessed as bacterial count per mg of cell protein at low extracellular compound concentration after 24 hrs2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
AID322533Antibacterial activity against Streptococcus pneumoniae infected Wistar rat CSF assessed as decrease in bacterial titer at 100 mg/kg, sc after 6 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID530842Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 7 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID558607Antimicrobial activity against Streptococcus pneumoniae isolate 1384 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID558597Antimicrobial activity against Streptococcus pneumoniae 9 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID521349Antimicrobial activity against Streptococcus pneumoniae isolate 909 obtained from bronchoalveolar lavage fluid of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID1210072Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID645040Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID425978Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 by NCCLS M7-A7 method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID584477Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN07 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID422659Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 29 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID544965Antimicrobial activity against Proteus mirabilis expressing extended-spectrum beta-lactamase by Etest based on single determinant2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID575332Antimicrobial activity against Escherichia coli 08-2712TC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID543271Antimicrobial activity against Streptococcus pneumoniae 3191 by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID546479Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 95% rat serum ultrafiltrate2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Assessment of oritavancin serum protein binding across species.
AID532910Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID545428Antimicrobial activity against Enterobacter cloacae obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID571025Antimicrobial activity against Escherichia coli ATCC 259222008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID577462Inhibition of Bocillin FL binding to PBP2b Thr446Ala/Ala-619-Gly mutant in laboratory-derived Streptococcus pneumoniae isolate R62010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.
AID425110Antimicrobial activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID1210073Inhibition of CYP2C19 in human liver microsomes using omeprazole substrate by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID508573Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as reduction of bacteremia at 20 mg/kg, ip measured after 1 day post infection2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID571008Antimicrobial activity against Escherichia coli ATCC 25922 by serial dilution twofold broth microdilution method in presence of 40 g/L human serum albumin2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID575325Antimicrobial activity against Salmonella Typhimurium 08-843 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID210367In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Streptococcus pneumoniae (3273)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID1335624Total clearance in monkey at 20 mg/kg, iv administered as bolus dose by HPLC method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID573377Antibacterial activity against imipenem-susceptible Acinetobacter assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID279255Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID534905Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID563519Antibacterial activity against Pseudomonas aeruginosa NY214 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID535759Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 00-002 expressing beta-lactamase TEM-1, MLST type ST-1590 and MAST type ST-270 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID549330Antimicrobial activity against Escherichia coli isolate 16 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID324845Antimicrobial activity against Neisseria gonorrhoeae 59 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID584467Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus vitulinus SVMP03 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID559581Antimicrobial activity against Chlamydophila pneumoniae infected in Vero cells2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.
AID571027Antimicrobial activity against Escherichia coli ATCC 25922 by in presence of human serum albumin2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID519642Antimicrobial activity against Escherichia coli EPI300 harboring pCC1 carrying beta-lactamase CTX-M-42 Pro167Thr mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID521356Antimicrobial activity against Streptococcus pneumoniae isolate 2907 obtained from sinusitis of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID577204Antimicrobial activity against Escherichia coli O157:H7 PT-40 in stationary phase encoding Stx-2 gene by broth macrodilution assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Different classes of antibiotics differentially influence shiga toxin production.
AID586085Antimicrobial activity against verocytotoxin-producing Escherichia coli isolate O157 obtained from human assessed as percentage of resistant isolates by disk diffusion method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26.
AID285691Antimicrobial susceptibility of Citrobacter freundii CF6010 isolate expressing carbapenemase KPC22007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID210368In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Streptococcus pneumoniae (3512)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID530844Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 9 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID645047Antibacterial activity against Serratia marcescens Mel 522 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID571017Bactericidal activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 at 8 times MIC after 24 hrs by time kill analysis in presence of 40 g/L bovine serum albumin2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID1762805Antibacterial activity against against Escherichia coli 06 assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID285337Antimicrobial activity against Escherichia coli qnrA1 producing urinary specimen isolate 13.52 by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
AID547535Antimicrobial activity against invasive Streptococcus anginosus obtained from non-cystic fibrosis patient assessed as non-susceptible isolates grown on brain heart infusion agar at 30 ug/ml after 24 hrs at 37 degC by disk diffusion method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.
AID318654Antibacterial activity against vancomycin-resistant Enterococcus faecium KU1778 clinical isolate by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1329015Antibacterial activity against Streptococcus pneumoniae PBS13992016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID369629Antimicrobial activity against beta-lactamase negative ampicillin-resistant Haemophilus influenzae by E-test2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID560221Antibacterial activity against Salmonella enterica serovar Typhimurium R200 expressing Outer membrane protein STM3031 after serial passage by Etest method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID524041Antibacterial activity against methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A by macrodilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID521427Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L2 beta lactamase gene by Etest2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID532903Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 ST 376 expressing beta-lactamase SHV-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID405802Inhibition of bocillin FL binding to penicillin-susceptible Streptococcus pneumoniae OC 8865 penicillin-binding protein 1a2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID1245149Inhibition of DAAO (unknown origin)2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
6-Hydroxy-1,2,4-triazine-3,5(2H,4H)-dione Derivatives as Novel D-Amino Acid Oxidase Inhibitors.
AID524034Antibacterial activity against penicillin-resistant Streptococcus pneumoniae 24 by macrodilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID583432Antimicrobial activity against methicillin-, tetracycline-susceptible and chromosomal mecA deficient Staphylococcus aureus COLnex2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level β-lactam resistance contains mutations in three genes.
AID1576577Effective permeability of compound incubated for 8 hrs by PAMPA2019MedChemComm, Dec-01, Volume: 10, Issue:12
Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.
AID558792Antimicrobial activity against extended spectrum beta-lactamase-expressing Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID324850Antimicrobial activity against Neisseria gonorrhoeae 128 isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.
AID528708Antibacterial activity against multidrug-resistant Streptococcus pneumoniae clinical isolate assessed as susceptibility level by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro activity of telavancin against resistant gram-positive bacteria.
AID528827Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID558796Antimicrobial activity against extended spectrum beta-lactamase-deficient Escherichia coli assessed as percent susceptible isolates by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID525341Decrease in severity of cortical damage in Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat at 100 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID1062042Antibacterial activity against multidrug-resistant Pseudomonas aeruginosa PAO1 after 24 hrs by broth microdilution method2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID544963Antimicrobial activity against Klebsiella pneumoniae expressing extended-spectrum beta-lactamase and beta-lactamase AmpC by Etest2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID1762802Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID560216Antibacterial activity against Salmonella enterica serovar Typhimurium R1 expressing Outer membrane protein STM3031 after serial passage by Etest method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID534083Antibacterial activity against cefotaxime-resistant Streptococcus pneumoniae assessed as percent susceptible isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID425994Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 by NCCLS M7-A7 method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID519743Antibacterial activity against Klebsiella pneumoniae INSRA1229 harboring SHV-72 Ile8Phe, Ala146Val, and Lys234Arg mutations by agar dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID586051Antimicrobial activity against Staphylococcus aureus clone 4-4 harboring staphylococcal cassette chromosome mec element type 1 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID508684Antibacterial activity against 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as reduction of bacteremia at 20 mg/kg, ip measured after 2 days post infection2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID535766Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 08-043 expressing beta-lactamase TEM-1, MLST type ST-7823 and MAST type ST-1288 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID587727Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-18-pLBII after 18 hrs by microdilution broth method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID370002Antimicrobial activity against Neisseria gonorrhoeae isolate with PBP2 pattern 12 mutant NG-MAST sequence type 1426 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID525346Toxicity in Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as decrease in CSF MIP-1alpha concentration at 50 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs by microsphere-based multiplex assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID586041Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type 5 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID716933Antibacterial activity against Acinetobacter baumannii UNMC 8872 after 24 hrs by CLSI broth microdilution method2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Design and synthesis of 2-aminothiazole based antimicrobials targeting MRSA.
AID341615Antibacterial activity against extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae P10045 by broth dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
AID425987Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 33 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1356836Antimicrobial activity against Enterobacter cloacae ATCC BAA-2468 by broth microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID532909Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 ST 327 expressing beta-lactamase TEM-1 and CTX-M-2 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID529197Antibacterial activity against ESBL-producing Escherichia coli assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID573369Antibacterial activity against ceftazidime-susceptible Proteus mirabilis assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID325445Antibacterial activity against Escherichia coli C921-61 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID1880854Antimicrobial activity against wild type Neisseria gonorrhoeae P strain incubated for 20 to 24 hrs by CLSI protocol based broth microdilution method2022ACS medicinal chemistry letters, Jun-09, Volume: 13, Issue:6
1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum.
AID573363Antibacterial activity against ceftazidime-nonsusceptible Klebsiella pneumoniae assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID524037Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae 1076 by macrodilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID12234881-Octanol-water distribution coefficient, log D of the compound at pH 7.42012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID1762807Antibacterial activity against against Escherichia coli 24 assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID1880851Antimicrobial activity against wild type Neisseria gonorrhoeae F strain incubated for 20 to 24 hrs by CLSI protocol based broth microdilution method2022ACS medicinal chemistry letters, Jun-09, Volume: 13, Issue:6
1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum.
AID524211Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP2A by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID1335621Total clearance in mouse at 20 mg/kg, iv administered as bolus dose by HPLC method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID519663Antimicrobial activity against Escherichia coli Irk1224 harboring beta-lactamase CTX-M-3 by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID573344Antibacterial activity against ceftazidime-nonsusceptible Citrobacter freundii assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID528840Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID583096Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 W87F mutant beta-lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID279267Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3243 with 23S rRNA A2059T mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1329018Antibacterial activity against Streptococcus pneumoniae PBS1399 infected in mouse assessed as protection against bacterial infection by measuring mouse survival administered intravenously as single dose after 2 hrs of infection measured on day 72016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID548474Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID422650Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 38 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID556837Bacteriostatic activity against methicillin-resistant Staphylococcus aureus ATCC 33591 infected in human keratinocytes assessed as change in bacterial count after 24 hrs2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
AID573365Antibacterial activity against ceftazidime-susceptible Morganella morganii assessed as susceptible isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID584475Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN05 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID574428Antimicrobial activity against Escherichia coli isolate 360T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from urine of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID534904Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID582763Antimicrobial activity against eaeA positive verocytotoxin-producing non-O157 Escherichia coli isolates obtained from human assessed as percentage of resistant isolates2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26.
AID528787Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID524217Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP2B by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID543423Antimicrobial activity against Escherichia coli XL-1 Blue transconjugant harboring beta-lactamase CTX-M-64 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID511290Antibacterial activity against Escherichia coli DH5alpha2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID575316Antimicrobial activity against Escherichia coli 03-8748TC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest2010Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10
IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID422687Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 by NCCLS M7-A7 method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID586050Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type U8 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID1335623Half life in monkey at 20 mg/kg, iv administered as bolus dose by HPLC method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID322528Effect on Streptococcus pneumoniae infection induced elevation of MMP9 level in Wistar rat CSF assessed as MMP-9/MMP-2 index at 100 mg/kg, sc after 24 hrs by gel zymography2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID528839Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID558594Antimicrobial activity against Streptococcus pneumoniae 6 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID684435Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method in presence of 5% pulmonary surfactant2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Reduced pulmonary surfactant interaction of daptomycin analogs via tryptophan replacement with alternative amino acids.
AID573351Antibacterial activity against ceftazidime-nonsusceptible Enterobacter cloacae assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID508535Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 20 mg/kg, ip measured after 1 day post infection2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID279812Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZR01 from patient sputum by agar dilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID645044Antibacterial activity against Streptococcus pneumoniae PEN-1 after 16 to 20 hrs by microbroth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.
AID528968Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID342245Increase in toxin level in epidemic Clostridium difficile BI9 infected CF1 mouse at 0.2 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID1062038Bactericidal activity against multidrug-resistant Escherichia coli BW54 after 24 hrs by CFU counting assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID425968Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 14 passages with gemifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID584293Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP03 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID534865Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID528819Antimicrobial activity against carbapenem-resistant Enterobacter cloacae assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID318644Antibacterial activity against methicillin-susceptible Staphylococcus aureus FDA 209P by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1546877Antibacterial activity against Acinetobacter baumannii ATCC 19606 assessed as reduction in microbial growth after 16 hrs by broth microdilution method2020Journal of natural products, 01-24, Volume: 83, Issue:1
Reisolation and Configurational Reinvestigation of Cottoquinazolines E-G from an Arthropod-Derived Strain of the Fungus
AID548328Antibacterial activity against Staphylococcus aureus after 16 hrs by serial dilution method2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and biological evaluation of aminoketones.
AID279268Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81F mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID571023Plasma protein binding in human at 400 ug/ml2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID1062045Antibacterial activity against ESBL-producing Escherichia coli BW55 after 24 hrs by broth microdilution method2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis and biological evaluation of α-hydroxyalkylphosphonates as new antimicrobial agents.
AID577452Antimicrobial activity against penicillin resistant Streptococcus pneumoniae isolate 8819 harboring PBP2b 443SSNA mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin.
AID548255Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID1546878Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in microbial growth after 16 hrs by broth microdilution method2020Journal of natural products, 01-24, Volume: 83, Issue:1
Reisolation and Configurational Reinvestigation of Cottoquinazolines E-G from an Arthropod-Derived Strain of the Fungus
AID534526Antimicrobial activity against Bacillus subtilis KCTC 2213 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID583095Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 W87A mutant beta-lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID573393Antibacterial activity against ceftazidime-susceptible Providencia sp. assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1207729Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits2013Scientific reports, , Volume: 3MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID534652Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID586084Antimicrobial activity against multidrug-resistant Neisseria gonorrhoeae isolates by Etest2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Characteristics and dissemination of mosaic penicillin-binding protein 2-harboring multidrug-resistant Neisseria gonorrhoeae isolates with reduced cephalosporin susceptibility in northern Taiwan.
AID369628Antimicrobial activity against beta-lactamase negative ampicillin-resistant Haemophilus influenzae by broth microdilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID325444Antibacterial activity against Escherichia coli K12 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID535764Antimicrobial activity against penicillin-producing Neisseria gonorrhoeae NGON 08-003 expressing beta-lactamase TEM-135, MLST type ST-7823 and MAST type ST-4013 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.
AID342254Effect on growth of fluoroquinolone-resistant epidemic Clostridium difficile NAP1 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.375 mg/day, sc for 5 days2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID318652Antibacterial activity against Enterococcus faecalis ATCC 29212 by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID584299Antibacterial activity against mecA-negative Staphylococcus fleurettii SFMN01 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID342243Increase in toxin level in nonepidemic Clostridium difficile ATCC 9689 infected in CF1 mouse at 0.2 mg/day, sc for 4 days assessed after 2 days of last treatment2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID543419Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID584480Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN10 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID524042Antibacterial activity against methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 by macrodilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID322322Antibacterial activity against Escherichia coli INSRA5905 isolates expressing CTX-M-15 and TEM-1B enzymes by agar dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID584474Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN04 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID532912Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID373055Antimicrobial activity against Escherichia coli BL21(DE3) by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID524210Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP2X by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID684436Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method in presence of 4% human serum albumin2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Reduced pulmonary surfactant interaction of daptomycin analogs via tryptophan replacement with alternative amino acids.
AID573130Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1404016Permeability of the compound by PAMPA2018European journal of medicinal chemistry, Feb-10, Volume: 145Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
AID405815Antibacterial activity against penicillin-resistant Streptococcus pneumoniae OC 8819 by CLSI method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID425972Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 by NCCLS M7-A7 method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID524032Antibacterial activity against penicillin-resistant Streptococcus pneumoniae 2688 by macrodilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID565811Antimicrobial activity against Neisseria meningitidis assessed as susceptible isolate by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.
AID342063Antimicrobial activity against nonepidemic Clostridium difficile J29 by broth dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID208463Tested for the minimum inhibitory concentration against Streptococcus pneumoniae 35122002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID370004Antimicrobial activity against Neisseria gonorrhoeae isolate bropyst serotype with PBP2 pattern 12 mutant NG-MAST sequence type 604 by agar plate dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.
AID561251Antibacterial activity against Streptococcus pneumoniae assessed as intermediate isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID524219Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP3 by competitive binding assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID574431Antimicrobial activity against Escherichia coli isolate 540 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from synovial fluid of patient by vitek-2 method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID573145Antibacterial activity against penicillin-susceptible Streptococcus viridans assessed as resistant isolates by CLSI M7-A7 broth microdilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID588115Antimicrobial activity against Neisseria gonorrhoeae clinical isolates harboring PBP2 XXXVIII pattern, deletion of nucleotide A from mtrA promoter, MAST 3553 after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID1803294Glutathione Peroxidase Activity Assay from Article 10.3109/14756366.2012.688042: \\Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.\\2013Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 28, Issue:4
Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.
AID1803292Glutathione Reductase Activity Assay from Article 10.3109/14756366.2012.688042: \\Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.\\2013Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 28, Issue:4
Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.
AID1803293Glutathione S-transferase Activity Assay from Article 10.3109/14756366.2012.688042: \\Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.\\2013Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 28, Issue:4
Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.
AID1803130Esterase Activity Assay from Article 10.3109/14756366.2011.604852: \\Effects of some drugs on human cord blood erythrocyte carbonic anhydrases I and II: an in vitro study.\\2012Journal of enzyme inhibition and medicinal chemistry, Oct, Volume: 27, Issue:5
Effects of some drugs on human cord blood erythrocyte carbonic anhydrases I and II: an in vitro study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (191)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (3.14)18.2507
2000's104 (54.45)29.6817
2010's74 (38.74)24.3611
2020's7 (3.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.04%)5.53%
Reviews5 (2.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other185 (96.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (154)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis [NCT03179384]Phase 49 participants (Actual)Interventional2017-06-26Completed
Parenteral Versus Combined Parenteral With Vancomycin-soaked Graft in Decreasing the Risk of Infection in ACL Reconstruction Surgery: A Randomized Controlled Trial [NCT06166381]288 participants (Anticipated)Interventional2023-12-15Not yet recruiting
The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial [NCT02800785]1,552 participants (Actual)Interventional2016-05-31Completed
Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis. A Randomized Double-blind Comparison [NCT00138801]Phase 3120 participants (Actual)Interventional2004-03-31Completed
Comparison of Ceftriaxone and Doxycycline for Treatment of Multiple Erythema Migrans [NCT01163994]500 participants (Anticipated)Interventional2010-06-30Recruiting
Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma: an Open-label, Randomised, Prospective Study [NCT05654896]Phase 3158 participants (Anticipated)Interventional2022-11-26Recruiting
Anerning Particle for Reducing the Application of Antibiotics of Childhood Community-acquired Pneumonia: a Randomized, Double Blind, Control of Placebo, Multi-center Clinical Study [NCT03675178]Phase 4216 participants (Anticipated)Interventional2018-09-22Not yet recruiting
A Randomized, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of a Single Dose of Oral AZD0914 Compared to Intramuscular Ceftriaxone in the Treatment of Male and Female Subjects With Uncomplicated Gonorrhea [NCT02257918]Phase 2180 participants (Actual)Interventional2014-11-25Completed
Impact of Cefotaxime and Ceftriaxone on the Emergence and Carrying of Multidrug-Resistant Bacteria and Relationship to Residual Antibiotic Levels in Stool [NCT03903783]34 participants (Actual)Interventional2019-04-30Completed
A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorr [NCT04010539]Phase 3628 participants (Actual)Interventional2019-10-21Completed
A Prospective, Randomized Controlled Trial of 2- Day vs. 5- Day Terlipressin and Ceftriaxone in the Prevention of Very Early Rebleeding in Patients With Acute Gastroesophageal Variceal Hemorrhage [NCT04056806]Phase 4100 participants (Anticipated)Interventional2019-08-31Recruiting
Population Pharmacokinetics of Anti-infective Drugs in Children in Anti-infectious Therapies [NCT03113344]800 participants (Anticipated)Observational [Patient Registry]2017-06-21Recruiting
Comparison of Efficacy of Two Combination Regimens for the Treatment of Uncomplicated Neisseria Gonorrhoeae and Chlamydia Trachomatis Coinfection [NCT05216744]Phase 2125 participants (Actual)Interventional2021-07-15Completed
Evaluation of Effects, Safety, Viral Load and Antibody Level of Functional Food Dietary Supplement Containing Grape Products in Controlled, Randomized Study Using SARSCoV-2 RT-PCR Positive Covid-19 Patients. [NCT05417997]Phase 371 participants (Actual)Interventional2021-05-29Completed
Antibiotic Prophylaxis for ERCP: a Comparison of Intravenous Ceftriaxone With Intravenous Moxifloxacin in the Prophylaxis of Cholangitis [NCT02098486]Phase 286 participants (Actual)Interventional2014-03-31Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
COMPARISON OF CLINICAL EFFICACY OF COMBINATION Amoxycillin Plus Clavulanic Acid and Oxacillin Plus Ceftriaxone for HOSPITAL TREATMENT OF COMMUNITY Acquired PNEUMONIA IN CHILDREN : A Randomized Clinical Study [NCT01166932]Phase 4104 participants (Actual)Interventional2005-04-30Completed
First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition [NCT03174236]Phase 32,000 participants (Anticipated)Interventional2017-09-04Active, not recruiting
Phase II Clinical Trial to Evaluate an Antibiotic Regimen Pharmacokinetic Applicable to Outpatient Parenteral Antimicrobial Therapy in Enterococcus Faecalis Infective Endocarditis [NCT03681431]Phase 212 participants (Actual)Interventional2018-04-23Active, not recruiting
A Randomized Controlled Trial Assessing Noninferiority of Three Antimicrobial Regimens for the Treatment of Grade III Open Fractures [NCT03560232]Phase 417 participants (Actual)Interventional2018-07-09Terminated(stopped due to Unable to recruit patients in a timely fashion and unable to recruit sufficient patients)
Typhoid Fever: Combined vs. Single Antibiotic Therapy. A Prospective Randomized Controlled Study in Nepal. [NCT02224040]Phase 4120 participants (Anticipated)Interventional2013-08-31Recruiting
Six- Versus Twelve-Week Therapy for Non-Surgically-Treated Diabetic Foot Osteomyelitis: A Multicenter Open-Label Controlled Randomized Study [NCT02123628]Phase 440 participants (Actual)Interventional2007-06-30Completed
Pilot for Vancomycin and Tobramycin Powder Use in Acute Open Fractures in the Emergency Department [NCT05849090]Early Phase 150 participants (Anticipated)Interventional2023-03-27Enrolling by invitation
Timing of Antibiotic Prophylaxis for Elective Cesarean Section: A Randomized Controlled Trial [NCT02177994]Phase 3328 participants (Actual)Interventional2013-09-30Completed
Randomized, Double-blind, Double-dummy, Active-controlled, Multi-centre Trial to Compare the Efficacy and Safety of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) With Meropenem in Infections Caused by β-Lactamase (ESBL and MBL) Producing Gram-Negative Bacteria [NCT03477422]Phase 3230 participants (Actual)Interventional2014-01-11Completed
Antibiotic Instillation in Acute Complex Appendicitis for Prevention of Deep Space Surgical Site Infections [NCT05470517]Phase 236 participants (Anticipated)Interventional2023-01-05Recruiting
Is Combination Antibiotic Therapy Superior to Monotherapy in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease [NCT04879030]Phase 2/Phase 3170 participants (Actual)Interventional2020-01-01Completed
A Single-Dose, Randomized, Three-way, Partially Blinded Crossover Study to Compare the Pharmacokinetics and Bioavailability of Ceftriaxone Administered as a 1 Gram Intravenous Infusion, a 1 Gram Subcutaneous Infusion and a 2 Gram Subcutaneous Infusion in [NCT02561442]Phase 2/Phase 318 participants (Actual)Interventional2015-10-31Completed
Population Pharmacokinetics and Pharmacodynamics of Beta-lactams of Interest in Adult Patients From Intensive Care Units [NCT03440216]20 participants (Anticipated)Interventional2018-03-15Recruiting
CHOICE Trial: Cellulitis at Home Or Inpatient in Children From ED [NCT02334124]190 participants (Actual)Interventional2015-01-31Completed
Experimental Human Infection With Isogenic Mutants of Neisseria Gonorrhoeae (LptA Trial) [NCT04870138]Phase 116 participants (Actual)Interventional2013-03-10Completed
Treatment Responses of Early Syphilis to Single-dose Ceftriaxone Plus Doxycycline Versus Single-dose Benzathine Penicillin G Plus Doxycycline in PLWH [NCT05980871]Phase 4300 participants (Anticipated)Interventional2023-03-10Recruiting
Chlamydia Trachomatis Immunology and Vaccinology Study: Determination of Protective T Cell Responses to Chlamydia Trachomatis Infection [NCT01150747]347 participants (Actual)Observational2011-01-31Completed
Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis [NCT01265173]Phase 4261 participants (Actual)Interventional2007-04-30Completed
Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) [NCT05156437]Phase 420 participants (Anticipated)Interventional2022-03-16Enrolling by invitation
Effect of Administration of 3rd Generation Cephalosporin (Ceftriaxone Versus Cefotaxime) on the Digestive Carrying of 3rd Generation Cephalosporin-resistant Enterobacteriaceae (EB C3G-R) [NCT03922919]Phase 4250 participants (Anticipated)Interventional2018-04-03Recruiting
Use of Antibiotics as an Adjuvant in Patients With Acute Severe Ulcerative Colitis: A Randomised Trial [NCT03794765]Phase 250 participants (Actual)Interventional2019-04-01Completed
A Prospective, Multicenter, Partially-Blinded, Randomized, Comparative Study to Evaluate the Safety, Tolerability and Efficacy of INVANZ Versus Ceftriaxone Sodium in the Treatment of Complicated Urinary Tract Infections in Adults [NCT01014013]Phase 3271 participants (Actual)Interventional2008-04-30Completed
Efficacy and Safety of CRO-SBT Performed in Children With Acute Bacterial Infection [NCT04066621]Phase 430 participants (Actual)Interventional2015-04-28Completed
Clearance of Asymptomatic Pharyngeal Carriage of Neisseria Gonorrhoeae With or Without Ceftriaxone Treatment: Randomized Non-inferiority Study [NCT05971550]Phase 3254 participants (Anticipated)Interventional2023-09-30Not yet recruiting
A Multi-center, Randomized, Open-label, Non Inferiority Trial to Evaluate the Efficacy and Safety of a Single, Oral Dose of Zoliflodacin Compared to a Combination of a Single Intramuscular Dose of Ceftriaxone and a Single Oral Dose of Azithromycin in the [NCT03959527]Phase 31,092 participants (Actual)Interventional2019-11-06Active, not recruiting
A Prospective, Randomized, Double-blinded, Multi-center Trial Assessing the Safety and Efficacy of Intravenous Administration BAY12-8039 (Moxifloxacin) 400mg Every 24 h Compared to Intravenous Ceftriaxone 2g Every 24h and Metronidazole 500mg Every 12h for [NCT00769171]Phase 3364 participants (Actual)Interventional2005-10-31Completed
Comparative Efficacy of Intravenous Cefuroxime and Ceftriaxone in Preventing Surgical Site Infection After Neurosurgical Procedures [NCT05398081]Phase 296 participants (Actual)Interventional2021-12-01Completed
A Prospective Randomized Controlled Trial to Investigate the Effects of Training Emergency Medical Services (EMS) Personnel in Recognizing and Initiating Treatment in the Prehospital Setting Together With Early Administration of Antibiotics for Patients S [NCT01988428]2,672 participants (Actual)Interventional2014-06-30Completed
A Randomized Clinical Trial of Oral Clarithromycin in Community-acquired Pneumonia to Attenuate Inflammatory Responses and Improve Outcomes: the ACCESS Clinical Trial [NCT04724044]Phase 3278 participants (Actual)Interventional2021-01-25Completed
A Randomized, Double-Blind, Multicenter Study of Ceftobiprole Medocaril Versus Placebo in the Treatment of Subjects Hospitalized With Community-Acquired Pneumonia [NCT00326287]Phase 3638 participants (Actual)Interventional2006-06-30Completed
A Randomized, Blank-controlled, Open Label Study of the Safety and Efficacy of Propranolol in Reducing Stroke Associated Pneumonia and Urinary Tract Infection [NCT05375240]Phase 245 participants (Anticipated)Interventional2022-06-30Not yet recruiting
A Multi-centre Study to Define Novel Individualised Dosing Regimens to Maximise Antibiotic Effectiveness for Treatment of Pneumonia in Intensive Care Units [NCT04986254]80 participants (Anticipated)Observational2019-10-17Recruiting
A Randomized Control Study to Determine the Efficacy and Safety of Combining Hemospray With Medical Standard of Care Treatment in the Management of Acute Variceal Bleeding in Cirrhotic Patients. [NCT03061604]105 participants (Actual)Interventional2014-11-30Completed
Phase 3, Randomized, Controlled Multicentric, Open-label Clinical Trial to Prove Non-Inferiority of Fosfomycin vs Meropenem or Ceftriaxone in the Treatment of Bacteriemic Urinary Infection Due to Multidrug Resistance in E.Coli [NCT02142751]Phase 3161 participants (Actual)Interventional2014-07-31Completed
Tebipenem-pivoxil as an Alternative to Ceftriaxone for Clinically Non-responding Children With Shigellosis: a Randomized Non-inferiority Trial [NCT05121974]Phase 2162 participants (Anticipated)Interventional2022-08-18Recruiting
Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP) [NCT03068741]Phase 42,040 participants (Anticipated)Interventional2020-03-23Recruiting
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707]Phase 310,000 participants (Anticipated)Interventional2016-04-11Recruiting
The Optimal Time for Intravenous Antibiotic Prophylaxis in Elective Cesarean Section: Randomized Comparative Study [NCT02742948]Phase 2600 participants (Anticipated)Interventional2016-04-30Not yet recruiting
Population Pharmacokinetics of Cephalosporins and Macrolides in Children With Community Acquired Pneumonia [NCT02775968]750 participants (Anticipated)Observational2017-06-21Recruiting
Clinical and Microbiological Parameters in Patients With Early Lyme Neuroborreliosis [NCT00910533]50 participants (Anticipated)Interventional2009-01-01Recruiting
Cefixime 800 mg Plus Doxycycline 100 mg b.i.d. for 7 Days Compared to Ceftriaxone 1 g Plus Azithromycin 2 g for Treatment of Urogenital, Rectal and Pharyngeal Gonorrhoea: A Randomised Controlled Trial [NCT06090565]Phase 4161 participants (Actual)Interventional2021-04-01Completed
Early Reduction of Post-opeRative Pain and Inflammation to Expedite Return to Function After KNEE Arthroscopy [NCT05149287]Phase 25 participants (Actual)Interventional2021-12-28Terminated(stopped due to Funding stopped)
A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone in the Treatment of Adult Subjects With Community-Acquired Pneumonia [NCT00509106]Phase 3622 participants (Actual)Interventional2007-07-31Completed
Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media [NCT02567825]250 participants (Actual)Interventional2015-11-30Completed
Modulation of Glutamatergic Neurotransmission in the Treatment of Bipolar Depression [NCT00566111]5 participants (Actual)Interventional2007-09-30Terminated(stopped due to Early indication of an unfavorable risk/benefit ratio.)
INcreased Flow Utilizing Subcutaneously-Enabled Ceftriaxone (INFUSE-Ceftriaxone) Study: A Phase I Study Comparing the Safety and Pharmacokinetics of Ceftriaxone Administered Subcutaneously With and Without Human Recombinant Hyaluronidase (HYLENEX Recombin [NCT00493220]Phase 130 participants (Actual)Interventional2007-06-30Completed
Experimental Human Infection With Isogenic Mutants of Neisseria Gonorrhoeae [NCT03840811]Phase 127 participants (Actual)Interventional2017-04-23Completed
Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding [NCT00838864]Phase 479 participants (Actual)Interventional2009-03-31Completed
A Phase 2 Randomized, Double-blind, Double-dummy Efficacy, Safety And Tolerability Study Of Iv Sulopenem With Switch To Oral Pf-03709270 Compared To Ceftriaxone With Step Down To Amoxicillin/Clavulanate Potassium (Augmentin) In Subjects With Community Acq [NCT00797108]Phase 235 participants (Actual)Interventional2009-01-31Completed
Supportive Care and Antibiotics for Severe Pneumonia Among Hospitalized Children [NCT04041791]Phase 34,392 participants (Anticipated)Interventional2019-08-19Recruiting
Multicenter, Randomized, And Double-Blind Study To Evaluate The Safety Of Tigecycline Versus A Ceftriaxone Regimen In The Treatment Of Complicated Intra-Abdominal Infections And Community-Acquired Pneumonia In Subjects Of 8-17 Years [NCT00914888]Phase 30 participants (Actual)Interventional2011-01-31Withdrawn
Ceftriaxone as Home Intravenous Therapy for Deep-Seated Staphylococcal Infections, a Randomized Non-Inferiority Trial [NCT04141787]Phase 4310 participants (Anticipated)Interventional2019-07-11Recruiting
Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock [NCT02473263]Phase 3398 participants (Actual)Interventional2016-05-09Completed
A National, Prospective, Randomized, Open Label Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin vs IV Ceftriaxone + IV Azithromycin Followed by PO Amoxicilline/Clavulanate and PO Clarithromycin in Subjects With Community-acquired Pneumonia [NCT00717561]Phase 360 participants (Actual)Interventional2008-02-29Completed
Randomized Trial of Short Antibiotic Course to Decrease Post ERCP Cholangitis [NCT03087656]Phase 4200 participants (Anticipated)Interventional2017-03-29Recruiting
Early Oral Step-down Antibiotic Therapy Versus Continuing Intravenous Therapy for Uncomplicated Gram-negative Bacteraemia (the INVEST Trial) [NCT05199324]Phase 4720 participants (Anticipated)Interventional2022-04-01Recruiting
A Study Evaluating Efficacy and Safety of Ceftriaxone Sodium and Sulbactam Sodium for Injection in the Treatment of Uncomplicated Urogenital Gonorrhea [NCT04202068]Phase 4113 participants (Actual)Interventional2015-07-03Completed
Efficacy and Safety Study of Short Term Antibiotic During Seven Days With Ceftriaxone Intravenous the First Day Then Cefixime the Second Day Till the Seventh Day of Acute Uncomplicated Pyelonephritis in Women Between 18 and 65 Years Old [NCT01390623]Phase 439 participants (Actual)Interventional2011-07-31Completed
Very Short-course Versus Standard Course Antibiotic Therapy in Patients With Acute ChOlangitis After Adequate Endoscopic BiliaRy drAinage [NCT05750966]440 participants (Anticipated)Interventional2023-07-19Recruiting
A Pilot Study of the Effect of Prophylactic Antibiotics on Hospitalized Patients With Advanced Cirrhosis [NCT04218695]Phase 432 participants (Actual)Interventional2020-08-24Completed
Prospective, Randomized, Open-Labeled, Active-Controlled Comparison of Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess: A Pilot Study [NCT00895089]Phase 424 participants (Actual)Interventional2009-05-31Completed
Doxycycline and Ceftriaxone in Patients With Suspected Early Lyme Neuroborreliosis and Normal CSF Cell Count. [NCT00942006]200 participants (Anticipated)Interventional2009-07-31Not yet recruiting
A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone, With Adjunctive Clarithromycin, in the Treatment of Adult Subjects With Community-Acquired Pneumonia [NCT00621504]Phase 3606 participants (Actual)Interventional2008-01-31Completed
An Open Label Randomized Controlled Trial Comparing the Effect of Ceftriaxone Plus Azithromycin Versus Ceftriaxone for the Treatment of Neisseria Gonorrhoeae on the Resistome [NCT05027516]Phase 442 participants (Actual)Interventional2022-01-17Completed
A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection [NCT00230971]Phase 4473 participants (Actual)Interventional2005-10-31Completed
Randomized Controlled Trial of Intramuscular Ceftriaxone Versus Procaine Penicillin Versus Cotrimoxazole and Gentamicin for Management of Serious Bacterial Infections in Young Infants in Community Settings [NCT00189384]Phase 3426 participants Interventional2003-11-30Active, not recruiting
A Prospective, Multicenter, Open, Randomized, Comparative Study to Evaluate the Safety and Efficacy of Ertapenem Versus it's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults [NCT00157898]Phase 4134 participants (Actual)Interventional2004-01-31Completed
Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS) [NCT00349622]Phase 3513 participants (Actual)Interventional2006-07-31Completed
A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection [NCT00195351]Phase 4467 participants (Actual)Interventional2005-09-30Completed
An Open-Label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of a Single Dose of Oral Solithromycin Compared to Single-Dose Intramuscular Ceftriaxone Plus Single-Dose Oral Azithromycin in the Treatment of Male and Female Patients With [NCT02210325]Phase 3264 participants (Actual)Interventional2014-08-31Completed
A Multicentric Randomized Double-Blind Phase 3 Trial Evaluating the Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Active Hidradenitis Suppurativa Patients Versus Tetracycline Derivative [NCT05821478]Phase 392 participants (Anticipated)Interventional2023-11-15Not yet recruiting
Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus (Relais Oral Dans le Traitement Des Endocardites à Streptocoques Multi-sensibles) [NCT02701595]Phase 3324 participants (Anticipated)Interventional2016-02-29Recruiting
The Importance of Anti-anaerobic Therapy for Acute PID [NCT01160640]Phase 2233 participants (Actual)Interventional2010-11-30Completed
Impact of the Choice of 3rd Generation Cephalosporins on the Emergence of Resistance in the Microbiota Intestinal. [NCT02659033]Phase 322 participants (Actual)Interventional2016-03-31Completed
Pharmacokinetics of Antimicrobials and Carriage of Antimicrobial Resistance Amongst Hospitalised Children With Severe Acute Malnutrition [NCT02746276]Phase 281 participants (Actual)Interventional2016-04-01Active, not recruiting
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Ceftriaxone Sodium/Metronidazole for the Prophylaxis of Surgical Site Infection Following Elective Col [NCT01254344]Phase 3599 participants (Actual)Interventional2010-12-31Completed
Comparison Between Ceftriaxone and Levofloxacin on Cytokine Expression Over Time in Severe Pneumococcal Pneumonia [NCT00429975]Phase 445 participants Interventional2004-08-31Terminated
Randomized, Open-label, Superiority Trial of the Effectiveness of Gatifloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Enteric Fever. [NCT01421693]Phase 4300 participants (Actual)Interventional2011-09-30Completed
A Multicenter Randomized Controlled Trial of Antibiotic Treatment in Children With Urinary Tract Infections: Oral Amoxicillin/Clavulanic Acid vs Initial iv Ceftriaxone. [NCT00161330]Phase 3440 participants Interventional2000-06-30Terminated
[NCT01756924]Phase 214 participants (Actual)Interventional2012-12-31Terminated(stopped due to This study has been terminated; alternative study designs are being considered. Fusidic acid remains available under an Expanded Access Protocol.)
A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals [NCT00000648]100 participants InterventionalCompleted
A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Local Tolerability, and Clinical Outcome of Ertapenem Versus Ceftriaxone in Pediatric Patients With Complicated Urinary Tract Infection, Skin and Soft Tissue I [NCT00451386]Phase 2400 participants Interventional2002-01-31Completed
A Multinational, Prospective, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Sequential Intravenous/Oral Moxifloxacin in Comparison to Intravenous Levofloxacin Plus Intravenous Ceftriaxone Followed by Oral Levofloxacin, in the Tr [NCT00431678]Phase 3738 participants (Actual)Interventional2004-01-31Completed
An Open Randomised Trial of Ceftriaxone v Penicillin and Gentamicin in Infant Severe Sepsis and Bacterial Meningitis in Malawi [NCT01247909]Phase 4351 participants (Actual)Interventional2010-04-30Completed
A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone Plus Vancomycin in Pediatric Subjects With Complicated Community-acquired Bacterial [NCT01669980]Phase 440 participants (Actual)Interventional2012-10-31Completed
A Phase 3, Multicenter, Unblind, Non-Comparative Study To Confirm Efficacy And Safety Of Intravenous Metronidazole In Patients With Intrabdominal Infection In Combination With Intravenous Ceftriaxone [NCT01473836]Phase 338 participants (Actual)Interventional2011-11-30Completed
Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients [NCT00002052]0 participants InterventionalCompleted
IV Ceftriaxone for Refractory Psychosis: a Controlled Trial [NCT00591318]Phase 1/Phase 212 participants (Actual)Interventional2007-10-10Terminated(stopped due to Study was terminated after enrolling 12 patients due to poor enrollment rates)
A Randomised Crossover Study of the Pharmacokinetics, Safety and Tolerability of Two Rectal Formulations of Ceftriaxone Compared to Parenteral Ceftriaxone, in Healthy Thai Adults. [NCT03895567]Phase 137 participants (Anticipated)Interventional2024-06-30Not yet recruiting
A Randomized, Double-blind Study of the Effect of Beta-lactam on Treatment Response in Patients Hospitalized With Bacterial Pneumonia [NCT00111644]Phase 2302 participants (Actual)Interventional2005-03-31Completed
Pharmacokinetics Variability of Ceftriaxone in Septic ICU Patients [NCT00449800]Phase 470 participants Interventional2006-07-31Recruiting
A Prospective, Multicenter, Open-Label, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-Abdominal Infections in Adults [NCT00481702]Phase 3300 participants Interventional2001-12-31Completed
A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia [NCT01371838]Phase 3848 participants (Actual)Interventional2011-12-31Completed
An Investigation of the Efficacy of the Glutamate Transporter GLT 1 in the Treatment of Bipolar Depression [NCT00512616]Phase 20 participants (Actual)Interventional2007-08-01Withdrawn
A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With Community-acquired Bacterial Pneumonia Requiring Hospital [NCT01530763]Phase 2/Phase 3161 participants (Actual)Interventional2012-09-30Completed
A Randomized, Multicenter, Open Label Trial Comparing Intravenous Zithromax® (Azithromycin) Plus Intravenous Rocephin® (Ceftriaxone) Followed By Oral Zithromax® (Azithromycin) With Intravenous Levaquin® (Levofloxacin) Followed By Oral Levaquin® (Levofloxa [NCT00035347]Phase 4219 participants (Actual)Interventional2001-01-31Completed
Phase 4 Study of Once-Daily Intramuscular Cefepime Versus Ceftriaxone for In-Home Treatment of Nursing Home-Acquired Pneumonia [NCT00358202]Phase 469 participants (Actual)Interventional2002-03-31Completed
PET and MRI Imaging of Persistent Lyme Encephalopathy [NCT00037479]Phase 265 participants Interventional1999-12-31Completed
A Randomized Trial to Investigate Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition in Mulago Hospital, Kampala, Uganda [NCT05051163]Phase 2/Phase 3300 participants (Anticipated)Interventional2021-06-14Recruiting
The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis [NCT01278017]Phase 4200 participants (Anticipated)Interventional2010-08-31Recruiting
Study of Lyme Neuroborreliosis: Epidemiology, Manifestations, Diagnostics and Treatment [NCT01635530]Phase 4210 participants (Actual)Interventional2012-08-31Completed
Therapeutic Monitoring of Ceftriaxone, Prescribed at High Doses, in the Treatment of Meningitis and Others Neurological Infections. [NCT01745679]Phase 4198 participants (Actual)Interventional2012-12-31Completed
A Phase 1b/2a, Multi-Center, Open-Label, 2-Period, Fixed-Sequence Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Healthy Adult Subjects With a Functioning Ileostomy [NCT02473640]Phase 1/Phase 215 participants (Actual)Interventional2015-06-30Completed
Prospective,Randomized,Open Label,European Multicenter Study of the Efficacy of the Linezolid-rifampin Combination Versus Standard of Care in the Treatment of Gram-positive. [NCT01757236]Phase 2100 participants (Anticipated)Interventional2012-10-31Recruiting
Assessing the Longitudinal Outcomes of Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA): a Randomized Controlled Trial [NCT05943223]Phase 216 participants (Anticipated)Interventional2024-01-31Not yet recruiting
A Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia [NCT03413384]Phase 2106 participants (Anticipated)Interventional2019-02-15Recruiting
Evaluation of Directed Antimicrobial Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy (TRUSP) [NCT01659866]Phase 4563 participants (Actual)Interventional2012-08-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease [NCT00001101]Phase 3194 participants InterventionalCompleted
A Phase I Trial of a Live, Genetically Modified Salmonella Typhimurium (VNP20009) for the Treatment of Cancer by Intratumoral Injection [NCT00004216]Phase 10 participants Interventional1999-08-31Completed
Division of Microbiology and Infectious Diseases, (DMID) 21-0018: Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae [NCT05294588]Phase 2140 participants (Anticipated)Interventional2022-04-18Recruiting
A Phase 2/3, Randomized, Open-Label, Multi-center Study to Determine the Safety and Efficacy of Solithromycin in Adolescents and Children With Suspected or Confirmed Community-Acquired Bacterial Pneumonia [NCT02605122]Phase 2/Phase 397 participants (Actual)Interventional2016-04-30Terminated(stopped due to Development not proceeding)
A Randomized Controlled Study Assessing Prolonged Parenteral Antibiotics Versus Single-time Intra-operative Intra-dermal Antibiotic Administration in Elective Clean and Clean-contaminated Surgeries for Prevention of Surgical Site Infections [NCT04975945]Phase 4250 participants (Anticipated)Interventional2021-08-31Recruiting
Comparison of Two Lengths of Treatment in Early-onset Ventilated Associated Pneumonia [NCT01559753]Phase 4225 participants (Actual)Interventional1998-01-31Completed
Multicenter, Randomized, And Double-Blind Study To Evaluate The Safety Of Tigecycline Versus A Ceftriaxone Regimen In The Treatment Of Complicated Intra-Abdominal Infections And Community-Acquired Pneumonia In Subjects Of 8-17 Years [NCT01602874]Phase 30 participants (Actual)Interventional2011-01-31Withdrawn
Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis: a Prospective Randomized Placebo-controlled Double-blind Multicenter Trial [NCT03012360]Phase 4154 participants (Anticipated)Interventional2018-02-08Recruiting
Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance [NCT04771884]300 participants (Anticipated)Observational2020-10-01Recruiting
Penile Fracture: A Prospective Randomized Study Comparing Erectile Function at 12 Months After Immediate Degloving Repair Versus Delayed Localized Repair [NCT03449940]46 participants (Actual)Interventional2015-01-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease [NCT00000938]Phase 366 participants InterventionalCompleted
A Comparative Evaluation of the Single-dose Efficacy of Oral Delafloxacin Versus the Single-dose Efficacy of an Intramuscular Injection of Ceftriaxone in Subjects With Uncomplicated Urogenital Gonorrhea [NCT02015637]Phase 3460 participants (Actual)Interventional2014-01-23Terminated
Antibiotic Prophylaxis in Critically Ill Patients After Suspected Aspiration [NCT05079620]Phase 4100 participants (Anticipated)Interventional2021-11-30Recruiting
A Crossover, Cluster Randomised Controlled Trial of Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients (SuDDICU) [NCT02389036]Phase 320,010 participants (Actual)Interventional2017-05-01Completed
Ceftriaxone Versus Chloramphenicol for Treatment of Severe Pneumonia in Children Aged Less Than Five Years at Mulago Hospital: A Randomized Controlled Trial [NCT00372541]Phase 3348 participants (Anticipated)Interventional2006-09-30Completed
Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery: A Double Blinded Randomized Controlled Trial [NCT02996656]88 participants (Anticipated)Interventional2016-12-31Recruiting
The Prevention of Primary Endogenous Ventilator-Associated Pneumonia: A Multicenter Randomized Trial Comparing Continuous Aspiration of Subglottic Content and a 3-Day Course of Ceftriaxone. [NCT00374959]Phase 480 participants Interventional2000-10-31Completed
New Antibiotic Treatment Options for Uncomplicated Anogenital Gonorrhoea Infections - a Double-blind Randomized Controlled Non-inferiority Trial [NCT03294395]Phase 3346 participants (Actual)Interventional2017-09-18Completed
Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins? [NCT02443285]Phase 3100 participants (Anticipated)Interventional2015-01-31Recruiting
Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection Due to Fluoroquinolones Susceptible Bacteria: a Multicentre, Non-inferiority, Double Blind, Randomized Placebo-controlled Trial [NCT02424461]Phase 3400 participants (Anticipated)Interventional2015-02-28Recruiting
Prospective Study of the Etiology, Pathogenesis, Clinical Picture and Outcome of Aseptic Meningitis in Slovenia [NCT02328469]800 participants (Anticipated)Observational2014-06-30Recruiting
Metabolic Potentiation of Aminoglycosides: a Novel Antimicrobial Strategy to Prevent Urinary Tract Infections (UROPOT TRIAL). [NCT05761405]Early Phase 190 participants (Anticipated)Interventional2023-10-16Not yet recruiting
Oral-only Antibiotics for Bone and Joint Infections in Children - A Nationwide Randomized Controlled Trial [NCT04563325]Phase 4180 participants (Actual)Interventional2020-09-15Active, not recruiting
A Multi-centre Randomised Open-label Active Comparator-controlled Non-inferiority Trial Comparing Oral to Intravenous Antibiotics in the Early Management of Klebsiella Pneumoniae Liver Abscess [NCT01723150]Phase 4152 participants (Actual)Interventional2013-11-05Completed
Safety and Efficacy of Single Daily Dose of Ceftriaxone and Metronidazole for Treatment of Complicated Appendicitis in Children [NCT01678365]Phase 443 participants (Actual)Interventional2008-07-31Completed
Efficacy and Safety of Selective Digestive Decontamination in the ICU With Rates of Antibiotic-resistant Bacteria [NCT04839653]60 participants (Anticipated)Interventional2021-05-01Recruiting
Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis [NCT00462020]102 participants (Actual)Interventional2007-03-31Completed
Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic Multipotent Mesenchymal Stem Cells of the Placenta and Umbilical Cord [NCT04461925]Phase 1/Phase 230 participants (Anticipated)Interventional2020-05-02Recruiting
Effect of Ceftriaxone on Neonatal Jaundice [NCT03133637]27 participants (Actual)Observational2016-03-31Completed
The EDGE Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy: Part 1 [NCT02384200]Phase 486 participants (Actual)Interventional2015-03-31Completed
A Multicenter, Multinational, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil Versus Ceftriaxone Plus Vancomycin in Adult Subjects With Community-acquired Bacterial Pneumonia at Risk for Infection Due to Methicill [NCT01645735]Phase 449 participants (Actual)Interventional2012-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00195351 (3) [back to overview]Number of Clinically Evaluable Patients With Clinical Response of Cure at Test-of-Cure (TOC) Visit.
NCT00195351 (3) [back to overview]Number of Microbiologically Evaluable Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit.
NCT00195351 (3) [back to overview]Number of Patients by Microbiologic Response at Test-of-Cure (TOC) Visit.
NCT00230971 (4) [back to overview]Number of Microbiologically Evaluable (ME) Patients by Microbiological Response at Test-of-Cure (TOC) Visit
NCT00230971 (4) [back to overview]Number of Days of Inpatient Healthcare Resource Utilization on or Before Test-of-Cure
NCT00230971 (4) [back to overview]Number of Microbiologically Evaluable (ME) Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit
NCT00230971 (4) [back to overview]Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-Cure (TOC) Visit
NCT00349622 (6) [back to overview]Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year
NCT00349622 (6) [back to overview]Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year
NCT00349622 (6) [back to overview]Survival
NCT00349622 (6) [back to overview]Change in % Vital Capacity From Screening to One Year
NCT00349622 (6) [back to overview]Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year
NCT00349622 (6) [back to overview]Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year
NCT00462020 (5) [back to overview]Total Healthcare Visits
NCT00462020 (5) [back to overview]Operative Time
NCT00462020 (5) [back to overview]Length of Stay After Operation
NCT00462020 (5) [back to overview]Abscess After Appendectomy
NCT00462020 (5) [back to overview]Time to Regular Diet
NCT00493220 (4) [back to overview]Cmax
NCT00493220 (4) [back to overview]Tmax
NCT00493220 (4) [back to overview]AUC0-t
NCT00493220 (4) [back to overview]AUC0-inf
NCT00509106 (1) [back to overview]Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at the Test of Cure (TOC) in the Modified Intent to Treat Efficacy (MITTE) Population
NCT00566111 (4) [back to overview]Change in Hamilton Depression Rating Scale (HDRS) Score From Baseline.
NCT00566111 (4) [back to overview]Number of Subjects Who Achieve Remission as Defined by a HDRS Score < 7.
NCT00566111 (4) [back to overview]Change in Ratings on the Clinical Global Impressions Scale for Bipolar Disorder (CGI-BP).
NCT00566111 (4) [back to overview]Change in Montgomery Asberg Depression Rating Scale (MADRS)Score From Baseline.
NCT00591318 (4) [back to overview]Scale for the Assessment of Positive Symptoms
NCT00591318 (4) [back to overview]Positive and Negative Syndrome Scale - Positive Subscale
NCT00591318 (4) [back to overview]Hamilton Depression Scale
NCT00591318 (4) [back to overview]Hamilton Anxiety Rating Scale
NCT00621504 (1) [back to overview]Clinical Cure Rate at Test-of-Cure (TOC) in the Modified Intent-to-Treat Efficacy (MITTE) Populations
NCT00797108 (8) [back to overview]Percentage of Participants With Clinical Response at Test of Cure (TOC) Visit
NCT00797108 (8) [back to overview]Number of Participants Who Died
NCT00797108 (8) [back to overview]Number of Participants With Abnormal Laboratory Test Findings
NCT00797108 (8) [back to overview]Number of Participants With Abnormal Physical Examination Findings
NCT00797108 (8) [back to overview]Change From Baseline in Community Acquired Pneumonia (CAP) Symptom Questionnaire at Test of Cure (TOC) and Follow-up Visit
NCT00797108 (8) [back to overview]Number of Participants With Categorical Change From Baseline in Vital Signs
NCT00797108 (8) [back to overview]Number of Participants With Microbiological Response at Test of Cure (TOC) Visit
NCT00797108 (8) [back to overview]Percentage of Participants With Clinical Response at End of Treatment (EOT) and Follow-up Visit
NCT01014013 (3) [back to overview]The Number of Patients Who Experience Any Drug-related Adverse Experiences Leading to Discontinuation of Parenteral Study Drug and the Number of Patients With Any Drug-related Serious Adverse Experiences (AEs) During Parenteral Treatment
NCT01014013 (3) [back to overview]Microbiological Response Assessment Profile
NCT01014013 (3) [back to overview]Clinical Response Assessment Profile
NCT01160640 (5) [back to overview]Identification of Endometrial Microorganisms Present Obtained From Women With or Without Evidence of Endometritis.
NCT01160640 (5) [back to overview]Clearance of Anaerobic Organisms From the Endometrium
NCT01160640 (5) [back to overview]The Eradication of M. Genitalium From the Lower and Upper Genital Tract Following Antibiotic Therapy for Acute PID.
NCT01160640 (5) [back to overview]The Prevalence of M. Genitalium in the Cervix and Endometrium From Women With Acute PID.
NCT01160640 (5) [back to overview]Resolution of Clinical Signs and Symptoms of Acute PID - Intention to Treat Analysis
NCT01254344 (2) [back to overview]Percentage of Participants With Favorable Clinical Response
NCT01254344 (2) [back to overview]Percentage of Participants With Success of Prophylaxis
NCT01371838 (16) [back to overview]Per-Patient Microbiological Response at Test of Cure (TOC) Visit in mMITT Population
NCT01371838 (16) [back to overview]Per-Patient Microbiological Response at Test of Cure (TOC) Visit in ME Population
NCT01371838 (16) [back to overview]Per-Pathogen Microbiological Response at Test of Cure (TOC) Visit by Pathogen in ME Population
NCT01371838 (16) [back to overview]Clinical Response at End of Treatment (EOT) Visit in CE Population
NCT01371838 (16) [back to overview]Clinical Response at Test of Cure (TOC) Visit by Pathogen in ME Population
NCT01371838 (16) [back to overview]Clinical Response at the Test of Cure (TOC) Visit in ME Population
NCT01371838 (16) [back to overview]Clinical Response at the Test of Cure (TOC) Visit in MITT Population
NCT01371838 (16) [back to overview]Clinical Relapse at the LFU Visit for Clinical Cure Patients at Test of Cure (TOC) Visit in MITT Population
NCT01371838 (16) [back to overview]Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at Test of Cure (TOC) in CE Population
NCT01371838 (16) [back to overview]Clinical Response at End of Treatment (EOT) Visit in MITT Population
NCT01371838 (16) [back to overview]Microbiological Re-infection/Recurrence at LFU Visit in ME Population
NCT01371838 (16) [back to overview]Microbiological Re-infection/Recurrence at LFU Visit in mMITT Population
NCT01371838 (16) [back to overview]Clinical Relapse at the LFU Visit for Clinical Cure Patients at Test of Cure (TOC) Visit in CE Population
NCT01371838 (16) [back to overview]Overall (Clinical and Radiographic) Success Rate at Test of Cure (TOC) Visit in CE Population
NCT01371838 (16) [back to overview]Overall (Clinical and Radiographic) Success Rate at Test of Cure (TOC) Visit in MITT Population
NCT01371838 (16) [back to overview]Clinical Response at the Test of Cure (TOC) Visit in mMITT Population
NCT01473836 (5) [back to overview]Percentage of Participants Who Was Assessed as Appropriate to Continue Treatment (Investigator Assessment)
NCT01473836 (5) [back to overview]Clinical Response: Response Rate (Investigator Assessment)
NCT01473836 (5) [back to overview]Bacteriological Response: Eradication Rate (Data Review Committee Assessment)
NCT01473836 (5) [back to overview]Bacteriological Response: Eradication Rate (Investigator Assessment)
NCT01473836 (5) [back to overview]Clinical Response: Response Rate (Data Review Committee Assessment)
NCT01645735 (4) [back to overview]Safety Evaluation
NCT01645735 (4) [back to overview]Clinical Outcome at Test of Cure (TOC) in the MITT Population
NCT01645735 (4) [back to overview]Clinical Response at Study Day 4 in the Modified Intent-to-Treat (MITT) Population
NCT01645735 (4) [back to overview]Microbiological Outcomes by Baseline Pathogen at TOC in the Microbiological Modified Intent-to-Treat (mMITT) Population
NCT01659866 (1) [back to overview]Number of Participants With Post-biopsy Infection.
NCT02257918 (14) [back to overview]Number of Participants With no Detectable N. Gonorrhoeae Nucleic Acid in Rectal Specimens in Each Study Arm
NCT02257918 (14) [back to overview]Median in Vitro MIC Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Rectal Site at Baseline
NCT02257918 (14) [back to overview]Median in Vitro MIC Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Urethral/Cervical Sites at Day 6
NCT02257918 (14) [back to overview]Median in Vitro Minimum Inhibitory Concentrations (MIC) Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Urethral/Cervical Sites at Baseline
NCT02257918 (14) [back to overview]Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) Considered Product-related.
NCT02257918 (14) [back to overview]Number of Participants With no Detectable N. Gonorrhoeae Nucleic Acid in Pharyngeal Specimens in Each Study Arm
NCT02257918 (14) [back to overview]Number of Participants With Clinical Cure in Each Study Arm
NCT02257918 (14) [back to overview]Number of Participants With Microbiological Cure at Pharyngeal Sites in Each Study Arm
NCT02257918 (14) [back to overview]Number of Participants With Microbiological Cure at Rectal Sites in Each Study Arm
NCT02257918 (14) [back to overview]Number of Participants With Microbiological Cure at Urethral or Cervical Sites in Each Study Arm
NCT02257918 (14) [back to overview]Number of Participants With no Detectable N. Gonorrhoeae Nucleic Acid in Urethral/Cervical Specimens in Each Study Arm at Baseline.
NCT02257918 (14) [back to overview]Number of Participants With no Detectable N. Gonorrhoeae Nucleic Acid in Urethral/Cervical Specimens in Each Study Arm at Day 6.
NCT02257918 (14) [back to overview]Median in Vitro MIC Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Pharyngeal Site at Baseline
NCT02257918 (14) [back to overview]Median in Vitro MIC Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Pharyngeal Site at Day 6
NCT02384200 (10) [back to overview]Hospital Length of Stay After Surgery
NCT02384200 (10) [back to overview]Number of Partcipants That Were Stone Free After Surgery
NCT02384200 (10) [back to overview]Number and Grade of Postoperative Complications Following Surgery as Graded by the Clavien-Dindo Complication Scale
NCT02384200 (10) [back to overview]Positive Bladder Urine Culture
NCT02384200 (10) [back to overview]Participants With Positive Renal Pelvic Urine Culture
NCT02384200 (10) [back to overview]Participants With Positive Kidney Stone Culture
NCT02384200 (10) [back to overview]Number of Participants With Postoperative Urinary Tract Infection (UTI)
NCT02384200 (10) [back to overview]Number of Participants With a Postoperative Fever Greater Than 38.3 Celsius
NCT02384200 (10) [back to overview]Number of Participants That Developed Sepsis After Surgery
NCT02384200 (10) [back to overview]Number of Participants Admitted to Intensive Care Unit (ICU) After Surgery
NCT02473640 (4) [back to overview]Ribaxamase Concentration in Intestinal Chyme Period 2
NCT02473640 (4) [back to overview]Ceftriaxone Concentration in Intestinal Chyme Period 1
NCT02473640 (4) [back to overview]Ceftriaxone Concentration in Intestinal Chyme Period 2
NCT02473640 (4) [back to overview]Ribaxamase Concentration in Intestinal Chyme Period 1
NCT02567825 (12) [back to overview]The Total Cost of Management of Recurrent Acute Otitis Media Per Quality Adjusted Life Days (QALDs) as a Measure of Cost-Effectiveness
NCT02567825 (12) [back to overview]The Rate of Occurrence of Acute Otitis Media (AOM) Episodes Per Child-Year
NCT02567825 (12) [back to overview]The Mean Score Representing Parental Satisfaction With Clinical Management
NCT02567825 (12) [back to overview]The Mean Days Per Year Children Receive Systemic Antimicrobials for AOM
NCT02567825 (12) [back to overview]The Mean Days Per Year Children Experience Tube Otorrhea
NCT02567825 (12) [back to overview]The Mean Days Per Year Children Experience AOM Symptoms With an Intact Tympanic Membrane (TM)
NCT02567825 (12) [back to overview]The Rate of Occurrence of Acute Otitis Media (AOM) Episodes Per Child-Year According to the Estimated Risk of Acute Otitis Media (AOM) Recurrences at Enrollment
NCT02567825 (12) [back to overview]The Mean Scores on the 6 Item Quality of Life Survey Questionnaire (OM-6)
NCT02567825 (12) [back to overview]The Mean Scores on the 6 Item Caregiver Impact Questionnaire (CIQ)
NCT02567825 (12) [back to overview]The Time to the First Episode of AOM
NCT02567825 (12) [back to overview]The Distribution of Children With a Penicillin-Nonsusceptible Nasopharyngeal or Throat Isolate At Any Follow-up Visit According to the Colonization Status at Enrollment
NCT02567825 (12) [back to overview]The Total Cost of Management of Recurrent Acute Otitis Media Per Quality Adjusted Life Days (QALDs) as a Measure of Cost-Effectiveness According to the Estimated Risk of Acute Otitis Media Recurrences at Enrollment
NCT02605122 (4) [back to overview]Summary of Clinical Improvement
NCT02605122 (4) [back to overview]Overview of Adverse Events By Treatment Arm
NCT02605122 (4) [back to overview]Summary of Early Clinical Response
NCT02605122 (4) [back to overview]Summary of Clinical Cure
NCT02800785 (8) [back to overview]Eventual Appendectomy Incidence Proportion
NCT02800785 (8) [back to overview]Number of Clinic Visits or Emergency Room Visits
NCT02800785 (8) [back to overview]Number of Participants With at Least One Complications From Treatment
NCT02800785 (8) [back to overview]Patient-reported Quality of Life as Measured by EuroQol (EQ-5D)
NCT02800785 (8) [back to overview]Rate of Participants With Perforated Appendicitis
NCT02800785 (8) [back to overview]Rates of Participants With Appendiceal Cancer
NCT02800785 (8) [back to overview]Total Number of Patients Who Had Resolution of Appendicitis Symptoms at 30 Days
NCT02800785 (8) [back to overview]Days in Hospital After Index Treatment Within 90 Days
NCT03840811 (7) [back to overview]Proportion of Participants With Occurrence of Bacteriuria in Non-competitive Infections, by Strain
NCT03840811 (7) [back to overview]Proportion of Participants That Become Infected as Defined by a Positive Urine or Urethral Swab Culture for Infections Initiated With Mixed Inocula
NCT03840811 (7) [back to overview]Proportion of Participants That Become Infected as Defined by a Positive Urine or Urethral Swab Culture Among Infections Initiated With Individual N. Gonorrhoeae Strains in Non-competitive Infections
NCT03840811 (7) [back to overview]Median Time From Inoculation to Treatment Among Infected Participants by Day 6, by Strain, in Non-competitive Infections
NCT03840811 (7) [back to overview]Proportion of Participants With Occurrence of Urethritis in Non-competitive Infections
NCT03840811 (7) [back to overview]The Competitive Index of the Mutant Compared to Wild Type Proportion of Organisms With the Predicted Competitive Advantage Recovered From Urine and/or Urethral Swab Specimens From Infected Participants
NCT03840811 (7) [back to overview]Proportion of Participants With Occurrence of Signs and Symptoms of Urethritis Attributable to Gonococcal Infection in Non-competitive Infections, by Strain
NCT04218695 (11) [back to overview]Biomarker of Infection
NCT04218695 (11) [back to overview]Incident ACLF
NCT04218695 (11) [back to overview]Incident C Difficile Colitis
NCT04218695 (11) [back to overview]Incident Variceal Hemorrhage
NCT04218695 (11) [back to overview]Increase in MELD-Na
NCT04218695 (11) [back to overview]Infections
NCT04218695 (11) [back to overview]Fungal Infection
NCT04218695 (11) [back to overview]Mortality
NCT04218695 (11) [back to overview]Length of Stay
NCT04218695 (11) [back to overview]30-day Mortality
NCT04218695 (11) [back to overview]Biomarker of Infection
NCT04870138 (25) [back to overview]MCP-1 Cytokine Levels in Urine
NCT04870138 (25) [back to overview]MCP-1 Cytokine Levels in Peripheral Blood
NCT04870138 (25) [back to overview]IP-10 Cytokine Levels in Urine
NCT04870138 (25) [back to overview]MIP-1Beta Cytokine Levels in Urine
NCT04870138 (25) [back to overview]VEGF Cytokine Levels in Peripheral Blood
NCT04870138 (25) [back to overview]Fractalkine Cytokine Levels in Peripheral Blood
NCT04870138 (25) [back to overview]Fractalkine Cytokine Levels in Urine
NCT04870138 (25) [back to overview]G-CSF Cytokine Levels in Peripheral Blood
NCT04870138 (25) [back to overview]G-CSF Cytokine Levels in Urine
NCT04870138 (25) [back to overview]VEGF Cytokine Levels in Urine
NCT04870138 (25) [back to overview]GRO Cytokine Levels in Peripheral Blood
NCT04870138 (25) [back to overview]GRO Cytokine Levels in Urine
NCT04870138 (25) [back to overview]IL-1RA Cytokine Levels in Peripheral Blood
NCT04870138 (25) [back to overview]MIP-1Beta Cytokine Levels in Peripheral Blood
NCT04870138 (25) [back to overview]IL-1RA Cytokine Levels in Urine
NCT04870138 (25) [back to overview]IL-8 Cytokine Levels in Peripheral Blood
NCT04870138 (25) [back to overview]IL-8 Cytokine Levels in Urine
NCT04870138 (25) [back to overview]Eotaxin Cytokine Levels in Urine
NCT04870138 (25) [back to overview]IP-10 Cytokine Levels in Peripheral Blood
NCT04870138 (25) [back to overview]EGF Cytokine Levels in Urine
NCT04870138 (25) [back to overview]EGF Cytokine Levels in Peripheral Blood
NCT04870138 (25) [back to overview]The Proportion of Wild Type (WT) Organisms Recovered From Urine and Urethral Swab Specimens From Individual Subjects Infected With Mixed Inoculum
NCT04870138 (25) [back to overview]Eotaxin Cytokine Levels in Peripheral Blood
NCT04870138 (25) [back to overview]The Proportion of Participants That Become Infected With Mixed Inoculum
NCT04870138 (25) [back to overview]The Proportion of Participants That Become Infected With Individual N. Gonorrhoeae Strains in Non-competitive Infections
NCT05149287 (3) [back to overview]Change in RU SATED Score
NCT05149287 (3) [back to overview]Post-operative Narcotic Use
NCT05149287 (3) [back to overview]Change in Visual Analog Scale (VAS) Pain Score

Number of Clinically Evaluable Patients With Clinical Response of Cure at Test-of-Cure (TOC) Visit.

The clinical response was assigned by the investigator according to the protocol-specified guidelines. A clinical response of cure was defined as: the test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection. (NCT00195351)
Timeframe: 10-21 days after the last dose of test article

Interventionparticipants (Number)
Tigecycline133
Ceftriaxone Sodium + Metronidazole139

[back to top]

Number of Microbiologically Evaluable Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit.

The clinical response was assigned by the investigator according to the protocol-specified guidelines. A clinical response of cure was defined as: the test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection. (NCT00195351)
Timeframe: 10-21 days after the last dose of test article

Interventionparticipants (Number)
Tigecycline91
Ceftriaxone Sodium + Metronidazole96

[back to top]

Number of Patients by Microbiologic Response at Test-of-Cure (TOC) Visit.

Microbiologic response assessed at patient level was combined microbiologic responses for all baseline isolates identified in intra-abdominal/blood cultures. Eradication=baseline isolate not recovered from primary infection site/blood; Presumed Eradication=no material available for culture but response was cure; Persistence=baseline isolate recovered from primary infection site/blood; Presumed Persistence=no material available for culture but response was failure; Superinfection=culture from primary infection site was positive for new isolate not identified at baseline & response was failure. (NCT00195351)
Timeframe: 10-21 days after the last dose of test article

,
Interventionparticipants (Number)
Eradication and presumed eradicationPersistence and presumed persistenceSuperinfection
Ceftriaxone Sodium + Metronidazole98393
Tigecycline94447

[back to top]

Number of Microbiologically Evaluable (ME) Patients by Microbiological Response at Test-of-Cure (TOC) Visit

Microbiological response was assessed at patient level was the combined responses for all baseline isolates identified in intra-abdominal and blood cultures. Eradication=baseline isolate not recovered from primary infection site/blood; Presumed Eradication=No sample for culture, clinical response was cure; Persistence=baseline isolate recovered from primary infection site/blood; Presumed Persistence=No sample available for culture, clinical response was failure; Superinfection=culture from primary infection site with new isolate not identified at baseline, clinical response was failure. (NCT00230971)
Timeframe: up to 6 weeks

,
Interventionparticipants (Number)
Eradication + Presumed EradicationPersistence + Presumed PersistenceSuperinfection
Ceftriaxone86220
Tigecycline98213

[back to top]

Number of Days of Inpatient Healthcare Resource Utilization on or Before Test-of-Cure

Healthcare resource utilization assessment included days of overall inpatient hospitalization, days of primary inpatient hospitalization, days of Intensive Care Unit (ICU) treatment and days of non-ICU inpatient hospitalization (NCT00230971)
Timeframe: up to 6 weeks

,
Interventiondays (Mean)
Overall inpatient hospitalizationPrimary inpatient hospitalizationICU treatmentInpatient hospitalization, non-ICU
Ceftriaxone12.6912.166.1410.80
Tigecycline13.0312.628.2411.09

[back to top]

Number of Microbiologically Evaluable (ME) Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit

ME population were subjects who were clinically evaluable and had baseline culture with at least 1 identified isolate that was susceptible to study drug and comparator. The clinical response was assigned by the investigator according to the protocol-specified guidelines. A clinical response of cure was defined as: the test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection. (NCT00230971)
Timeframe: up to 6 weeks

Interventionparticipants (Number)
Tigecycline97
Ceftriaxone86

[back to top]

Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-Cure (TOC) Visit

CE population were those who completed TOC assessment of cure or failure (but not indeterminate) or, in case of premature discontinuation due to lack of efficacy, had completed end of treatment assessment such that assessment of clinical response could be made. Clinical response was assigned by investigator per protocol-specified guidelines and defined as: test article and initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection. TOC performed 10-28 days after last dose of study drug. (NCT00230971)
Timeframe: up to 6 weeks

Interventionparticipants (Number)
Tigecycline162
Ceftriaxone150

[back to top]

Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year

"Amyotrophic Lateral Sclerosis Functional Rating Scale, Revised (ALSFRS-R) is a quickly administered (five minute) ordinal rating scale used to determine patients' assessment of their capability and independence in 12 functional activities/questions. The 12 functional activities/questions are rated on a scale of 0 to 4 for a total scoring range of 0-48, with 48 representing optimal function. All 12 activities are relevant in ALS.~This outcome measure calculation is based on measurements every 8 weeks from the Baseline Visit up until one year." (NCT00349622)
Timeframe: Every 8 weeks for one year

Interventionunits on a scale per 8 weeks (Mean)
Ceftriaxone-1.1311
Placebo-1.2208

[back to top]

Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year

"Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally.~HHD analysis was performed using Percent Change from Baseline. Each subject's baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles.~This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year." (NCT00349622)
Timeframe: Every 12 weeks for one Year

InterventionPercent change per 12 weeks (Mean)
Ceftriaxone-5.2735
Placebo-5.5526

[back to top]

Survival

Survival is presented as median day of survival for each group. Survival is defined as time to death, tracheostomy or the initiation of permanent assisted ventilation (PAV). (NCT00349622)
Timeframe: From date of randomization until date of death, tracheostomy, or the initiation of permanent assisted ventilation (PAV). This was assessed at time of each participant's drug discontinuation and every 2 months thereafter for the life of the study (6 yrs)

Interventiondays (Median)
Ceftriaxone664
Placebo581

[back to top]

Change in % Vital Capacity From Screening to One Year

"Vital Capacity is measured as the percent predicted per subject based on age, gender, and height, and is performed as a Slow Vital Capacity.~This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year." (NCT00349622)
Timeframe: Every 12 weeks for one Year

Interventionpercent change in VC per 12 weeks (Mean)
Ceftriaxone-2.772
Placebo-3.0826

[back to top]

Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year

"The ALS-Specific Quality of Life Scale (ALSQOL). was developed, tested, and validated in subjects with ALS, and is not a health-related quality of life scale. The scale consists of 59 questions that ask about severity of the symptoms of ALS, mood and affect, intimacy, and social issues. Each question for the ALSQOL is scored from 0-10. With 59 questions, total score ranges from 0-590 with scores simply added, with 590 representing highest quality of life. However since 10 is maximally weighted towards negative values on some questions and positive values on others, the following questions must have results transposed (Simply reverse the scale, for instance 10=0 and 0=10) prior to analysis: 1-10, 11, 16, 19, 24, 26, 28, 32, 35, 36, 38, and 41. Optional items are 50, 53, 56, and 59. These questions are not included on any scale or in any quantitative analyses.~This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year." (NCT00349622)
Timeframe: Every 12 weeks for one Year

Interventionunits on a scale per 12 weeks (Mean)
Ceftriaxone-3.5084
Placebo-3.4401

[back to top]

Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year

"Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally.~HHD analysis was performed using Percent Change from Baseline. Each subject's baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles.~This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year." (NCT00349622)
Timeframe: Every 12 weeks for one Year

InterventionPercent change per 12 weeks (Mean)
Ceftriaxone-4.1530
Placebo-4.4807

[back to top]

Total Healthcare Visits

(NCT00462020)
Timeframe: 1 month

InterventionVisits (Mean)
IV Only3.1
IV and Oral Abx3.1

[back to top]

Operative Time

(NCT00462020)
Timeframe: 1 month

InterventionMinutes (Mean)
IV Only41.06
IV and Oral Abx46.30

[back to top]

Length of Stay After Operation

(NCT00462020)
Timeframe: 1 month

InterventionDays (Mean)
IV Only6.06
IV and Oral Abx4.48

[back to top]

Abscess After Appendectomy

(NCT00462020)
Timeframe: 1 month

Interventionnumber of patients (Number)
IV Only10
IV and Oral Abx10

[back to top]

Time to Regular Diet

(NCT00462020)
Timeframe: 1 month

InterventionHours (Mean)
IV Only68.00
IV and Oral Abx61.42

[back to top]

Cmax

Maximum measured plasma ceftriaxone concentration (NCT00493220)
Timeframe: at the time of the highest measured plasma ceftriaxone concentration

Interventionµg/mL (Mean)
HYLENEX SC92.0
Placebo SC82.2
Intravenous150

[back to top]

Tmax

Time to maximum measured plasma ceftriaxone concentration (NCT00493220)
Timeframe: from start of ceftriaxone administration until time of maximum measured plasma ceftriaxone concentration

Interventionhr (Median)
HYLENEX SC2.02
Placebo SC3.02
Intravenous0.502

[back to top]

AUC0-t

Area under the drug concentration-time curve from time zero to the time of the last measurable concentration (calculated by the linear trapezoidal method) (NCT00493220)
Timeframe: Start of ceftriaxone administration through time of last measureable plasma ceftriaxone concentration

Interventionμg*hr/mL (Mean)
HYLENEX SC1139.3
Placebo SC1115.6
Intravenous1065.3

[back to top]

AUC0-inf

Area under the drug concentration-time curve from time zero to infinity, calculated as AUC0-t + Ct/kel (Ct = time of last measurable concentration; kel = terminal elimination rate constant) (NCT00493220)
Timeframe: from the start of ceftriaxone administration to infinity

Interventionµg*hr/mL (Mean)
HYLENEX SC1162.6
Placebo SC1141.3
Intravenous1085.8

[back to top]

Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at the Test of Cure (TOC) in the Modified Intent to Treat Efficacy (MITTE) Population

"Cure:Total resolution of all signs and symptoms of pneumonia (ie,CABP), or improvement to such an extent that further antimicrobial therapy was not necessary~Failure: Any of the following:~Persistence, incomplete clinical resolution, or worsening in signs and symptoms of CABP that required alternative antimicrobial therapy~Treatment-limiting adverse event (AE) leading to discontinuation of study drug therapy, when subject required alternative antimicrobial therapy to treat the pneumonia~Death wherein pneumonia (ie,CABP) was considered causative~Indeterminate: Inability to determine an outcome" (NCT00509106)
Timeframe: 8-15 days after last dose of study drug

,
Interventionparticipants (Number)
Clinical cureClinical failureIndeterminate
Ceftaroline Fosamil for Injection235477
IV Ceftriaxone2065611

[back to top]

Change in Hamilton Depression Rating Scale (HDRS) Score From Baseline.

Number of patients with scores that decreased at four weeks. (NCT00566111)
Timeframe: 4 weeks

Interventionparticipants (Number)
Ceftriaxone2
Placebo1

[back to top]

Number of Subjects Who Achieve Remission as Defined by a HDRS Score < 7.

(NCT00566111)
Timeframe: 4 weeks

Interventionparticipants (Number)
Ceftriaxone0
Placebo0

[back to top]

Change in Ratings on the Clinical Global Impressions Scale for Bipolar Disorder (CGI-BP).

The number of patients that had a decrease on CGI-BP at 4 weeks. (NCT00566111)
Timeframe: 4 weeks

Interventionparticipants (Number)
Ceftriaxone2
Placebo1

[back to top]

Change in Montgomery Asberg Depression Rating Scale (MADRS)Score From Baseline.

The number of patients that had a decrease on MADRS at 4 weeks. (NCT00566111)
Timeframe: 4 weeks

Interventionparticipants (Number)
Ceftriaxone2
Placebo0

[back to top]

Scale for the Assessment of Positive Symptoms

"Scale evaluates positive symptoms of psychosis rated on a scale of 0-5 for each of the 34 items (0 for absent and 5 for severe).~Minimum score is 0 and the maximum score is 170; higher scores are worse." (NCT00591318)
Timeframe: Last observation assessed occurring from baseline through to the end of week 8

Interventionscore on a scale (Mean)
Ceftriaxone27.8
Placebo22.7

[back to top]

Positive and Negative Syndrome Scale - Positive Subscale

"Positive and Negative Syndrome Scale (PANSS) - 7 point scale where 1 is absent and 7 is extreme The positive scale has 7 items. Altogether there are 7 items for the total score (range is a minimum of 7 to a maximum of 49). Lower scores indicate better health.~We report the Positive scale" (NCT00591318)
Timeframe: Last observation assessed occurring from baseline through to the end of week 8

Interventionscore on a scale (Mean)
Ceftriaxone Arm Results17.6
Placebo Arm Results18.6

[back to top]

Hamilton Depression Scale

"This is a clinician-administered scale of depression severity with 17 items with scores ranging from 0-7 with higher scores indicating greater severity of depression.~The range is 0-119, where higher scores indicate greater depression" (NCT00591318)
Timeframe: Last observation assessed occurring from baseline through to the end of week 8

Interventionscore on a scale (Mean)
Ceftriaxone15.4
Placebo7.7

[back to top]

Hamilton Anxiety Rating Scale

"The Hamilton Anxiety Rating Scale is a clinician-administered scale of 14 items, with each item rated 0-4 where 4 is the most severe.~The range is 0-56 where the higher values indicate greater anxiety." (NCT00591318)
Timeframe: Last observation assessed occurring from baseline through to the end of week 8

Interventionscore on a scale (Mean)
Ceftriaxone6.2
Placebo5.8

[back to top]

Clinical Cure Rate at Test-of-Cure (TOC) in the Modified Intent-to-Treat Efficacy (MITTE) Populations

"Cure:Total resolution of all signs and symptoms of pneumonia (ie,CABP), or improvement to such an extent that further antimicrobial therapy was not necessary~Failure: Any of the following:~Persistence, incomplete clinical resolution, or worsening in signs and symptoms of CABP that required alternative antimicrobial therapy~Treatment-limiting adverse event (AE) leading to discontinuation of study drug therapy, when subject required alternative antimicrobial therapy to treat the pneumonia~Death wherein pneumonia (ie,CABP) was considered causative~Indeterminate: Inability to determine an outcome" (NCT00621504)
Timeframe: 8 to 15 days after last dose of study drug

,
Interventionparticipants (Number)
Clinical CureClinical FailureIndeterminate
Ceftaroline Fosamil for Injection2443413
IV Ceftriaxone233589

[back to top]

Percentage of Participants With Clinical Response at Test of Cure (TOC) Visit

"Clinical response (CR) was based primarily on global assessment of clinical presentation of participant made by investigator at evaluation time point. At TOC (7 to 14 days after end of treatment [EOT]) CR was evaluated as cure=resolution of clinical signs and symptoms related to the acute infection, or clinical improvement in which no additional antibiotics were deemed necessary when compared to baseline; failure=persistence or progression of baseline signs and symptoms of pneumonia (for example: body temperature, white blood cell [WBC] count, respiratory rate, auscultatory findings, cough, sputum production), development of new pulmonary or extrapulmonary clinical findings consistent with active infection and those participants that were not assessed for clinical response due to early discontinuation; indeterminate=extenuating circumstances precluded classification to 1 of the above." (NCT00797108)
Timeframe: 7 to 14 days after end of treatment

,,
Interventionpercentage of participants (Number)
CureFailureIndeterminate
Ceftriaxone and Amoxicillin/Clavulanate62.525.012.5
Sulopenem (Multi Intravenous Dose) and PF-0370927087.512.50
Sulopenem (Single Intravenous Dose) and PF-0370927090.010.00

[back to top]

Number of Participants Who Died

(NCT00797108)
Timeframe: Baseline up to 15 to 28 days after EOT

Interventionparticipants (Number)
Sulopenem (Single Intravenous Dose) and PF-037092700
Sulopenem (Multi Intravenous Dose) and PF-037092700
Ceftriaxone and Amoxicillin/Clavulanate0

[back to top]

Number of Participants With Abnormal Laboratory Test Findings

Criteria for laboratory abnormalities: hemoglobin (Hb), hematocrit, red blood cell (RBC) (less than [<] 0.8*lower limit of normal [LLN]); reticulocyte (absolute and percentage) (<0.5*LLN or greater than [>] 1.5*upper LN [ULN]); platelet (<0.5*LLN or >1.75*ULN); white blood cell (WBC) (<0.6*LLN or >1.5*ULN); lymphocyte, neutrophil (<0.8*LLN or >1.2*ULN); eosinophil, monocyte, basophil (>1.2*ULN); bilirubin (BR) (>1.5*ULN); aspartate and alanine aminotransferase, gamma-glutamyl transpeptidase, alkaline phosphatase, lactate dehydrogenase (>3.0*ULN); total protein, albumin (<0.8*LLN or >1.2*ULN);blood urea nitrogen, creatinine (>1.3*ULN); sodium (<0.95*LLN or >1.05*ULN); potassium, chloride, calcium, magnesium, bicarbonate (<0.9*LLN or >1.1*ULN); glucose (<0.6*LLN or >1.5*ULN); urine (pH [<4.5 or >8], glucose, protein, blood, ketone [>=1]). Total number of participants with abnormal laboratory values were reported. (NCT00797108)
Timeframe: Baseline up to 15 to 28 days after EOT

Interventionparticipants (Number)
Sulopenem (Single Intravenous Dose) and PF-037092707
Sulopenem (Multi Intravenous Dose) and PF-037092708
Ceftriaxone and Amoxicillin/Clavulanate9

[back to top]

Number of Participants With Abnormal Physical Examination Findings

A physical examination included an examination of the general appearance, skin, heart, head, eyes, ears, nose, throat, breasts, abdomen, musculoskeletal, neck, neurological, extremities, and others. Criteria for abnormal physical findings were based on investigator's discretion. (NCT00797108)
Timeframe: Last observation (up to 15-28 days after EOT, approximately 38 days)

Interventionparticipants (Number)
Sulopenem (Single Intravenous Dose) and PF-037092700
Sulopenem (Multi Intravenous Dose) and PF-037092701
Ceftriaxone and Amoxicillin/Clavulanate0

[back to top]

Change From Baseline in Community Acquired Pneumonia (CAP) Symptom Questionnaire at Test of Cure (TOC) and Follow-up Visit

The CAP Symptom Questionnaire was a participant reported questionnaire administered by interview. It consisted of 12 items (coughing, chest pains, shortness of breath, sweating, chills, headache, nausea, muscle pain, lack of appetite, trouble concentrating, trouble sleeping, and fatigue). Depending on if the participant had or not had symptoms/problems, they were asked how much they had been bothered by the symptoms/problems over the previous 24 hours. CAP items were rated on the 6-point response scale (0 = participant did not have symptom/problem: 1 = not at all, 2 = a little, 3 = moderately, 4 = quite a bit, 5 = extremely; if the participant had the symptom/problem and were bothered). All 12 items score were summed and averaged to produce a CAP symptom score (range, 0 to 6). High values indicated poorer outcomes (higher symptom bothersomeness). (NCT00797108)
Timeframe: Baseline, TOC (7 to 14 days after end of treatment), Follow-up (15 to 28 days after EOT)

,,
Interventionunits on a scale (Mean)
Baseline (n=10, 8, 8)Change at TOC (n=9, 7, 6)Change at Follow-up Visit (n=10, 8, 8)
Ceftriaxone and Amoxicillin/Clavulanate2.57-1.74-1.52
Sulopenem (Multi Intravenous Dose) and PF-037092702.75-2.02-1.89
Sulopenem (Single Intravenous Dose) and PF-037092702.17-1.43-1.39

[back to top]

Number of Participants With Categorical Change From Baseline in Vital Signs

Participants who met the categorical criteria for increase in vital signs data were reported. Categorical criteria for increase from baseline vital signs data: supine and sitting systolic blood pressure (BP) of greater than or equal to (>=) 30 millimeter of mercury (mmHg); supine and sitting diastolic BP of >=20 mmHg. (NCT00797108)
Timeframe: Baseline up to 15 to 28 days after EOT

,,
Interventionparticipants (Number)
Supine Systolic BP >=30 mmHg (n=3, 5, 4)Sitting Systolic BP >=30 mmHg (n=7, 6, 6)Supine Diastolic BP >=20 mmHg (n=3, 5, 4)Sitting Diastolic BP >=20 mmHg (n=7, 6, 6)
Ceftriaxone and Amoxicillin/Clavulanate1120
Sulopenem (Multi Intravenous Dose) and PF-037092702121
Sulopenem (Single Intravenous Dose) and PF-037092700204

[back to top]

Number of Participants With Microbiological Response at Test of Cure (TOC) Visit

Microbiological response assessed at participant level. Eradication=the absence of the original pathogens from the post-treatment TOC culture of specimen from the original site of infection. Presumed eradication=the complete resolution of signs and symptoms associated with cessation of culturable specimen (for example, sputum). Persistence=the presence of the original pathogen in the post-treatment TOC culture specimen from the original site of infection. Presumed persistence=in a participant who was judged to be a clinical failure and a culture of specimen was not possible or was not done, it was presumed that there was persistence of the pathogen. Not applicable microbiologic response included participants that did not have post-treatment microbiologic cultures due to early discontinuation. Data reported for eradication is combination of eradication and presumed eradication data and data reported for persistence is combination of persistence and presumed persistence data. (NCT00797108)
Timeframe: 7 to 14 days after EOT

,,
Interventionparticipants (Number)
EradicationPersistenceNot Applicable
Ceftriaxone and Amoxicillin/Clavulanate301
Sulopenem (Multi Intravenous Dose) and PF-03709270401
Sulopenem (Single Intravenous Dose) and PF-03709270400

[back to top]

Percentage of Participants With Clinical Response at End of Treatment (EOT) and Follow-up Visit

"CR was based primarily on global assessment of clinical presentation of participant made by investigator at evaluation time point. At EOT (Day 7 to 10) and follow-up (15 to 28 days after EOT), CR was evaluated as cure=resolution of clinical signs and symptoms related to the acute infection, or clinical improvement in which no additional antibiotics were deemed necessary when compared to baseline; failure=persistence or progression of baseline signs and symptoms of pneumonia, development of new pulmonary or extrapulmonary clinical findings consistent with active infection and those participants that were not assessed for clinical response due to early discontinuation; with additional CR evaluated as improvement= of few not all signs and symptoms of pneumonia when compared to baseline and no additional antibacterial treatment required at EOT and indeterminate=extenuating circumstances precluded classification to 1 of the above at follow-up." (NCT00797108)
Timeframe: EOT (Day 7 to 10) , Follow-up (15 to 28 days after EOT)

,,
Interventionpercentage of participants (Number)
EOT: CureEOT: ImprovementEOT: FailureFollow-up: CureFollow-up: FailureFollow-up: Indeterminate
Ceftriaxone and Amoxicillin/Clavulanate75.012.512.562.512.525.0
Sulopenem (Multi Intravenous Dose) and PF-0370927075.025.00.087.50.012.5
Sulopenem (Single Intravenous Dose) and PF-0370927060.030.010.090.00.010.0

[back to top] [back to top]

Microbiological Response Assessment Profile

The difference in favorable microbiological response rates between the 2 treatment groups (MK0826 response rate minus ceftriaxone response rate) was assessed (NCT01014013)
Timeframe: 5 to 9 days post-therapy

InterventionParticipants (Number)
MK082658
Ceftriaxone63

[back to top]

Clinical Response Assessment Profile

The difference in favorable clinical response rates between the 2 treatment groups (MK0826 response rate minus ceftriaxone response rate) was assessed (NCT01014013)
Timeframe: 5 to 9 days post-therapy

InterventionParticipants (Number)
MK082664
Ceftriaxone70

[back to top]

Identification of Endometrial Microorganisms Present Obtained From Women With or Without Evidence of Endometritis.

Identification of endometrial microorganisms present obtained from women with or without evidence of endometritis using a combination of culture methods, rRna sequencing and whole genomic sequencing. The aim is to identify the etiology of endometritis. (NCT01160640)
Timeframe: enrollment

,
Interventionparticipants (Number)
Chlamydia trachomatisNeisseria gonorrhoeaeMycoplasma genitaliumHaemophilus influenzaeGardnerella vaginalisAtopobium vaginaeAnaerobic gram negative rodsAnaerobic gram positive cocciAnaerobic gram positive rods
Histological Endometritis Absent5251251381111
Histological Endometritis Present1781252278104

[back to top]

Clearance of Anaerobic Organisms From the Endometrium

Clearance of anaerobic microorganisms from the endometrium at the 30 day follow-up visit among women who had anaerobic microorganisms detected in their endometrial tissue sample at enrollment. Clearance is defined as no anaerobic microorganisms detected in the endometrial tissue biopsy sample collected at the 30-day visit. (NCT01160640)
Timeframe: Enrollment to 30 days

,
Interventionparticipants (Number)
Clearance of anaerobesAnaerobes detected
Ceftriaxone, Doxycycline, Metronidazole181
Ceftriaxone, Doxycycline, Placebo147

[back to top]

The Eradication of M. Genitalium From the Lower and Upper Genital Tract Following Antibiotic Therapy for Acute PID.

M. genitalium not detected in the cervical and endometrial cultures by nucleic acid amplification testing at the 30 day visit among women who had M. genitalium detected at either anatomical site at the enrollment visit. (NCT01160640)
Timeframe: Enrollment to 30 days

,
Interventionparticipants (Number)
Not detected in cervix & endometriumDetected in cervix or endometrium
Ceftriaxone, Doxycycline, Metronidazole94
Ceftriaxone, Doxycycline, Placebo813

[back to top]

The Prevalence of M. Genitalium in the Cervix and Endometrium From Women With Acute PID.

The number of women who had M. genitalium detected in cervical and endometrial biopsy cultures by nucleic acid amplification tests at enrollment. (NCT01160640)
Timeframe: enrollment

,
Interventionparticipants (Number)
Detected in cervix onlyDetected in cervix and endometriumDetected in endometrium onlyNot detected in cervix and endometrium
Ceftriaxone, Doxycycline, Metronidazole125297
Ceftriaxone, Doxycycline, Placebo168390

[back to top]

Resolution of Clinical Signs and Symptoms of Acute PID - Intention to Treat Analysis

Clinical response to treatment is improvement (reduction) of the McCormack Scale total score from baseline to day 3 follow-up visit. Participants without a 3-day measure were considered treatment failures. (NCT01160640)
Timeframe: Enrollment to 3 day follow up visit

,
Interventionparticipants (Number)
Clinical responseNo response
Ceftriaxone, Doxycycline, Metronidazole9620
Ceftriaxone, Doxycycline, Placebo9423

[back to top]

Percentage of Participants With Favorable Clinical Response

Percentage of participants who have no signs or symptoms of infection at the surgical site and do not require surgical intervention for infection (NCT01254344)
Timeframe: 4 weeks posttreatment

Interventionpercentage of participants (Number)
Ertapenem96.8
Ceftriaxone/Metronidazole95.5

[back to top]

Percentage of Participants With Success of Prophylaxis

Percentage of participants who have no signs or symptoms of infection at the surgical site, do not require surgical intervention for infection, and have no need for further antimicrobial therapy (NCT01254344)
Timeframe: From study drug dose (day of surgery) up to 4 weeks post therapy

Interventionpercentage of participants (Number)
Ertapenem90.4
Ceftriaxone/Metronidazole90.3

[back to top]

Per-Patient Microbiological Response at Test of Cure (TOC) Visit in mMITT Population

An outcome is considered as favourable if the per-pathogen response for that subject is either Eradication (An adequate source specimen demonstrates absence of the original baseline pathogen) or presumed eradication (An adequate source specimen was not available to culture and the patient was assessed as a clinical cure). Here, an adequate source specimen is defined as any sample that may yield the growth of a CABP pathogen eg, blood, respiratory specimens, or pleural fluid. (NCT01371838)
Timeframe: 7-20 days after last day of study drug administration

,
InterventionParticipants (Number)
FavourableUnfavourableIndeterminate
Ceftaroline 600mg6893
Ceftriaxone 2g67218

[back to top]

Per-Patient Microbiological Response at Test of Cure (TOC) Visit in ME Population

An outcome is considered as favourable if the per-pathogen response for that subject is either Eradication (An adequate source specimen demonstrates absence of the original baseline pathogen) or presumed eradication (An adequate source specimen was not available to culture and the patient was assessed as a clinical cure). Here, an adequate source specimen is defined as any sample that may yield the growth of a CABP pathogen eg, blood, respiratory specimens, or pleural fluid. (NCT01371838)
Timeframe: 7-20 days after last day of study drug administration

,
InterventionParticipants (Number)
FavourableUnfavourable
Ceftaroline 600mg507
Ceftriaxone 2g4715

[back to top]

Per-Pathogen Microbiological Response at Test of Cure (TOC) Visit by Pathogen in ME Population

(NCT01371838)
Timeframe: 7-20 days after last dose of study drug

,
InterventionParticipants (Number)
Staphylococcus aureusFavourable - Staphylococcus aureusUnfavourable - Staphylococcus aureusStreptococcus pneumoniaeFavourable - Streptococcus pneumoniaeUnfavourable - Streptococcus pneumoniaeEscherichia coliFavourable - Escherichia coliUnfavourable - Escherichia coliHaemophilus influenzaeFavourable - Haemophilus influenzaeUnfavourable - Haemophilus influenzaeKlebsiella pneumoniaeFavourable - Klebsiella pneumoniaeUnfavourable - Klebsiella pneumoniae
Ceftaroline 600mg440221933301211114113
Ceftriaxone 2g4221513265176116124

[back to top]

Clinical Response at End of Treatment (EOT) Visit in CE Population

(NCT01371838)
Timeframe: Last day of study drug administration

,
InterventionParticipants (Number)
Clinical CureClinical Failure
Ceftaroline 600mg22236
Ceftriaxone 2g18654

[back to top]

Clinical Response at Test of Cure (TOC) Visit by Pathogen in ME Population

(NCT01371838)
Timeframe: 7-20 days after last dose of study drug

,
InterventionParticipants (Number)
Staphylococcus aureusClinical Cure - Staphylococcus aureusClinical Failure - Staphylococcus aureusStreptococcus pneumoniaeClinical Cure - Streptococcus pneumoniaeClinical Failure - Streptococcus pneumoniaeEscherichia coliClinical Cure - Escherichia coliClinical Failure - Escherichia coliHaemophilus influenzaeClinical Cure - Haemophilus influenzaeClinical Failure - Haemophilus influenzaeKlebsiella pneumoniaeClinical Cure - Klebsiella pneumoniaeClinical Failure - Klebsiella pneumoniae
Ceftaroline 600mg440221933301211114113
Ceftriaxone 2g4221513265176116124

[back to top]

Clinical Response at the Test of Cure (TOC) Visit in ME Population

(NCT01371838)
Timeframe: 7-20 days after last day of study drug administration

,
InterventionParticipants (Number)
Clinical CureClinical Failure
Ceftaroline 600mg507
Ceftriaxone 2g4715

[back to top]

Clinical Response at the Test of Cure (TOC) Visit in MITT Population

(NCT01371838)
Timeframe: 7-20 days after last day of study drug administration

,
InterventionParticipants (Number)
Clinical CureClinical FailureIndeterminate
Ceftaroline 600mg3055323
Ceftriaxone 2g2569135

[back to top]

Clinical Relapse at the LFU Visit for Clinical Cure Patients at Test of Cure (TOC) Visit in MITT Population

(NCT01371838)
Timeframe: 21-42 days after last day of study drug administration

,
InterventionParticipants (Number)
Clinical relapseNo Clinical relapseIndeterminate
Ceftaroline 600mg286712
Ceftriaxone 2g24457

[back to top]

Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at Test of Cure (TOC) in CE Population

Cure:Total resolution of all signs and symptoms of pneumonia (ie,CABP), or improvement to such an extent that further antimicrobial therapy was not necessary Failure: Any of the following: •Persistence, incomplete clinical resolution, or worsening in signs and symptoms of CABP that required alternative antimicrobial therapy •Treatment-limiting AE leading to discontinuation of study drug therapy, when subject required alternative antimicrobial therapy to treat the pneumonia •Death wherein pneumonia (ie,CABP) was considered causative Indeterminate: Inability to determine an outcome (NCT01371838)
Timeframe: 7-20 days after last dose of study drug

,
InterventionParticipants (Number)
Clinical CureClinical Failure
Ceftaroline 600mg21741
Ceftriaxone 2g17862

[back to top]

Clinical Response at End of Treatment (EOT) Visit in MITT Population

(NCT01371838)
Timeframe: Last day of study drug administration

,
InterventionParticipants (Number)
Clinical CureClinical FailureIndeterminate
Ceftaroline 600mg3214515
Ceftriaxone 2g2818219

[back to top]

Microbiological Re-infection/Recurrence at LFU Visit in ME Population

(NCT01371838)
Timeframe: 21-42 days after last dose of study drug

,
InterventionParticipants (Number)
Super-InfectionFavourable response at TOCNo Re-Infection Or RecurranceRe-Infection Or Recurrance
Ceftaroline 600mg050500
Ceftriaxone 2g147461

[back to top]

Microbiological Re-infection/Recurrence at LFU Visit in mMITT Population

(NCT01371838)
Timeframe: 21-42 days after last dose of study drug

,
InterventionParticipants (Number)
Super-InfectionFavourable response at TOCNo Re-Infection Or RecurranceRe-Infection Or Recurrance
Ceftaroline 600mg068680
Ceftriaxone 2g267661

[back to top]

Clinical Relapse at the LFU Visit for Clinical Cure Patients at Test of Cure (TOC) Visit in CE Population

(NCT01371838)
Timeframe: 21-42 days after last day of study drug administration

,
InterventionParticipants (Number)
Clinical relapseNo Clinical relapseIndeterminate
Ceftaroline 600mg199612
Ceftriaxone 2g16738

[back to top]

Overall (Clinical and Radiographic) Success Rate at Test of Cure (TOC) Visit in CE Population

(NCT01371838)
Timeframe: 7-20 days after last dose of study drug

,
InterventionParticipants (Number)
SuccessFailure
Ceftaroline 600mg21741
Ceftriaxone 2g17862

[back to top]

Overall (Clinical and Radiographic) Success Rate at Test of Cure (TOC) Visit in MITT Population

(NCT01371838)
Timeframe: 7-20 days after last day of study drug administration

,
InterventionParticipants (Number)
SuccessFailureIndeterminate
Ceftaroline 600mg3055323
Ceftriaxone 2g2569135

[back to top]

Clinical Response at the Test of Cure (TOC) Visit in mMITT Population

(NCT01371838)
Timeframe: 7-20 days after last day of study drug administration

,
InterventionParticipants (Number)
Clinical CureClinical FailureIndeterminate
Ceftaroline 600mg6893
Ceftriaxone 2g67218

[back to top]

Percentage of Participants Who Was Assessed as Appropriate to Continue Treatment (Investigator Assessment)

"The appropriateness of treatment continuation was evaluated on Day 4 by the investigator as continuation, discontinuation or indeterminate based on the clinical response. The percentage of participants was calculated from the following formula; number of participants assessed as continuation over total number of participants that excluding ones assessed as indeterminate multiplied by 100." (NCT01473836)
Timeframe: Baseline to Day 4

Interventionpercentage of participants (Number)
Metronidazole/Ceftriaxone100.0

[back to top]

Clinical Response: Response Rate (Investigator Assessment)

"Clinical response was evaluated by the investigator as effective (cured or improved), ineffective (not meeting effective criteria), or indeterminate at the end of treatment (EOT) and the test of cure (TOC: 7 days after EOT) based on clinical symptoms, ultrasound images and necessity of other treatment. TOC was the primary analysis of this outcome measure. Cured = clinical symptoms and abnormal findings at the start of the study were disappeared and considered other antibiotics were not required during the study and after the assessment time point. Improved = clinical symptoms and abnormal findings at the start of the study were improved and considered other antibiotics were not required during the study and after the assessment time point. Response rate was calculated from the following formula; number of participants evaluated as effective over total number of participants that excluding ones evaluated as indeterminate multiplied by 100." (NCT01473836)
Timeframe: Baseline to EOT (up to 14 days), TOC

Interventionpercentage of participants (Number)
End of Treatment (n=30)Test of Cure (n=29)
Metronidazole/Ceftriaxone96.7100.0

[back to top]

Bacteriological Response: Eradication Rate (Data Review Committee Assessment)

"Bacteriological response was evaluated as eradication (eradication, presumed eradication or colonization), persistence, or indeterminate by the data review committee, at Day 4, at the end of treatment (EOT), and the test of cure (TOC: 7 days after EOT). Eradication Rate was calculated from the following formula, number of participants with bacteria eradication, presumed eradication or colonization over total number of participants that excluding ones evaluated as indeterminate multiplied by 100." (NCT01473836)
Timeframe: Baseline to Day 4, EOT (up to 14 days), TOC

Interventionpercentage of participants (Number)
Day 4End of TreatmentTest of Cure
Metronidazole/Ceftriaxone100.0100.0100.0

[back to top]

Bacteriological Response: Eradication Rate (Investigator Assessment)

"Bacteriological response was evaluated as eradication (eradication, presumed eradication or colonization), persistence, or indeterminate by the investigator at the end of treatment (EOT), and the test of cure (TOC: 7 days after EOT). Eradication Rate was calculated from the following formula, number of participants with bacteria eradication, presumed eradication or colonization over total number of participants that excluding ones evaluated as indeterminate multiplied by 100." (NCT01473836)
Timeframe: Baseline to Day 4, EOT (up to 14 days), TOC

Interventionpercentage of participants (Number)
Day 4EOTTOC
Metronidazole/Ceftriaxone100.0100.0100.0

[back to top]

Clinical Response: Response Rate (Data Review Committee Assessment)

"Clinical response was evaluated by the data review committee as effective (cured or improved), ineffective (not meeting effective criteria), or indeterminate at the end of treatment (EOT) and the test of cure (TOC: 7 days after EOT) based on clinical symptoms, ultrasound images and necessity of other treatment. TOC was the primary analysis of this outcome measure. Cured = clinical symptoms and abnormal findings at the start of the study were disappeared and considered other antibiotics were not required during the study and after the assessment time point. Improved = clinical symptoms and abnormal findings at the start of the study were improved and considered other antibiotics were not required during the study and after the assessment time point. Response rate was calculated from the following formula; number of participants evaluated as effective over total number of participants that excluding ones evaluated as indeterminate multiplied by 100." (NCT01473836)
Timeframe: Baseline to EOT (up to 14 days), TOC

Interventionpercentage of participants (Number)
End of Treatment (n=30)Test of Cure (n=30)
Metronidazole/Ceftriaxone96.696.7

[back to top]

Safety Evaluation

Adverse events (AEs), serious adverse events (SAEs), deaths, discontinuation due to AEs (NCT01645735)
Timeframe: Baseline (Day 0) to Day 49

,
Interventionparticipants (Number)
Any TEAEAny study drug-related TEAEsAny SAEsAny study drug-related SAEsDiscontinuation of IV or oral study drug due to AEDiscontinuation of IV study drug only due to AEDeaths
Ceftaroline17330111
Ceftriaxone Plus Vancomycin9220110

[back to top]

Clinical Outcome at Test of Cure (TOC) in the MITT Population

"An assessment of clinical outcome was made by the Investigator at TOC. The clinical outcome categories were:~Cure: Resolution of all acute signs and symptoms of CABP or improvement to such an extent that no further antimicrobial therapy was required~Failure: Subjects who meet either of the following criteria:~Incomplete resolution or worsening of CABP signs and symptoms or development of new CABP signs or symptoms requiring alternative nonstudy antimicrobial therapy~Death in which CABP is contributory~Indeterminate: Study data are not available for evaluation of efficacy for any reason, including:~Death in which CABP is clearly noncontributory~Lost to follow-up~Extenuating circumstances precluding classification as a cure or failure~A favorable clinical outcome at Test-of Cure (TOC) was clinical cure." (NCT01645735)
Timeframe: Test of Cure, an average of 3 weeks

,
Interventionparticipants (Number)
Clinical CureClinical FailureIndeterminate
Ceftaroline2732
Ceftriaxone Plus Vancomycin1520

[back to top]

Clinical Response at Study Day 4 in the Modified Intent-to-Treat (MITT) Population

"Clinical response was defined as meeting all of the following criteria:~Symptom Improvement - Improvement in at least 2 and no worsening of any of the following symptoms compared to baseline:~Cough~Dyspnea~Sputum production~Chest pain~Clinical Stability (per Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) guidelines; Mandell et al, 2007):~Temperature ≤ 37.8°C~Heart rate ≤ 100 beats/min~Respiratory rate ≤ 24 breaths/min~Systolic blood pressure ≥ 90 mmHg~Oxygen saturation ≥ 90%~Confusion/disorientation absent" (NCT01645735)
Timeframe: Study Day 4

,
Interventionparticipants (Number)
ResponderNon-ResponderIncomplete Data
Ceftaroline14162
Ceftriaxone Plus Vancomycin881

[back to top]

Microbiological Outcomes by Baseline Pathogen at TOC in the Microbiological Modified Intent-to-Treat (mMITT) Population

An overall microbiological outcome was derived based on the subject's baseline pathogen. As no follow-up specimens were collected at the TOC visit for any subjects, all microbiological outcomes were derived based strictly on clinical outcomes, as either presumed eradication (ie, source specimen was not available to culture and the subject was assessed as clinical cure) , presumed persistence (ie, source specimen was not available to culture and the subject was assessed as a clinical failure), or indeterminate (ie, source specimen was not available to culture and the subject's clinical response was assessed as indeterminate). (NCT01645735)
Timeframe: Test of Cure, an average of 3 weeks

,
Interventionparticipants (Number)
Presumed eradicationPresumed persistenceIndeterminate
Ceftaroline2302
Ceftriaxone Plus Vancomycin1220

[back to top]

Number of Participants With Post-biopsy Infection.

To measure and compare the rates of infection following TRUSP in subjects with and without CR-GNB. This measure is number of participants with post-biopsy infection. (NCT01659866)
Timeframe: 30 days post-biopsy

Interventionparticipants (Number)
Cipro-susceptible6
Cipro-resistant3

[back to top]

Number of Participants With no Detectable N. Gonorrhoeae Nucleic Acid in Rectal Specimens in Each Study Arm

Gonorrhea and Chlamydia nucleic acid amplification tests (GC/CT NAAT) were performed at baseline and Day 6 with specimens collected at the rectal site. Detectable nucleic acid was derived from GC/CT NAAT testing. If N. gonorrhoeae nucleic acid was detected, the result of the test was classified as positive. If no nucleic acid was detected, the result of the test was classified as negative. If a clear result could not be determined for any reason, the result of the test was classified as indeterminate. (NCT02257918)
Timeframe: Baseline and Day 6

,,
InterventionParticipants (Count of Participants)
BaselineDay 6
AZD0914/ETX0914 2000mg05
AZD0914/ETX0914 3000mg07
Ceftriaxone 500mg03

[back to top]

Median in Vitro MIC Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Rectal Site at Baseline

For all positive cultures of specimens collected from the rectum, isolates were collected and tested for antimicrobial susceptibility profiles and the MIC was determined. MIC was defined as the lowest concentration of an antimicrobial that inhibited the visible growth of a microorganism after overnight incubation. The MIC breakpoint was a chosen concentration of an antibiotic which defines whether a bacterial isolate is susceptible or resistant to the antibiotic. If the MIC was less than or equal to the susceptibility breakpoint, the bacteria was considered susceptible to the antibiotic. If the MIC was greater than this value, the bacteria was considered intermediate or resistant to the antibiotic. (NCT02257918)
Timeframe: Day 1 (Baseline)

,,
Interventionµg/mL (Median)
AZD0914/ETX0914Ceftriaxone
AZD0914/ETX0914 2000mg0.0600.004
AZD0914/ETX0914 3000mg0.0930.008
Ceftriaxone 500mg0.1250.004

[back to top]

Median in Vitro MIC Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Urethral/Cervical Sites at Day 6

For all positive cultures of specimens collected from the urethra or cervix, isolates were collected and tested for antimicrobial susceptibility profiles and the MIC was determined. MIC was defined as the lowest concentration of an antimicrobial that inhibited the visible growth of a microorganism after overnight incubation. The MIC breakpoint was a chosen concentration of an antibiotic which defines whether a bacterial isolate is susceptible or resistant to the antibiotic. If the MIC was less than or equal to the susceptibility breakpoint, the bacteria was considered susceptible to the antibiotic. If the MIC was greater than this value, the bacteria was considered intermediate or resistant to the antibiotic. (NCT02257918)
Timeframe: Day 6

,
Interventionµg/mL (Median)
AZD0914/ETX0914Ceftriaxone
AZD0914/ETX0914 2000mg0.1880.012
AZD0914/ETX0914 3000mg0.0600.001

[back to top]

Median in Vitro Minimum Inhibitory Concentrations (MIC) Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Urethral/Cervical Sites at Baseline

For all positive cultures of specimens collected from the urethra or cervix, isolates were collected and tested for antimicrobial susceptibility profiles and the minimum inhibitory concentration (MIC) was determined. MIC was defined as the lowest concentration of an antimicrobial that inhibited the visible growth of a microorganism after overnight incubation. The MIC breakpoint was a chosen concentration of an antibiotic which defines whether a bacterial isolate is susceptible or resistant to the antibiotic. If the MIC was less than or equal to the susceptibility breakpoint, the bacteria was considered susceptible to the antibiotic. If the MIC was greater than this value, the bacteria was considered intermediate or resistant to the antibiotic. (NCT02257918)
Timeframe: Day 1 (Baseline)

,,
Interventionµg/mL (Median)
AZD0914/ETX0914Ceftriaxone
AZD0914/ETX0914 2000mg0.1250.008
AZD0914/ETX0914 3000mg0.0930.008
Ceftriaxone 500mg0.0600.004

[back to top]

Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) Considered Product-related.

Adverse events are defined as any untoward medical occurrence regardless of its causal relationship to the study treatment. Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required inpatient hospitalization or prolongation thereof was a congenital anomaly/birth defect; or may have jeopardized the subject or required intervention to prevent one of the outcomes. Relationship to study product was determined by the investigator and defined as a reasonable possibility that the study product caused the adverse event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event. (NCT02257918)
Timeframe: Day 1 through Day 31

,,
InterventionParticipants (Count of Participants)
Related AEsRelated SAEs
AZD0914/ETX0914 2000mg90
AZD0914/ETX0914 3000mg120
Ceftriaxone 500mg60

[back to top]

Number of Participants With no Detectable N. Gonorrhoeae Nucleic Acid in Pharyngeal Specimens in Each Study Arm

Gonorrhea and Chlamydia nucleic acid amplification tests (GC/CT NAAT) were performed at baseline and Day 6 with specimens collected at the pharyngeal site. Detectable nucleic acid was derived from GC/CT NAAT testing. If N. gonorrhoeae nucleic acid was detected, the result of the test was classified as positive. If no nucleic acid was detected, the result of the test was classified as negative. If a clear result could not be determined for any reason, the result of the test was classified as indeterminate. (NCT02257918)
Timeframe: Baseline and Day 6

,,
InterventionParticipants (Count of Participants)
BaselineDay 6
AZD0914/ETX0914 2000mg02
AZD0914/ETX0914 3000mg06
Ceftriaxone 500mg02

[back to top]

Number of Participants With Clinical Cure in Each Study Arm

A clinical cure was defined as the resolution of all signs and symptoms of gonorrhea (e.g. cervical/vaginal/urethral discharge, dysuria, dyspareunia, vulvovaginal irritation, sore throat) that were present at enrollment with the exception of vaginal discharge due to yeast vaginitis or bacterial vaginosis. A clinical failure was defined by the presence of any sign or symptom of gonorrhea that was also present at enrollment with the exception of vaginal discharge due to yeast vaginitis or bacterial vaginosis. The investigator also submitted his/her determination of whether the participant met or did not meet the criteria for clinical cure (or whether it is unknown if the participant met the criteria). In the event the investigator's assessment of clinical cure did not coincide with the definitions of clinical cure/failure, the investigator's assessment was the final adjudicator. (NCT02257918)
Timeframe: Day 6

InterventionParticipants (Count of Participants)
AZD0914/ETX0914 2000mg52
AZD0914/ETX0914 3000mg46
Ceftriaxone 500mg26

[back to top]

Number of Participants With Microbiological Cure at Pharyngeal Sites in Each Study Arm

Microbiological cure was assessed at the Test of Cure visit (TOC). Microbiological Cure was derived from the Neisseria gonorrhoeae culture result and assessed by anatomical site. All subjects were swabbed at the pharyngeal site. Remel RapID NH tests were performed on pure cultures obtained from swab specimens. A participant was defined as a microbiological cure if N. gonorrhoeae was not detectable by culture at TOC. (NCT02257918)
Timeframe: Day 6

InterventionParticipants (Count of Participants)
AZD0914/ETX0914 2000mg4
AZD0914/ETX0914 3000mg9
Ceftriaxone 500mg4

[back to top]

Number of Participants With Microbiological Cure at Rectal Sites in Each Study Arm

Microbiological cure was assessed at the TOC visit. Microbiological cure was derived from the Neisseria gonorrhoeae culture result and assessed by anatomical site. All participants were swabbed at the rectal site. Remel RapID NH tests were performed on pure cultures obtained from swab specimens. A subject was defined as a microbiological cure if N. gonorrhoeae was not detectable by culture at TOC. (NCT02257918)
Timeframe: Day 6

InterventionParticipants (Count of Participants)
AZD0914/ETX0914 2000mg5
AZD0914/ETX0914 3000mg7
Ceftriaxone 500mg3

[back to top]

Number of Participants With Microbiological Cure at Urethral or Cervical Sites in Each Study Arm

Microbiological cure was assessed at the Test of Cure visit (TOC). Microbiological Cure was derived from the Neisseria gonorrhoeae culture result and assessed by anatomical site. Male participants were swabbed at the urethral site and female participants at the cervical site. Remel RapID NH tests were performed on pure cultures obtained from swab specimens. A participant was defined as a microbiological cure if N. gonorrhoeae was not detectable by culture at TOC. (NCT02257918)
Timeframe: Day 6

InterventionParticipants (Count of Participants)
AZD0914/ETX0914 2000mg55
AZD0914/ETX0914 3000mg54
Ceftriaxone 500mg28

[back to top]

Number of Participants With no Detectable N. Gonorrhoeae Nucleic Acid in Urethral/Cervical Specimens in Each Study Arm at Baseline.

Gonorrhea and Chlamydia nucleic acid amplification tests (GC/CT NAAT) were performed at baseline with specimens collected at the cervical/urethral site. Detectable nucleic acid was derived from GC/CT NAAT testing. If N. gonorrhoeae nucleic acid was detected, the result of the test was classified as positive. If no nucleic acid was detected, the result of the test was classified as negative. If a clear result could not be determined for any reason, the result of the test was classified as indeterminate. (NCT02257918)
Timeframe: Day 1 (Baseline)

InterventionParticipants (Count of Participants)
AZD0914/ETX0914 2000mg0
AZD0914/ETX0914 3000mg0
Ceftriaxone 500mg1

[back to top]

Number of Participants With no Detectable N. Gonorrhoeae Nucleic Acid in Urethral/Cervical Specimens in Each Study Arm at Day 6.

Gonorrhea and Chlamydia nucleic acid amplification tests (GC/CT NAAT) were performed at Day 6 with specimens collected at the cervical/urethral site. Detectable nucleic acid was derived from GC/CT NAAT testing. If N. gonorrhoeae nucleic acid was detected, the result of the test was classified as positive. If no nucleic acid was detected, the result of the test was classified as negative. If a clear result could not be determined for any reason, the result of the test was classified as indeterminate. (NCT02257918)
Timeframe: Day 6

InterventionParticipants (Count of Participants)
AZD0914/ETX0914 2000mg48
AZD0914/ETX0914 3000mg42
Ceftriaxone 500mg25

[back to top]

Median in Vitro MIC Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Pharyngeal Site at Baseline

For all positive cultures of specimens collected from the pharynx, isolates were collected and tested for antimicrobial susceptibility profiles and the MIC was determined. MIC was defined as the lowest concentration of an antimicrobial that inhibited the visible growth of a microorganism after overnight incubation. The MIC breakpoint was a chosen concentration of an antibiotic which defines whether a bacterial isolate is susceptible or resistant to the antibiotic. If the MIC was less than or equal to the susceptibility breakpoint, the bacteria was considered susceptible to the antibiotic. If the MIC was greater than this value, the bacteria was considered intermediate or resistant to the antibiotic. (NCT02257918)
Timeframe: Day 1 (Baseline)

,,
Interventionµg/mL (Median)
AZD0914/ETX0914Ceftriaxone
AZD0914/ETX0914 2000mg0.0600.008
AZD0914/ETX0914 3000mg0.1250.008
Ceftriaxone 500mg0.0930.006

[back to top]

Median in Vitro MIC Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Pharyngeal Site at Day 6

For all positive cultures of specimens collected from the pharynx, isolates were collected and tested for antimicrobial susceptibility profiles and the MIC was determined. MIC was defined as the lowest concentration of an antimicrobial that inhibited the visible growth of a microorganism after overnight incubation. The MIC breakpoint was a chosen concentration of an antibiotic which defines whether a bacterial isolate is susceptible or resistant to the antibiotic. If the MIC was less than or equal to the susceptibility breakpoint, the bacteria was considered susceptible to the antibiotic. If the MIC was greater than this value, the bacteria was considered intermediate or resistant to the antibiotic. (NCT02257918)
Timeframe: Day 6

,
Interventionµg/mL (Median)
AZD0914/ETX0914Ceftriaxone
AZD0914/ETX0914 2000mg0.1250.012
AZD0914/ETX0914 3000mg0.0930.012

[back to top]

Hospital Length of Stay After Surgery

Number of days in a hospital setting after kidney stone surgery (defined as number of midnights in hospitalization) (NCT02384200)
Timeframe: Within 12 weeks following day of surgery

Interventiondays (Mean)
Antibiotic1.097
No Preoperative Oral Antibiotics1.467

[back to top]

Number of Partcipants That Were Stone Free After Surgery

the absence of stone fragments >2mm on postoperative imaging following kidney stone surgery (PCNL) (NCT02384200)
Timeframe: Within 12 weeks following day of surgery

InterventionParticipants (Count of Participants)
Antibiotic22
No Preoperative Oral Antibiotics25

[back to top]

Number and Grade of Postoperative Complications Following Surgery as Graded by the Clavien-Dindo Complication Scale

The Clavien-Dindo grading scale, originally described in 2004, is a widely used throughout surgery to grade adverse events (i.e. complications) which occur as a result of surgical procedures; it is used in most urology units and has become the standard classification system for many surgical specialities. The grading system uses a Grade I - Grade V scale, with Grade V being the most severe. (NCT02384200)
Timeframe: Within 12 weeks following day of surgery

,
Interventionparticipants (Number)
Grade IGrade IIGrade IIIAGrade IIIBGrade IV & V
Antibiotic83030
No Preoperative Oral Antibiotics45140

[back to top]

Positive Bladder Urine Culture

bladder urine culture taken during kidney stone surgery (NCT02384200)
Timeframe: once, within 30 minutes of start of surgery

InterventionParticipants (Count of Participants)
Antibiotic1
No Preoperative Oral Antibiotics1

[back to top]

Participants With Positive Renal Pelvic Urine Culture

percutaneously taken renal pelvic urine culture (NCT02384200)
Timeframe: once at time of surgery, within 10 minutes of obtaining percutaneous access to the kidney

InterventionParticipants (Count of Participants)
Antibiotic1
No Preoperative Oral Antibiotics1

[back to top]

Participants With Positive Kidney Stone Culture

Kidney stone sent for culture (NCT02384200)
Timeframe: once, within 6 hours of start of surgery

InterventionParticipants (Count of Participants)
Antibiotic4
No Preoperative Oral Antibiotics4

[back to top]

Number of Participants With Postoperative Urinary Tract Infection (UTI)

symptomatic urinary tract infection (NCT02384200)
Timeframe: Within 12 weeks following day of surgery

InterventionParticipants (Count of Participants)
Antibiotic2
No Preoperative Oral Antibiotics0

[back to top]

Number of Participants With a Postoperative Fever Greater Than 38.3 Celsius

Body temperature >= 38.3 degrees Celsius (NCT02384200)
Timeframe: within 7 days following day of surgery

InterventionParticipants (Count of Participants)
Antibiotic0
No Preoperative Oral Antibiotics1

[back to top]

Number of Participants That Developed Sepsis After Surgery

"Sepsis will be defined by the 2012 International Guidelines for Management of Severe Sepsis and Septic Shock where 2 or more of the following variables are present and temporally associated~Temp > 38.3 C or <36 C~Heart Rate > 90/min (at least 12 hrs after surgery)~Respiratory Rate > 20/min (at least 12 hrs after surgery)~Altered mental status: defined as lack of orientation to either name, place, or time/date.~Systolic Blood Pressure (SBP) < 90 mmHg, Mean Arterial Pressure < 70 mmHg, or SBP decrease >40 mmHg in adults~WBC >12000 or < 4000" (NCT02384200)
Timeframe: Within 7 days following day of surgery

InterventionParticipants (Count of Participants)
Antibiotic5
No Preoperative Oral Antibiotics6

[back to top]

Number of Participants Admitted to Intensive Care Unit (ICU) After Surgery

admission to ICU level nursing unit during primary hospitalization following kidney stone surgery (PCNL). (NCT02384200)
Timeframe: within 7 days following day of surgery

InterventionParticipants (Count of Participants)
Antibiotic2
No Preoperative Oral Antibiotics0

[back to top]

Ribaxamase Concentration in Intestinal Chyme Period 2

Concentrations of ribaximase (SYN-004) in intestinal chyme (NCT02473640)
Timeframe: 0-8.5 hours

Interventionng/mL (Mean)
Hour 0Hour 0.5Hour 1.5Hour 2.5Hour 3.5Hour 4.5Hour 5.5Hour 6.5Hour 7.5Hour 8.5
150 mg SYN-0040.0043628197745669366369642316388743475635092

[back to top]

Ceftriaxone Concentration in Intestinal Chyme Period 1

Ceftriaxone concentration in the presence of SYN-004 and the absence of esomeprazole. (NCT02473640)
Timeframe: 0-8.5 hours

Interventionug/mL (Mean)
Hour 0Hour 0.5Hour 1.5Hour 2.5Hour 3.5Hour 4.5Hour 5.5Hour 6.5Hour 7.5Hour 8.5
150 mg SYN-0040.000.005.60150.90231.40173.0029.001.400.102.00

[back to top]

Ceftriaxone Concentration in Intestinal Chyme Period 2

Ceftriaxone concentration in the presence of SYN-004 and the absence of esomeprazole. (NCT02473640)
Timeframe: 0-8.5 hours

Interventionug/mL (Mean)
Hour 0Hour 0.5Hour 1.5Hour 2.5Hour 3.5Hour 4.5Hour 5.5Hour 6.5Hour 7.5Hour 8.5
150 mg SYN-0040.000.009.8031.7042.8080.500.800.100.000.20

[back to top]

Ribaxamase Concentration in Intestinal Chyme Period 1

Concentrations of ribaximase (SYN-004) in intestinal chyme (NCT02473640)
Timeframe: 0-8.5 hours

Interventionng/mL (Mean)
Hour 0Hour 0.5Hour 1.5Hour 2.5Hour 3.5Hour 4.5Hour 5.5Hour 6.5Hour 7.5Hour 8.5
150 mg SYN-0040.0021113167275679573090103171153274111946

[back to top]

The Total Cost of Management of Recurrent Acute Otitis Media Per Quality Adjusted Life Days (QALDs) as a Measure of Cost-Effectiveness

Total costs in US dollars were calculated by summing costs of lost wages, office visits, medical procedures, hospitalizations, and medications. Total QALDs were calculated by summing daily utility values. A utility value of 1.0 was assumed for days without AOM, otorrhea, or hospitalization. For days where these states were reported, published utility values associated with each state were used. To arrive at the final measure, total costs were divided by total utility values. (NCT02567825)
Timeframe: Day 1 until Day 786. The mean length of actual follow-up was 662 days / 1.8 years.

InterventionUS dollars per quality adjusted life day (Number)
Surgical Management7.19
Non-Surgical Management5.79

[back to top]

The Rate of Occurrence of Acute Otitis Media (AOM) Episodes Per Child-Year

An episode of AOM is considered a discrete occurrence if symptoms and signs persisted for, or recurred, 17 or more days after the start of antimicrobial treatment. The rate is calculated by dividing the total number of occurrences by the total number of years of follow-up. Multiple imputation was used when follow-up was incomplete. (NCT02567825)
Timeframe: Day 1 until Day 786. The mean length of actual follow-up was 662 days / 1.8 years. For each child with incomplete 2-year follow-up, multiple imputation was used and values for the remaining days/years were imputed.

InterventionOccurrences per child-year (Mean)
Surgical Management1.48
Non-Surgical Management1.56

[back to top]

The Mean Score Representing Parental Satisfaction With Clinical Management

At the end-of-study visit, parents were asked to rate their level of satisfaction with their child's assigned management using a 5-point scale with higher numbers indicating greater satisfaction, specifically 1 = very dissatisfied, 2 = somewhat dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = somewhat satisfied, and 5 = very satisfied. (NCT02567825)
Timeframe: The end-of-study visit. The mean day for this visit was 726.

InterventionScore on a scale (Mean)
Surgical Management4.64
Non-Surgical Management4.43

[back to top]

The Mean Days Per Year Children Receive Systemic Antimicrobials for AOM

Systemic antibiotics include Amoxicillin-Clavulanate, Ceftriaxone, Cefdinir, Amoxicillin, Azithromycin, Clindamycin, Levofloxacin, Bactrim, Cefprozil, Omnicef and Trimethoprim-Sulfamethoxazole. The days per year, for each child, is calculated by dividing the total number of days the child receives systemic antimicrobials for AOM (based on the recorded start and stop dates) by the total number of years of follow-up. (NCT02567825)
Timeframe: Day 1 until Day 786. The mean length of follow-up was 662 days / 1.8 years.

InterventionDays per year (Mean)
Surgical Management8.76
Non-Surgical Management12.92

[back to top]

The Mean Days Per Year Children Experience Tube Otorrhea

Adverse events, including tube-associated otorrhea, were collected from enrollment through the end of study. Each study visit included a review of adverse events. Any such event that occurred since the previous visit was recorded, including the date of onset and the date of resolution. For each child, the days per year of tube otorrhea is calculated by dividing the total number of days of tube otorrhea (based on dates of onset and resolution) by the total number of years of follow-up. (NCT02567825)
Timeframe: Day 1 until Day 786. The mean length of follow-up was 662 days / 1.8 years.

InterventionDays per year (Mean)
Surgical Management7.96
Non-Surgical Management2.83

[back to top]

The Mean Days Per Year Children Experience AOM Symptoms With an Intact Tympanic Membrane (TM)

For a given child, if a day of follow-up coincides with a study visit, the status of the right and left TMs are recorded at the ear exam. If a day of follow-up does not coincide with a study visit the status of each TM is assumed to be the same as the status on the prior day. Scores are used from the 5-item Acute Otitis Media Severity of Symptoms (AOM-SOS) scale (version 4.0) in which parents are asked to rate symptoms, as compared with the child's usual state, as none, a little, or a lot, with corresponding scores of 0, 1, and 2. Total scores range from 0 to 10, with higher scores indicating greater severity of symptoms. Scores are recorded at study visits and on diaries. The total number of days with an intact TM and a AOM-SOS score greater than or equal to 1 is divided by the total number of years of follow-up to arrive at the days per year with AOM symptoms and an intact TM. (NCT02567825)
Timeframe: Day 1 until Day 786. The mean length of follow-up was 662 days / 1.8 years.

InterventionDays per year (Mean)
Surgical Management2.00
Non-Surgical Management8.33

[back to top]

The Rate of Occurrence of Acute Otitis Media (AOM) Episodes Per Child-Year According to the Estimated Risk of Acute Otitis Media (AOM) Recurrences at Enrollment

An episode of AOM is considered a discrete occurrence if symptoms and signs persisted for, or recurred, >=17 days after the start of antimicrobial treatment. The rate is calculated by dividing the total # of occurrences by the total # of years of follow-up. Risk of recurrences was based on early age of onset of AOM; numerous and/or frequent previous AOM episodes; receipt of multiple courses of antibiotic; eligibility for enrollment first evident during warm-weather months; parental characterization of previous AOM episodes as severe; eligibility for enrollment despite nonexposure to other young children; moderate or marked tympanic membrane (TM) bulging with previous AOM episodes; most previous AOM episodes in both ears; and a high score on the Acute Otitis Media Severity of Symptom scale (with scores ranging from 0 to 10 and higher scores indicating greater severity of symptoms) during screening and/or at enrollment. Multiple imputation was used when follow-up was incomplete. (NCT02567825)
Timeframe: Day 1 until Day 786. The mean length of actual follow-up was 662 days / 1.8 years. For each child with incomplete 2-year follow-up, multiple imputation was used and values for the remaining days/years were imputed.

,
InterventionOccurrences per child-year (Mean)
Children considered at low risk of AOM recurrenceChildren considered at high risk of AOM recurrence
Non-Surgical Management1.561.56
Surgical Management1.281.67

[back to top]

The Mean Scores on the 6 Item Quality of Life Survey Questionnaire (OM-6)

The OM-6 is a 6 item quality of life assessment addressing physical suffering, hearing loss, speech impairment, emotional distress, activity limitations and caregiver concerns. Responses are regarded on an ordinal scale ranging from 1 (no problem) to 7 (greatest problem). The average response, i.e., score, for these 6 items is calculated. The overall child's quality of life (QOL) score, also captured on the OM-6, is expressed on an ordinal response scale that ranges from 0 (worst quality of life) to 10 (best quality). A OM-6 is administered to the parent every 16 weeks after randomization and occasionally at sick visits. (NCT02567825)
Timeframe: Day 1 until Day 786.

,
InterventionScore on a scale (Mean)
OM-6 survey scoreOM-6 survey--Children's overall QOL score
Non-Surgical Management1.558.37
Surgical Management1.58.45

[back to top]

The Mean Scores on the 6 Item Caregiver Impact Questionnaire (CIQ)

The Caregiver Impact Questionnaire (CIQ) is a 6 item assessment addressing lack of sleep, absence from work or education, canceling of family activities, changing daily activities, feeling nervous and feeling helpless. Each of these responses is expanded to a continuous scale from 0 (no impact on caregiver) to 100 (greatest impact). The average response, i.e., score, for these 6 items is calculated. The overall caregiver's quality of life (QOL) score, also captured on the CIQ, is expressed on a ordinal response scale that ranges from 0 (worst quality of life) to 10 (best quality). The CIQ is administered to the parent every 16 weeks after randomization and occasionally at sick visits. (NCT02567825)
Timeframe: Day 1 until Day 786.

,
InterventionScore on a scale (Mean)
Caregiver impact questionnaire scoreCaregiver impact questionnaire--Caregiver's overall QOL score
Non-Surgical Management10.938.50
Surgical Management10.828.55

[back to top]

The Time to the First Episode of AOM

The time to the first episode of AOM is defined as the time, expressed in months, from randomization until the first episode of AOM. (NCT02567825)
Timeframe: Day 1 until Day 786. The mean length of follow-up was 662 days / 21.8 months.

InterventionMonths (Median)
Surgical Management4.34
Non-Surgical Management2.33

[back to top]

The Distribution of Children With a Penicillin-Nonsusceptible Nasopharyngeal or Throat Isolate At Any Follow-up Visit According to the Colonization Status at Enrollment

Throat specimens were obtained mainly from children older than 24 months of age. The penicillin-nonsusceptible pathogens considered are penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae and ß-lactamase-positive Haemophilus influenzae. Susceptibility to penicillin was defined as follows: susceptible as a minimum inhibitory concentration (MIC) of <0.1 μg/mL; intermediate as an MIC of 0.1 to 1μg/mL; and resistant as an MIC of >1 μg/mL. (NCT02567825)
Timeframe: Day 1 until Day 786.

InterventionParticipants (Count of Participants)
No pathogens at enrollment72440667No pathogens at enrollment72440668Positive only for at least 1 penicillin-susceptible pathogen at enrollment72440667Positive only for at least 1 penicillin-susceptible pathogen at enrollment72440668Positive for at least 1 penicillin-nonsusceptible pathogen at enrollment72440667Positive for at least 1 penicillin-nonsusceptible pathogen at enrollment72440668
Penicillin-nonsusceptible isolate at a follow-up vNo penicillin-nonsusceptible isolate at a follow-u
Surgical Management25
Non-Surgical Management24
Surgical Management12
Non-Surgical Management11
Surgical Management22
Non-Surgical Management20
Surgical Management11
Non-Surgical Management15
Surgical Management38
Non-Surgical Management34
Surgical Management5
Non-Surgical Management9

[back to top]

The Total Cost of Management of Recurrent Acute Otitis Media Per Quality Adjusted Life Days (QALDs) as a Measure of Cost-Effectiveness According to the Estimated Risk of Acute Otitis Media Recurrences at Enrollment

Total costs in US dollars were calculated by summing costs of lost wages, office visits, medical procedures, hospitalizations, and medications. Total QALDs were calculated by summing daily utility values. A utility value of 1.0 was assumed for days without AOM, otorrhea, or hospitalization. For days where these states were reported, published utility values associated with each state were used. To arrive at the final measure, total costs were divided by total utility values. The estimated risk of AOM at enrollment is described under both Baseline Characteristics and Outcome Measure #2. (NCT02567825)
Timeframe: Day 1 until Day 786. The mean length of actual follow-up was 662 days / 1.8 years.

,
InterventionUS dollars per quality adjusted life day (Number)
Children considered at low risk of AOM recurrenceChildren considered at high risk of AOM recurrence
Non-Surgical Management5.705.91
Surgical Management6.258.00

[back to top]

Summary of Clinical Improvement

Clinical improvement was assessed using the latest efficacy evaluation conducted on last day of treatment (+48 hours), and was defined identically to the early clinical response. (NCT02605122)
Timeframe: Last day of Treatment (+48 hours)

Interventionpercentage of participants (Number)
Solithromycin64.5
Standard of Care81

[back to top]

Overview of Adverse Events By Treatment Arm

Summary of subjects experiencing Treatment Emergent Adverse Events (TEAE) through Day 16 visit and Treatment Emergent Serious Adverse Events (TESAE) through Day 28 visit (28 days +/- 4 days after randomization) (NCT02605122)
Timeframe: Up to 28 days post-treatment

,
InterventionParticipants (Count of Participants)
TEAETESAE
Solithromycin241
Standard of Care71

[back to top]

Summary of Early Clinical Response

Early clinical response (ECR) was defined using the latest efficacy evaluation from Day 2 (if subject discharged prior to Day 2), Day3, or Day 4, and was defined as improvement in at least 1 presenting sign/symptom of CABP with no deterioration in any signs/symptoms of CABP and no requirement for an additional antibiotic. (NCT02605122)
Timeframe: During Treatment Days 3 to 4

Interventionpercentage of participants (Number)
Solithromycin66.7
Standard of Care46.7

[back to top]

Summary of Clinical Cure

Clinical cure was assessed using the latest efficacy evaluation conducted on Day 16 (+/- 4 days) post-randomization, and was defined as resolution of all presenting signs/symptoms of CABP (excluding cough), no development of new signs/symptoms of CABP, and no requirement for an additional antibiotic. (NCT02605122)
Timeframe: Short-term follow-up at 16 days (+/- 4 days)

Interventionpercentage of participants (Number)
Solithromycin60.0
Standard of Care68.4

[back to top]

Eventual Appendectomy Incidence Proportion

incidence proportion of appendectomy within 90 days post randomization among those randomized to antibiotics (NCT02800785)
Timeframe: 90 days post randomization

Interventionincidence proportion (Number)
Antibiotics Therapy Arm0.29

[back to top]

Number of Clinic Visits or Emergency Room Visits

Total number of participants with any visit to emergency department or urgent care clinic after index treatment within 90 days (NCT02800785)
Timeframe: 90 days post randomization

Interventionvisits (Number)
Antibiotics Therapy Arm55
Appendectomy Arm26

[back to top]

Number of Participants With at Least One Complications From Treatment

Comparison of the number of participants with at least one surgical complication and antibiotic complications. (NCT02800785)
Timeframe: 90 days

InterventionParticipants (Count of Participants)
Antibiotics Therapy Arm37
Appendectomy Arm21

[back to top]

Patient-reported Quality of Life as Measured by EuroQol (EQ-5D)

The primary evaluation of patient-reported quality of life, as measured by the EuroQuol-5D at four-weeks, will be conducted using an intention-to-treat (ITT) analysis, where patients' data are analyzed according to the patients' randomized treatment assignment. EQ5D assesses health status in terms of five dimensions of health. The maximum score of 1 indicates the best health state, the minimum score is 0 (as score as bad as being dead). (NCT02800785)
Timeframe: Four-weeks after randomization

Interventionscore on a scale (Mean)
Antibiotics Therapy Arm0.92
Appendectomy Arm0.91

[back to top]

Rate of Participants With Perforated Appendicitis

Rates of patients who had perforated appendicitis will be calculated for each arm among those received an appendectomy. (NCT02800785)
Timeframe: 90 days post enrollment

InterventionParticipants (Count of Participants)
Antibiotics Therapy Arm59
Appendectomy Arm99

[back to top]

Rates of Participants With Appendiceal Cancer

Rates of appendiceal cancer among participants will be calculated among the antibiotics and appendectomy arms. (NCT02800785)
Timeframe: Through study completion, up to 2 years

InterventionParticipants (Count of Participants)
Antibiotics Therapy Arm4
Appendectomy Arm6

[back to top]

Total Number of Patients Who Had Resolution of Appendicitis Symptoms at 30 Days

Total Number of Patients who had resolution of appendicitis symptoms at 30 Days. This was measured as absence of fever and abdominal pain and tenderness. (NCT02800785)
Timeframe: at 30 days

InterventionParticipants (Count of Participants)
Antibiotics Therapy Arm462
Appendectomy Arm466

[back to top]

Days in Hospital After Index Treatment Within 90 Days

Mean number of days in the hospital per participant calculated at 90 days post randomization. (Number of days/Number of Participants in Therapy Arm who responded to the 90 day survey question) (NCT02800785)
Timeframe: 90 days post randomization

InterventionDays per participant (rate) (Mean)
Antibiotics Therapy Arm0.68
Appendectomy Arm0.15

[back to top]

Proportion of Participants With Occurrence of Bacteriuria in Non-competitive Infections, by Strain

Bacteriuria is defined as Log10 cfu N. gonorrhoeae/mL urine sediment. (NCT03840811)
Timeframe: Day of occurrence, any day between Day 2 and Day 6

Interventionproportion of participants (Number)
Mutant FA75370.86
Wild-type FA10901.00

[back to top]

Proportion of Participants That Become Infected as Defined by a Positive Urine or Urethral Swab Culture for Infections Initiated With Mixed Inocula

Infection is defined by a positive urine or urethral swab culture. The proportion of infected participants by Day 6 with N. gonorrhoeae was assessed in each trial among participants with infections initiated with mixed inocula. Participants could become infected and received treatment any day before or on day 6. (NCT03840811)
Timeframe: day of infection, any day between Day 2 and Day 6

Interventionproportion of participants (Number)
Mixed FA1090/FA75371.00

[back to top]

Proportion of Participants That Become Infected as Defined by a Positive Urine or Urethral Swab Culture Among Infections Initiated With Individual N. Gonorrhoeae Strains in Non-competitive Infections

Infection is defined by a positive urine or urethral swab culture. The proportion of infected participants by Day 6 with N. gonorrhoeae was assessed in each trial by group among participants with non-competitive infections. Participants could become infected and received treatment any day before or on day 6. (NCT03840811)
Timeframe: day of infection, any day between Day 2 and Day 6

Interventionproportion of participants (Number)
Mutant FA75370.86
Wild-type FA10901.00

[back to top]

Median Time From Inoculation to Treatment Among Infected Participants by Day 6, by Strain, in Non-competitive Infections

The median time from inoculation to antibiotic treatment were calculated for each group. (NCT03840811)
Timeframe: Day 2 through the day of treatment, up to Day 6

Interventiondays (Median)
Mutant FA75373.0
Wild-type FA10903.0

[back to top]

Proportion of Participants With Occurrence of Urethritis in Non-competitive Infections

Urethritis is defined as >= 5.8 Log10 WBC/mL urine sediment. (NCT03840811)
Timeframe: Day of occurrence, any day between Day 2 and Day 6

Interventionproportion of participants (Number)
Mutant FA75371.00
Wild-type FA10901.00

[back to top]

The Competitive Index of the Mutant Compared to Wild Type Proportion of Organisms With the Predicted Competitive Advantage Recovered From Urine and/or Urethral Swab Specimens From Infected Participants

"The competitive index (CI) is defined by the ratio of colony forming units (cfu) of the two strains recovered from urine cultures on the day of treatment (output) compared to the ratio of strains in the inoculum (input):~CI = mutant cfu(output)/wild-type cfu(output) ÷ mutant cfu(input)/wild-type cfu(input).~The CI is used to assess whether the fitness of a given mutant is different than that of wild-type, and CI as a ratio is compared to 1. If it's not significantly different than 1, then no significant difference in the fitness was observed. Mutant or wild-type cfu values of 0 were replaced by 1 in the calculation of competitive index.~The assessment was performed in the MtrD trial mixed group." (NCT03840811)
Timeframe: Baseline and the day of treatment, any day between Day 2 and Day 6

Interventionratio (Median)
Mixed FA1090/FA753715.11

[back to top]

Proportion of Participants With Occurrence of Signs and Symptoms of Urethritis Attributable to Gonococcal Infection in Non-competitive Infections, by Strain

Participants with any subjective symptoms or objective signs (observed urethral discharge) during period 01 (post-inoculation and before treatment which can occur on or before day 6) from the Solicited Events Form were captured. (NCT03840811)
Timeframe: Day of occurrence, any day between Day 2 and Day 6

Interventionproportion of participants (Number)
Mutant FA75371.00
Wild-type FA10901.00

[back to top]

Biomarker of Infection

Procalcitonin (NCT04218695)
Timeframe: Once at time of randomization

Interventionng/mL (Median)
Treatment0.25
Placebo0.44

[back to top]

Incident ACLF

(by NACSELD) or change in CLIF-C ACLF score (NCT04218695)
Timeframe: During hospital admission up to 30 days

InterventionParticipants (Count of Participants)
Treatment5
Placebo3

[back to top]

Incident C Difficile Colitis

Positive stool toxin/PCR with new onset diarrhea (NCT04218695)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Treatment0
Placebo1

[back to top]

Incident Variceal Hemorrhage

Incident variceal hemorrhage (NCT04218695)
Timeframe: During hospital admission up to 30 days

InterventionParticipants (Count of Participants)
Treatment0
Placebo0

[back to top]

Increase in MELD-Na

>2 pts (NCT04218695)
Timeframe: Upon discharge (or at 30 days)

InterventionParticipants (Count of Participants)
Treatment3
Placebo3

[back to top]

Infections

Incident bacterial infection after enrollment (NCT04218695)
Timeframe: For 7 days or until end of hospital stay

InterventionParticipants (Count of Participants)
Treatment2
Placebo5

[back to top]

Fungal Infection

Incident fungal infection (by culture data or requirement for new anti-fungal medication) (NCT04218695)
Timeframe: During hospital admission up to 30 days

InterventionParticipants (Count of Participants)
Treatment0
Placebo0

[back to top]

Mortality

In-hospital (NCT04218695)
Timeframe: Up to 30 days

InterventionParticipants (Count of Participants)
Treatment1
Placebo4

[back to top]

Length of Stay

Days in hospital after randomization (NCT04218695)
Timeframe: Up to 30 days

Interventiondays (Median)
Treatment9
Placebo10

[back to top]

30-day Mortality

Includes f/u after discharge (NCT04218695)
Timeframe: Up to 30-days

InterventionParticipants (Count of Participants)
Treatment2
Placebo5

[back to top]

Biomarker of Infection

C-reactive protein (NCT04218695)
Timeframe: Once at time of randomization

Interventionmg/L (Median)
Treatment9.7
Placebo11.0

[back to top]

MCP-1 Cytokine Levels in Urine

MCP-1 Cytokine levels in urine collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. Only the cytokines measured in both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of detection are excluded. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA757.7622.5491.7
Wild-type FA1090 A25113.0233.9137.9

[back to top]

MCP-1 Cytokine Levels in Peripheral Blood

MCP-1 Cytokine levels in peripheral blood collected from subjects were measured at the eligibility testing visit, during experimental infection and at the follow-up visit. Only cytokines detected during experimental infection in > 50% of peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA428.0563.0379.2
Wild-type FA1090 A25339.7271.7284.1

[back to top]

IP-10 Cytokine Levels in Urine

IP-10 Cytokine levels in urine collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. Only the cytokines measured in both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of detection are excluded. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA64.5387.8177.8
Wild-type FA1090 A2523.4411.423.7

[back to top]

MIP-1Beta Cytokine Levels in Urine

MIP-1Beta Cytokine levels in urine collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. Only the cytokines measured in both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of detection are excluded. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA2.116.61.6
Wild-type FA1090 A251.622.01.6

[back to top]

VEGF Cytokine Levels in Peripheral Blood

VEGF Cytokine levels in peripheral blood collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA321.1340.3334.1
Wild-type FA1090 A25480.7376.7409.9

[back to top]

Fractalkine Cytokine Levels in Peripheral Blood

Fractalkine Cytokine levels in peripheral blood collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA202.2248.3222.2
Wild-type FA1090 A25761.8762.9853.7

[back to top]

Fractalkine Cytokine Levels in Urine

Fractalkine Cytokine levels in urine collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. Only the cytokines measured in both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of detection are excluded. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA137.257.075.5
Wild-type FA1090 A2558.571.086.9

[back to top]

G-CSF Cytokine Levels in Peripheral Blood

G-CSF Cytokine levels in peripheral blood collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA32.537.819.2
Wild-type FA1090 A2581.691.472.9

[back to top]

G-CSF Cytokine Levels in Urine

G-CSF Cytokine levels in urine collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. Only the cytokines measured in both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of detection are excluded. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA16.6113.118.3
Wild-type FA1090 A2525.6207.19.5

[back to top]

VEGF Cytokine Levels in Urine

VEGF Cytokine levels in urine collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. Only the cytokines measured in both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of detection are excluded. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA104.9171.8185.1
Wild-type FA1090 A2545.3111.371.8

[back to top]

GRO Cytokine Levels in Peripheral Blood

GRO Cytokine levels in peripheral blood collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA1003.9436.4403.1
Wild-type FA1090 A25433.5507.3605.5

[back to top]

GRO Cytokine Levels in Urine

GRO Cytokine levels in urine collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. Only the cytokines measured in both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of detection are excluded. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA13.854.728.9
Wild-type FA1090 A253.5224.64.0

[back to top]

IL-1RA Cytokine Levels in Peripheral Blood

IL-1RA Cytokine levels in peripheral blood collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA145.6144.0106.2
Wild-type FA1090 A25104.594.097.7

[back to top]

MIP-1Beta Cytokine Levels in Peripheral Blood

MIP-1Beta Cytokine levels in peripheral blood collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA45.448.439.4
Wild-type FA1090 A2542.937.836.0

[back to top]

IL-1RA Cytokine Levels in Urine

IL-1RA Cytokine levels in urine collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. Only the cytokines measured in both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of detection are excluded. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA210.9205.2138.8
Wild-type FA1090 A2544.972.164.1

[back to top]

IL-8 Cytokine Levels in Peripheral Blood

IL-8 Cytokine levels in peripheral blood collected from subjects were measured at the eligibility testing visit, during experimental infection and at the follow-up visit. Only cytokines detected during experimental infection in > 50% of peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA17.323.018.0
Wild-type FA1090 A2522.121.621.2

[back to top]

IL-8 Cytokine Levels in Urine

IL-8 Cytokine levels in urine collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. Only the cytokines measured in both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of detection are excluded. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA1.635.36.3
Wild-type FA1090 A251.632.91.6

[back to top]

Eotaxin Cytokine Levels in Urine

Eotaxin Cytokine levels in urine collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. Only the cytokines measured in both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of detection are excluded. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA5.25.97.1
Wild-type FA1090 A252.75.42.2

[back to top]

IP-10 Cytokine Levels in Peripheral Blood

IP-10 Cytokine levels in peripheral blood collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA630.8781.0516.0
Wild-type FA1090 A25598.4790.3361.9

[back to top]

EGF Cytokine Levels in Urine

EGF Cytokine levels in urine collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. Only the cytokines measured in both the urine and peripheral blood samples are included. Cytokine outcome values reported below the limit of detection are excluded. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA7333.27358.17358.1
Wild-type FA1090 A256600.98325.28490.4

[back to top]

EGF Cytokine Levels in Peripheral Blood

EGF Cytokine levels in peripheral blood collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA85.042.637.9
Wild-type FA1090 A2533.529.642.9

[back to top]

The Proportion of Wild Type (WT) Organisms Recovered From Urine and Urethral Swab Specimens From Individual Subjects Infected With Mixed Inoculum

Infection defined as reported symptoms of urethritis, including urethral discharge or dysuria, plus presence of gram-negative intracellular diplococci in a urethral swab smear. Participants could become infected and received treatment any day before or on day 5. (NCT04870138)
Timeframe: Baseline (Day 0) and the day of infection (any day between Day 1 and Day 5)

Interventionproportion of WT organisms recovered (Mean)
Mixed FA7527/FA1090 A251.0

[back to top]

Eotaxin Cytokine Levels in Peripheral Blood

Eotaxin cytokine levels in peripheral blood collected from subjects were measured at the screening visit, during experimental infection and at the follow-up visit. Only cytokines detected during the treatment visit upon experimental infection or day 5 in > 50% of peripheral blood samples are included. Cytokine outcome values reported below the limit of quantitation are assigned 1/2 the lower limit of quantitation for calculation of mean values; limits of 95% confidence intervals are bounded by 1/2 the lower limit of quantitation and the upper limit of quantitation for each cytokine. (NCT04870138)
Timeframe: Screening Visit (Day -30 to Day -1), Treatment Visit (Day 1 to Day 5), and Follow-Up Visit (3 to 7 days following Treatment Visit)

,
Interventionpg/mL (Mean)
Screening VisitTreatment VisitFollow-Up Visit
Mutant FA7527 - LptA351.9422.7407.1
Wild-type FA1090 A25267.4247.3218.3

[back to top]

The Proportion of Participants That Become Infected With Mixed Inoculum

Infection defined as reported symptoms of urethritis, including urethral discharge or dysuria, plus presence of gram-negative intracellular diplococci in a urethral swab smear. Participants could become infected and received treatment any day before or on day 5. (NCT04870138)
Timeframe: Day of infection, any day between Day 1 and Day 5

Interventionproportion of participants (Number)
Mixed FA7527/FA1090 A250.83

[back to top]

The Proportion of Participants That Become Infected With Individual N. Gonorrhoeae Strains in Non-competitive Infections

Infection defined as reported symptoms of urethritis, including urethral discharge or dysuria, plus presence of gram-negative intracellular diplococci in a urethral swab smear. The proportion of infected participants by Day 5 with N. gonorrhoeae was assessed by group among participants with non-competitive infections. Participants could become infected and received treatment any day before or on day 5. (NCT04870138)
Timeframe: Day of infection, any day between Day 1 and Day 5

Interventionproportion of participants (Number)
Mutant FA7527 - LptA0.80
Wild-type FA1090 A251.00

[back to top]

Change in RU SATED Score

The Regularity, Sleep Quality, Alertness, Timing, Efficiency, Duration scale for sleep (RU SATED) ranges from 0 to 30, with higher scores indicating better sleep health. (NCT05149287)
Timeframe: Pre-operative, 2 months post-operative

Interventionunits on a scale (Mean)
Experimental1
Placebo-0.5

[back to top]

Post-operative Narcotic Use

Post-operative narcotic use will be monitored with self-reported medication consumption at the first post-operative visit, which will take place 5-12 days post-operative. The milligrams of morphine equivalent (MME) will be calculated based on patient responses with greater MME indicative of increased postoperative use of narcotic pain medications. (NCT05149287)
Timeframe: 5-12 days post-operative

Interventionmilligrams of morphine equivalent (MME) (Mean)
Experimental15
Placebo5.5

[back to top]

Change in Visual Analog Scale (VAS) Pain Score

The Visual analog scale scores range from 0 to 10 with greater scores indicative of greater pain. (NCT05149287)
Timeframe: Pre-operative, 2 months post-operative

Interventionunits on a scale (Mean)
Experimental-2.67
Placebo-2.1

[back to top]